US20230219887A1 - Solid forms comprising an oxime ether compound, compositions and methods of use thereof - Google Patents
Solid forms comprising an oxime ether compound, compositions and methods of use thereof Download PDFInfo
- Publication number
- US20230219887A1 US20230219887A1 US18/185,555 US202318185555A US2023219887A1 US 20230219887 A1 US20230219887 A1 US 20230219887A1 US 202318185555 A US202318185555 A US 202318185555A US 2023219887 A1 US2023219887 A1 US 2023219887A1
- Authority
- US
- United States
- Prior art keywords
- solid
- compound
- certain embodiments
- ray powder
- solid form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007787 solid Substances 0.000 title claims abstract description 521
- 238000000034 method Methods 0.000 title claims abstract description 86
- 239000000203 mixture Substances 0.000 title claims abstract description 58
- -1 oxime ether compound Chemical class 0.000 title abstract description 19
- KIHYPELVXPAIDH-HNSNBQBZSA-N 1-[[4-[(e)-n-[[4-cyclohexyl-3-(trifluoromethyl)phenyl]methoxy]-c-methylcarbonimidoyl]-2-ethylphenyl]methyl]azetidine-3-carboxylic acid Chemical compound CCC1=CC(C(\C)=N\OCC=2C=C(C(C3CCCCC3)=CC=2)C(F)(F)F)=CC=C1CN1CC(C(O)=O)C1 KIHYPELVXPAIDH-HNSNBQBZSA-N 0.000 claims abstract description 5
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 166
- 239000008194 pharmaceutical composition Substances 0.000 claims description 49
- 201000006417 multiple sclerosis Diseases 0.000 claims description 18
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 239000002552 dosage form Substances 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 3
- 238000009472 formulation Methods 0.000 abstract description 11
- 230000008569 process Effects 0.000 abstract description 3
- 229940125904 compound 1 Drugs 0.000 description 149
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 141
- 239000002904 solvent Substances 0.000 description 90
- 239000002002 slurry Substances 0.000 description 75
- 238000000113 differential scanning calorimetry Methods 0.000 description 48
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 45
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 42
- 238000001914 filtration Methods 0.000 description 41
- 238000002411 thermogravimetry Methods 0.000 description 41
- 238000001035 drying Methods 0.000 description 39
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 36
- 150000001875 compounds Chemical class 0.000 description 34
- 238000003756 stirring Methods 0.000 description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 34
- 238000002441 X-ray diffraction Methods 0.000 description 31
- 238000001757 thermogravimetry curve Methods 0.000 description 30
- 239000000126 substance Substances 0.000 description 29
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 28
- 239000000243 solution Substances 0.000 description 27
- 238000001228 spectrum Methods 0.000 description 27
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 26
- 238000005079 FT-Raman Methods 0.000 description 25
- 201000010099 disease Diseases 0.000 description 23
- 208000035475 disorder Diseases 0.000 description 22
- 239000013078 crystal Substances 0.000 description 21
- 230000001351 cycling effect Effects 0.000 description 20
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 18
- 238000005259 measurement Methods 0.000 description 17
- IEJIGPNLZYLLBP-UHFFFAOYSA-N dimethyl carbonate Chemical compound COC(=O)OC IEJIGPNLZYLLBP-UHFFFAOYSA-N 0.000 description 16
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
- 239000002253 acid Substances 0.000 description 15
- 238000001704 evaporation Methods 0.000 description 15
- 238000004519 manufacturing process Methods 0.000 description 15
- 238000001144 powder X-ray diffraction data Methods 0.000 description 15
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 14
- 238000001237 Raman spectrum Methods 0.000 description 14
- 239000012458 free base Substances 0.000 description 14
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 13
- 229910052757 nitrogen Inorganic materials 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 201000004681 Psoriasis Diseases 0.000 description 12
- 241000282414 Homo sapiens Species 0.000 description 11
- 239000000706 filtrate Substances 0.000 description 11
- 238000002156 mixing Methods 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 10
- 238000004090 dissolution Methods 0.000 description 10
- 239000011261 inert gas Substances 0.000 description 10
- 238000001907 polarising light microscopy Methods 0.000 description 10
- 238000010926 purge Methods 0.000 description 10
- 206010039073 rheumatoid arthritis Diseases 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 206010009900 Colitis ulcerative Diseases 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 201000006704 Ulcerative Colitis Diseases 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 230000001363 autoimmune Effects 0.000 description 9
- 239000007891 compressed tablet Substances 0.000 description 9
- 229910001873 dinitrogen Inorganic materials 0.000 description 9
- 238000010438 heat treatment Methods 0.000 description 9
- 239000012453 solvate Substances 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- 208000023275 Autoimmune disease Diseases 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 229920002472 Starch Polymers 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- 230000002757 inflammatory effect Effects 0.000 description 8
- 206010025135 lupus erythematosus Diseases 0.000 description 8
- 238000010899 nucleation Methods 0.000 description 8
- 238000007911 parenteral administration Methods 0.000 description 8
- 235000019698 starch Nutrition 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 208000011231 Crohn disease Diseases 0.000 description 7
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 7
- 229910052786 argon Inorganic materials 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 229920001577 copolymer Polymers 0.000 description 7
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 208000005987 polymyositis Diseases 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 230000009885 systemic effect Effects 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 201000002481 Myositis Diseases 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 6
- 229910052782 aluminium Inorganic materials 0.000 description 6
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 6
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 6
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 6
- 208000023328 Basedow disease Diseases 0.000 description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 5
- 239000005977 Ethylene Substances 0.000 description 5
- 208000015023 Graves' disease Diseases 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 229930195725 Mannitol Natural products 0.000 description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 5
- 239000012901 Milli-Q water Substances 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 description 5
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 description 5
- 239000012296 anti-solvent Substances 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 208000037976 chronic inflammation Diseases 0.000 description 5
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 5
- 239000000306 component Substances 0.000 description 5
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 229960001375 lactose Drugs 0.000 description 5
- 239000000594 mannitol Substances 0.000 description 5
- 235000010355 mannitol Nutrition 0.000 description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 235000002639 sodium chloride Nutrition 0.000 description 5
- 239000000600 sorbitol Substances 0.000 description 5
- 235000010356 sorbitol Nutrition 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 229940032147 starch Drugs 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000002076 thermal analysis method Methods 0.000 description 5
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 4
- 206010004659 Biliary cirrhosis Diseases 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 4
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical group CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 4
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 208000012902 Nervous system disease Diseases 0.000 description 4
- 206010034277 Pemphigoid Diseases 0.000 description 4
- 238000001069 Raman spectroscopy Methods 0.000 description 4
- 206010040070 Septic Shock Diseases 0.000 description 4
- 102100025750 Sphingosine 1-phosphate receptor 1 Human genes 0.000 description 4
- 101710155454 Sphingosine 1-phosphate receptor 1 Proteins 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 208000000594 bullous pemphigoid Diseases 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 239000007884 disintegrant Substances 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 206010021198 ichthyosis Diseases 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 208000028867 ischemia Diseases 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 238000000386 microscopy Methods 0.000 description 4
- 210000001589 microsome Anatomy 0.000 description 4
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 4
- 238000000399 optical microscopy Methods 0.000 description 4
- 239000006186 oral dosage form Substances 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 201000000306 sarcoidosis Diseases 0.000 description 4
- 239000012047 saturated solution Substances 0.000 description 4
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 description 4
- 238000004611 spectroscopical analysis Methods 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 229960004793 sucrose Drugs 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 241000416162 Astragalus gummifer Species 0.000 description 3
- 229920000858 Cyclodextrin Polymers 0.000 description 3
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 3
- 102000007438 Interferon alpha-beta Receptor Human genes 0.000 description 3
- 108010086140 Interferon alpha-beta Receptor Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical group CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- 208000005777 Lupus Nephritis Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920001615 Tragacanth Polymers 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 229960004853 betadex Drugs 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 235000012343 cottonseed oil Nutrition 0.000 description 3
- 239000002385 cottonseed oil Substances 0.000 description 3
- 201000001981 dermatomyositis Diseases 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 3
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 230000003228 microsomal effect Effects 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 3
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 238000004626 scanning electron microscopy Methods 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 235000010487 tragacanth Nutrition 0.000 description 3
- 229940116362 tragacanth Drugs 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 2
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 229910002483 Cu Ka Inorganic materials 0.000 description 2
- 208000021709 Delayed Graft Function Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 239000001116 FEMA 4028 Substances 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 208000003084 Graves Ophthalmopathy Diseases 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- 206010019799 Hepatitis viral Diseases 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 238000004566 IR spectroscopy Methods 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 208000004852 Lung Injury Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 description 2
- 208000029578 Muscle disease Diseases 0.000 description 2
- 208000009525 Myocarditis Diseases 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- 208000013901 Nephropathies and tubular disease Diseases 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- 208000031845 Pernicious anaemia Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 206010038460 Renal haemorrhage Diseases 0.000 description 2
- 206010062237 Renal impairment Diseases 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- 206010062106 Respiratory tract infection viral Diseases 0.000 description 2
- 208000006289 Rett Syndrome Diseases 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- 239000008156 Ringer's lactate solution Substances 0.000 description 2
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 2
- 206010039966 Senile dementia Diseases 0.000 description 2
- 229920001800 Shellac Polymers 0.000 description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 208000000389 T-cell leukemia Diseases 0.000 description 2
- 206010042971 T-cell lymphoma Diseases 0.000 description 2
- 206010044248 Toxic shock syndrome Diseases 0.000 description 2
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 2
- 206010069363 Traumatic lung injury Diseases 0.000 description 2
- 206010044541 Traumatic shock Diseases 0.000 description 2
- 206010046851 Uveitis Diseases 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 2
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 201000009961 allergic asthma Diseases 0.000 description 2
- 208000002205 allergic conjunctivitis Diseases 0.000 description 2
- 208000002029 allergic contact dermatitis Diseases 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- 208000004631 alopecia areata Diseases 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000008135 aqueous vehicle Substances 0.000 description 2
- 208000024998 atopic conjunctivitis Diseases 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229940105329 carboxymethylcellulose Drugs 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 239000007910 chewable tablet Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000009838 combustion analysis Methods 0.000 description 2
- 239000008139 complexing agent Substances 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229960000913 crospovidone Drugs 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 239000008355 dextrose injection Substances 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000002050 diffraction method Methods 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229940126534 drug product Drugs 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- 239000007941 film coated tablet Substances 0.000 description 2
- 238000009501 film coating Methods 0.000 description 2
- 239000007888 film coating Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000003517 fume Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- 201000010659 intrinsic asthma Diseases 0.000 description 2
- 208000001875 irritant dermatitis Diseases 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 206010023332 keratitis Diseases 0.000 description 2
- 201000010666 keratoconjunctivitis Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000002356 laser light scattering Methods 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 239000003589 local anesthetic agent Substances 0.000 description 2
- 229960005015 local anesthetics Drugs 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 231100000515 lung injury Toxicity 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 206010028417 myasthenia gravis Diseases 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- 239000002687 nonaqueous vehicle Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000003921 particle size analysis Methods 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
- ZQBAKBUEJOMQEX-UHFFFAOYSA-N phenyl salicylate Chemical compound OC1=CC=CC=C1C(=O)OC1=CC=CC=C1 ZQBAKBUEJOMQEX-UHFFFAOYSA-N 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000003345 scintillation counting Methods 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 208000008742 seborrheic dermatitis Diseases 0.000 description 2
- 230000036303 septic shock Effects 0.000 description 2
- 239000003352 sequestering agent Substances 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 239000004208 shellac Substances 0.000 description 2
- 229940113147 shellac Drugs 0.000 description 2
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 2
- 235000013874 shellac Nutrition 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 229920002379 silicone rubber Polymers 0.000 description 2
- 238000004467 single crystal X-ray diffraction Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000007940 sugar coated tablet Substances 0.000 description 2
- 238000009495 sugar coating Methods 0.000 description 2
- 231100000617 superantigen Toxicity 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 229940117013 triethanolamine oleate Drugs 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 201000001862 viral hepatitis Diseases 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- 235000012431 wafers Nutrition 0.000 description 2
- 239000008136 water-miscible vehicle Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- WGIMXKDCVCTHGW-UHFFFAOYSA-N 2-(2-hydroxyethoxy)ethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCOCCO WGIMXKDCVCTHGW-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- OEPOKWHJYJXUGD-UHFFFAOYSA-N 2-(3-phenylmethoxyphenyl)-1,3-thiazole-4-carbaldehyde Chemical compound O=CC1=CSC(C=2C=C(OCC=3C=CC=CC=3)C=CC=2)=N1 OEPOKWHJYJXUGD-UHFFFAOYSA-N 0.000 description 1
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 1
- UBLAMKHIFZBBSS-UHFFFAOYSA-N 3-Methylbutyl pentanoate Chemical compound CCCCC(=O)OCCC(C)C UBLAMKHIFZBBSS-UHFFFAOYSA-N 0.000 description 1
- NZAQRZWBQUIBSF-UHFFFAOYSA-N 4-(4-sulfobutoxy)butane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCOCCCCS(O)(=O)=O NZAQRZWBQUIBSF-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 239000004709 Chlorinated polyethylene Substances 0.000 description 1
- 241000206575 Chondrus crispus Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 229910000530 Gallium indium arsenide Inorganic materials 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000218652 Larix Species 0.000 description 1
- 235000005590 Larix decidua Nutrition 0.000 description 1
- 241000195947 Lycopodium Species 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 229910017502 Nd:YVO4 Inorganic materials 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 229920012485 Plasticized Polyvinyl chloride Polymers 0.000 description 1
- 239000005062 Polybutadiene Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 238000000441 X-ray spectroscopy Methods 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 239000000420 anogeissus latifolia wall. gum Substances 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229920005549 butyl rubber Polymers 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229940095672 calcium sulfate Drugs 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 229940023913 cation exchange resins Drugs 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 150000001896 cresols Chemical class 0.000 description 1
- 229960005168 croscarmellose Drugs 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000004807 desolvation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940096516 dextrates Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000007911 effervescent powder Substances 0.000 description 1
- 238000002003 electron diffraction Methods 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 229920005558 epichlorohydrin rubber Polymers 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- HQQADJVZYDDRJT-UHFFFAOYSA-N ethene;prop-1-ene Chemical group C=C.CC=C HQQADJVZYDDRJT-UHFFFAOYSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000001408 fungistatic effect Effects 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940049654 glyceryl behenate Drugs 0.000 description 1
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 1
- 229940046813 glyceryl palmitostearate Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000019314 gum ghatti Nutrition 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 239000008173 hydrogenated soybean oil Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 239000007946 hypodermic tablet Substances 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006749 inflammatory damage Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007915 intraurethral administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 229920000554 ionomer Polymers 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 239000007942 layered tablet Substances 0.000 description 1
- 229940059904 light mineral oil Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 210000001853 liver microsome Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229940057917 medium chain triglycerides Drugs 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000009251 neurologic dysfunction Effects 0.000 description 1
- 208000015015 neurological dysfunction Diseases 0.000 description 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
- LYGJENNIWJXYER-BJUDXGSMSA-N nitromethane Chemical group [11CH3][N+]([O-])=O LYGJENNIWJXYER-BJUDXGSMSA-N 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 235000019645 odor Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229960000969 phenyl salicylate Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960000540 polacrilin potassium Drugs 0.000 description 1
- 229920001490 poly(butyl methacrylate) polymer Polymers 0.000 description 1
- 229920001084 poly(chloroprene) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920003223 poly(pyromellitimide-1,4-diphenyl ether) Polymers 0.000 description 1
- 229920002857 polybutadiene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229940068886 polyethylene glycol 300 Drugs 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 229920001195 polyisoprene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- WVWZXTJUCNEUAE-UHFFFAOYSA-M potassium;1,2-bis(ethenyl)benzene;2-methylprop-2-enoate Chemical compound [K+].CC(=C)C([O-])=O.C=CC1=CC=CC=C1C=C WVWZXTJUCNEUAE-UHFFFAOYSA-M 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229960001309 procaine hydrochloride Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 229940093625 propylene glycol monostearate Drugs 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 239000008175 ready-to-use sterile solution Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- 235000019613 sensory perceptions of taste Nutrition 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008137 solubility enhancer Substances 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 230000035923 taste sensation Effects 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 229920001897 terpolymer Polymers 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 230000009974 thixotropic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 229920011532 unplasticized polyvinyl chloride Polymers 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000002460 vibrational spectroscopy Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 238000003963 x-ray microscopy Methods 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Definitions
- solid forms comprising (E)-1-(4-(1-(((4-cyclohexyl-3-(trifluoromethyl)benzyl)oxy)imino)ethyl)-2-ethylbenzyl)azetidine-3-carboxylic acid, or a tautomer thereof.
- Pharmaceutical compositions comprising such solid forms and methods of use of such solid forms for treating, preventing, and managing various disorders are also provided herein.
- the immune system When the immune system functions normally, it produces a response intended to protect against harmful or foreign substances such as bacteria, parasites, and cancerous cells. Autoimmune diseases arise when the immune system attacks one or more of the body's normal constituents as if they were a foreign substance. These attacks cause inflammation and tissue damage that may lead to autoimmune disorders. There are more than 80 diseases that occur as a result of the body's autoimmune response to various harmful or foreign substances, affecting more than 23.5 million people in the United States.
- autoimmune or chronic inflammatory diseases include Graves' disease, Type 1 diabetes, multiple sclerosis, inflammatory bowel disease, systemic lupus, polymyositis, dermatomyositis, lupus nephritis, rheumatoid arthritis, and psoriasis.
- MS Multiple Sclerosis
- myelin the protective sheath that covers nerve fibers in the brain and spinal cord.
- relapsing forms the protective sheath that covers nerve fibers in the brain and spinal cord.
- progressive forms the most common neurologic, disabling disease in young adults.
- Permanent neurological dysfunction can result from incomplete recovery from acute relapses or as a consequence of slow progression of disability.
- amorphous solids are sometimes selected on the basis of, e.g., an enhanced dissolution profile, while crystalline solids may be desirable for properties such as, e.g., physical or chemical stability (see, e.g., S. R. Vippagunta et al., Adv. Drug. Deliv. Rev., (2001) 48:3-26; L. Yu, Adv. Drug. Deliv. Rev., (2001) 48:27-42).
- Solid forms comprising Compound 1 (e.g., crystalline forms, amorphous forms, polymorphs or mixtures thereof):
- described herein is a solid form comprising Compound 1, or a tautomer thereof:
- the solid form which has an X-ray powder diffraction pattern comprising three or more characteristic peaks at approximately 2.3, 3.9, 7.7, 11.5, or 20.9° 2 ⁇ .
- the solid form has an X-ray powder diffraction pattern comprising four or more characteristic peaks at approximately 2.3, 3.9, 7.7, 11.5, or 20.9° 2 ⁇ .
- the solid form has an X-ray powder diffraction pattern comprising five or more characteristic peaks at approximately 2.3, 3.9, 7.7, 11.5, or 20.9° 2 ⁇ .
- the solid form has an X-ray powder diffraction pattern substantially as shown in FIG. 1 .
- the solid form has a DSC thermogram comprising an endothermic event with a peak maximum temperature of about 54° C. and another endothermic event with an onset temperature of about 102° C.
- the solid form is solvated by isopropyl ether.
- the solid form which has an X-ray powder diffraction pattern comprising three or more characteristic peaks at approximately 2.3, 2.8, 7.7, 8.4, 11.5, or 20.9° 2 ⁇ .
- the solid form has an X-ray powder diffraction pattern comprising four or more characteristic peaks at approximately 2.3, 2.8, 7.7, 8.4, 11.5, or 20.9° 2 ⁇ .
- the solid form has an X-ray powder diffraction pattern comprising five or more characteristic peaks at approximately 2.3, 2.8, 7.7, 8.4, 11.5, or 20.9° 2 ⁇ .
- the solid form has an X-ray powder diffraction pattern comprising six characteristic peaks at approximately 2.3, 2.8, 7.7, 8.4, 11.5, or 20.9° 2 ⁇ . In a certain embodiment, the solid form has an X-ray powder diffraction pattern substantially as shown in FIG. 5 . In a certain embodiment, the solid form has a DSC thermograph comprising a first endothermic event with an onset temperature of about 40.2° C. and a peak maximum temperature of about 47.7° C. In a certain embodiment, the solid form is solvated by cyclohexane.
- the solid form which has an X-ray powder diffraction pattern comprising three or more characteristic peaks at approximately 2.2, 3.9, 6.5, 7.7, 11.5, or 20.9° 2 ⁇ .
- the solid form has an X-ray powder diffraction pattern comprising four or more characteristic peaks at approximately 2.2, 3.9, 6.5, 7.7, 11.5, or 20.9° 2 ⁇ .
- the solid form has an X-ray powder diffraction pattern comprising five or more characteristic peaks at approximately 2.2, 3.9, 6.5, 7.7, 11.5, or 20.9° 2 ⁇ .
- the solid form has an X-ray powder diffraction pattern comprising six characteristic peaks at approximately 2.2, 3.9, 6.5, 7.7, 11.5, or 20.9° 2 ⁇ . In a certain embodiment, the solid form has an X-ray powder diffraction pattern substantially as shown in FIG. 9 . In a certain embodiment, the solid form has a DSC thermogram comprising an endothermic event with an onset temperature of about 101.7° C. In a certain embodiment, the solid form is solvated by heptane.
- the solid form which has an X-ray powder diffraction pattern comprising three or more characteristic peaks at approximately 3.7, 7.3, 11.0, 18.3, or 22.9° 2 ⁇ .
- the solid form has an X-ray powder diffraction pattern comprising four or more characteristic peaks at approximately 3.7, 7.3, 11.0, 18.3, or 22.9° 2 ⁇ .
- the solid form has an X-ray powder diffraction pattern comprising five characteristic peaks at approximately 3.7, 7.3, 11.0, 18.3, or 22.9° 2 ⁇ .
- the solid form has an X-ray powder diffraction pattern substantially as shown in FIG. 13 .
- the solid form has a DSC thermogram comprising an endothermic event with an onset temperature of about 96° C. and a peak maximum temperature of about 111° C.
- the solid form is non-solvated.
- the solid form which has an X-ray powder diffraction pattern comprising three or more characteristic peaks at approximately 3.9, 7.7, 11.6, 14.3, 20.9, or 24.5° 2 ⁇ .
- the solid form has an X-ray powder diffraction pattern comprising four or more characteristic peaks at approximately 3.9, 7.7, 11.6, 14.3, 20.9, or 24.5° 2 ⁇ .
- the solid form has an X-ray powder diffraction pattern comprising five or more characteristic peaks at approximately 3.9, 7.7, 11.6, 14.3, 20.9, or 24.5° 2 ⁇ .
- the solid form has an X-ray powder diffraction pattern comprising six characteristic peaks at approximately 3.9, 7.7, 11.6, 14.3, 20.9, or 24.5° 2 ⁇ . In a certain embodiment, the solid form has an X-ray powder diffraction pattern substantially as shown in FIG. 17 . In a certain embodiment, the solid form has a DSC thermogram comprising an endothermic event with an onset temperature of about 106° C. In a certain embodiment, the solid form is non-solvated.
- the solid form which has an X-ray powder diffraction pattern comprising three or more characteristic peaks at approximately 3.3, 9.9, 14.8, 19.9, 20.4, or 23.5° 2 ⁇ .
- the solid form has an X-ray powder diffraction pattern comprising four or more characteristic peaks at approximately 3.3, 9.9, 14.8, 19.9, 20.4, or 23.5° 2 ⁇ .
- the solid form has an X-ray powder diffraction pattern comprising five or more characteristic peaks at approximately 3.3, 9.9, 14.8, 19.9, 20.4, or 23.5° 2 ⁇ .
- the solid form has an X-ray powder diffraction pattern comprising six characteristic peaks at approximately 3.3, 9.9, 14.8, 19.9, 20.4, or 23.5° 2 ⁇ . In a certain embodiment, the solid form has an X-ray powder diffraction pattern substantially as shown in FIG. 21 . In a certain embodiment, the solid form has a DSC thermogram comprising an endothermic event with an onset temperature of about 48° C. and a peak maximum temperature of about 63° C. In a certain embodiment, the solid form is solvated by dimethyl carbonate.
- the solid form which has an X-ray powder diffraction pattern comprising three or more characteristic peaks at approximately 3.6, 7.2, 10.8, 17.8, 18.0, 18.3, or 21.7° 2 ⁇ .
- the solid form has an X-ray powder diffraction pattern comprising four or more characteristic peaks at approximately 3.6, 7.2, 10.8, 17.8, 18.0, 18.3, or 21.7° 2 ⁇ .
- the solid form has an X-ray powder diffraction pattern comprising five or more characteristic peaks at approximately 3.6, 7.2, 10.8, 17.8, 18.0, 18.3, or 21.7° 2 ⁇ .
- the solid form has an X-ray powder diffraction pattern comprising six or more characteristic peaks at approximately 3.6, 7.2, 10.8, 17.8, 18.0, 18.3, or 21.7° 2 ⁇ . In a certain embodiment, the solid form has an X-ray powder diffraction pattern comprising seven characteristic peaks at approximately 3.6, 7.2, 10.8, 17.8, 18.0, 18.3, or 21.7° 2 ⁇ . In a certain embodiment, the solid form has an X-ray powder diffraction pattern substantially as shown in FIG. 25 . In a certain embodiment, the solid form has a DSC thermogram comprising an endothermic event with a peak maximum temperature of about 56° C. and a second endothermic event with a peak maximum temperature of about 94° C. In a certain embodiment, the solid form is hydrated.
- the solid form which has an X-ray powder diffraction pattern comprising three or more characteristic peaks at approximately 4.0, 12.0, 17.6, 20.1 or 21.5° 2 ⁇ .
- the solid form has an X-ray powder diffraction pattern comprising four or more characteristic peaks at approximately 4.0, 12.0, 17.6, 20.1 or 21.5° 2 ⁇ .
- the solid form an X-ray powder diffraction pattern comprising five characteristic peaks at approximately 4.0, 12.0, 17.6, 20.1 or 21.5° 2 ⁇ .
- the solid form has an X-ray powder diffraction pattern substantially as shown in FIG. 29 .
- the solid form has a DSC thermogram comprising an endothermic event with a peak maximum temperature of about 54° C. and a second endothermic event with an onset temperature of about 82° C. and a peak maximum temperature of about 93° C.
- the solid form is hydrated.
- compositions comprising one or more of the solid forms described herein.
- the solid form is no less than 95% pure.
- the pharmaceutical composition further comprises a second solid form described herein.
- the pharmaceutical composition further comprises an amorphous form of Compound 1.
- the pharmaceutical composition further comprises a pharmaceutically acceptable excipient or carrier.
- the pharmaceutical composition is a single unit dosage form.
- the pharmaceutical composition is a tablet.
- the pharmaceutical composition is a capsule.
- provided herein is a method of treating multiple sclerosis, wherein the method comprises administering to a patient in need thereof a therapeutically effective amount of a solid form described herein. In another embodiment, provided herein is a method of treating multiple sclerosis, wherein the method comprises administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition described herein.
- provided herein is a method of treating psoriasis, wherein the method comprises administering to a patient in need thereof a therapeutically effective amount of a solid form described herein.
- a method of treating psoriasis wherein the method comprises administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical formulation described herein.
- provided herein is a method of treating polymyositis, wherein the method comprises administering to a patient in need thereof a therapeutically effective amount of a solid form described herein.
- a method of treating polymyositis wherein the method comprises administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical formulation described herein.
- a solid form comprising Compound 1, or a tautomer thereof:
- a solid form comprising Compound 1, or a tautomer thereof:
- a solid form comprising Compound 1, or a tautomer thereof:
- a solid form comprising Compound 1, or a tautomer thereof:
- a solid form comprising Compound 1, or a tautomer thereof:
- a solid form comprising Compound 1, or a tautomer thereof:
- a solid form comprising Compound 1, or a tautomer thereof:
- a solid form comprising Compound 1, or a tautomer thereof:
- the solid form which has an X-ray powder diffraction pattern comprising three or more characteristic peaks at approximately 7.9, 11.9, 13.4, 15.7, 17.4, or 20.0° 2 ⁇ .
- the solid form has an X-ray powder diffraction pattern comprising four or more characteristic peaks at approximately 7.9, 11.9, 13.4, 15.7, 17.4, or 20.0° 2 ⁇ .
- the solid form has an X-ray powder diffraction pattern comprising five or more characteristic peaks at approximately 7.9, 11.9, 13.4, 15.7, 17.4, or 20.0° 2 ⁇ .
- the solid form has an X-ray powder diffraction pattern comprising six or more characteristic peaks at approximately 7.9, 11.9, 13.4, 15.7, 17.4, or 20.0° 2 ⁇ . In certain embodiments, the solid form has an X-ray powder diffraction pattern substantially as shown in FIG. 33 . In certain embodiments, the solid form has a DSC thermogram comprising an endothermic event with an onset temperature of 143.4° C.
- the solid form which has an X-ray powder diffraction pattern comprising three or more characteristic peaks at approximately 7.3, 8.0, 10.0, 10.9, 12.0, 17.5, or 20.1° 2 ⁇ .
- the solid form has an X-ray powder diffraction pattern comprising four or more characteristic peaks at approximately 7.3, 8.0, 10.0, 10.9, 12.0, 17.5, or 20.1° 2 ⁇ .
- the solid form has an X-ray powder diffraction pattern comprising five or more characteristic peaks at approximately 7.3, 8.0, 10.0, 10.9, 12.0, 17.5, or 20.1° 2 ⁇ .
- the solid form has an X-ray powder diffraction pattern comprising six or more characteristic peaks at approximately 7.3, 8.0, 10.0, 10.9, 12.0, 17.5, or 20.1° 2 ⁇ . In certain embodiments, the solid form has an X-ray powder diffraction pattern substantially as shown in FIG. 36 . In certain embodiments, the solid form has a DSC thermogram comprising endothermic events with peak maximum temperatures of approximately 98.9° C. and 113.7° C., respectively.
- the solid form has an X-ray powder diffraction pattern comprising three or more characteristic peaks at approximately 11.5, 12.0, 13.4, 17.5, 20.1, or 21.3° 2 ⁇ .
- the solid form has an X-ray powder diffraction pattern comprising four or more characteristic peaks at approximately 11.5, 12.0, 13.4, 17.5, 20.1, or 21.3° 2 ⁇ .
- the solid form has an X-ray powder diffraction pattern comprising five or more characteristic peaks at approximately 11.5, 12.0, 13.4, 17.5, 20.1, or 21.3° 2 ⁇ .
- the solid form has an X-ray powder diffraction pattern comprising six or more characteristic peaks at approximately 11.5, 12.0, 13.4, 17.5, 20.1, or 21.3° 2 ⁇ .
- the solid form has an X-ray powder diffraction pattern substantially as shown in FIG. 38 .
- the solid form which has an X-ray powder diffraction pattern comprising three or more characteristic peaks at approximately 7.2, 9.5, 12.0, 16.4, 18.2, or 22.8° 2 ⁇ .
- the solid form has an X-ray powder diffraction pattern comprising four or more characteristic peaks at approximately 7.2, 9.5, 12.0, 16.4, 18.2, or 22.8° 2 ⁇ .
- the solid form has an X-ray powder diffraction pattern comprising five or more characteristic peaks at approximately 7.2, 9.5, 12.0, 16.4, 18.2, or 22.8° 2 ⁇ .
- the solid form has an X-ray powder diffraction pattern comprising six or more characteristic peaks at approximately 7.2, 9.5, 12.0, 16.4, 18.2, or 22.8° 2 ⁇ . In certain embodiments, the solid form has an X-ray powder diffraction pattern substantially as shown in FIG. 40 .
- a solid form comprising Compound 1, or a tautomer thereof:
- the solid form which has an X-ray powder diffraction pattern comprising three or more characteristic peaks at approximately 12.0, 13.5, 17.7, 20.1, 21.6, or 23.7° 2 ⁇ .
- the solid form has an X-ray powder diffraction pattern comprising four or more characteristic peaks at approximately 12.0, 13.5, 17.7, 20.1, 21.6, or 23.7° 2 ⁇ .
- the solid form has an X-ray powder diffraction pattern comprising five or more characteristic peaks at approximately 12.0, 13.5, 17.7, 20.1, 21.6, or 23.7° 2 ⁇ .
- the solid form has an X-ray powder diffraction pattern comprising six or more characteristic peaks at approximately 12.0, 13.5, 17.7, 20.1, 21.6, or 23.7° 2 ⁇ . In certain embodiments, the solid form has an X-ray powder diffraction pattern substantially as shown in FIG. 42 . In certain embodiments, the solid form has a DSC thermogram comprising an endothermic event with an onset temperature of approximately 85.7° C.
- a solid form comprising Compound 1, or a tautomer thereof:
- a solid form comprising Compound 1, or a tautomer thereof:
- a solid form comprising Compound 1, or a tautomer thereof:
- a solid form comprising Compound 1, or a tautomer thereof:
- a solid form comprising Compound 1, or a tautomer thereof:
- FIG. 1 depicts a PXRD pattern of Form A of Compound 1.
- FIG. 2 depicts an FT-Raman spectrum of Form A of Compound 1.
- FIG. 3 depicts differential scanning calorimetry/thermal gravimetric analysis of Form A of Compound 1.
- FIG. 4 depicts polarized-light microscopy of Form A of Compound 1.
- FIG. 5 depicts a PXRD pattern of Form B of Compound 1.
- FIG. 6 depicts an FT-Raman spectrum of Form B of Compound 1.
- FIG. 7 depicts differential scanning calorimetry/thermal gravimetric analysis of Form B of Compound 1.
- FIG. 8 depicts polarized-light microscopy of Form B of Compound 1.
- FIG. 9 depicts a PXRD pattern of Form C of Compound 1.
- FIG. 10 depicts an FT-Raman spectrum of Form C of Compound 1.
- FIG. 11 depicts differential scanning calorimetry/thermal gravimetric analysis of Form C of Compound 1.
- FIG. 12 depicts polarized-light microscopy of Form C of Compound 1.
- FIG. 13 depicts a PXRD pattern of Form D of Compound 1.
- FIG. 14 depicts an FT-Raman spectrum of Form D of Compound 1.
- FIG. 15 depicts differential scanning calorimetry/thermal gravimetric analysis of Form D of Compound 1.
- FIG. 16 depicts polarized-light microscopy of Form D of Compound 1.
- FIG. 17 depicts a PXRD pattern of Form E of Compound 1.
- FIG. 18 depicts an FT-Raman spectrum of Form E of Compound 1.
- FIG. 19 depicts differential scanning calorimetry/thermal gravimetric analysis of Form E of Compound 1.
- FIG. 20 depicts polarized-light microscopy of Form E of Compound 1.
- FIG. 21 depicts a PXRD pattern of Form F of Compound 1.
- FIG. 22 depicts an FT-Raman spectrum of Form F of Compound 1.
- FIG. 23 depicts differential scanning calorimetry/thermal gravimetric analysis of Form F of Compound 1.
- FIG. 24 depicts polarized-light microscopy of Form F of Compound 1.
- FIG. 25 depicts a PXRD pattern of Form H of Compound 1.
- FIG. 26 depicts an FT-Raman spectrum of Form H of Compound 1.
- FIG. 27 depicts differential scanning calorimetry/thermal gravimetric analysis of Form H of Compound 1.
- FIG. 28 depicts polarized-light microscopy of Form H of Compound 1.
- FIG. 29 depicts a PXRD pattern of Form I of Compound 1.
- FIG. 30 depicts an FT-Raman spectrum of Form I of Compound 1.
- FIG. 31 depicts differential scanning calorimetry/thermal gravimetric analysis of Form I of Compound 1.
- FIG. 32 depicts polarized-light microscopy of Form I of Compound 1.
- FIG. 33 depicts a PXRD pattern of Form J of Compound 1.
- FIG. 34 depicts a Raman spectrum of Form J of Compound 1.
- FIG. 35 depicts differential scanning calorimetry/thermal gravimetric analysis of Form J of Compound 1.
- FIG. 36 depicts a PXRD pattern of Form K of Compound 1.
- FIG. 37 depicts differential scanning calorimetry/thermal gravimetric analysis of Form K of Compound 1.
- FIG. 38 depicts a PXRD pattern of Form L of Compound 1.
- FIG. 39 depicts a Raman spectrum of Form L of Compound 1.
- FIG. 40 depicts a PXRD pattern of Form M of Compound 1.
- FIG. 41 depicts a Raman spectrum of Form M of Compound 1.
- FIG. 42 depicts a PXRD pattern of Form N of Compound 1.
- FIG. 43 depicts a Raman spectrum of Form N of Compound 1.
- FIG. 44 depicts differential scanning calorimetry/thermal gravimetric analysis of Form N of Compound 1.
- the terms “about” and “approximately,” when used in connection with a numeric value or range of values which is provided to characterize a particular solid form e.g., a specific temperature or temperature range, such as, for example, that describes a melting, dehydration, desolvation, or glass transition temperature; a mass change, such as, for example, a mass change as a function of temperature or humidity; a solvent or water content, in terms of, for example, mass or a percentage; or a peak position, such as, for example, in analysis by, for example, infrared (IR) or Raman spectroscopy or X-ray powder diffractometry (PXRD); indicate that the value or range of values may deviate to an extent deemed reasonable to one of ordinary skill in the art while still describing the solid form.
- IR infrared
- PXRD X-ray powder diffractometry
- Techniques for characterizing crystal forms and amorphous forms include, but are not limited to, thermal gravimetric analysis (TGA), differential scanning calorimetry (DSC), PXRD, single-crystal X-ray diffractometry, vibrational spectroscopy, e.g., IR and Raman spectroscopy, solid-state and solution nuclear magnetic resonance (NMR) spectroscopy, optical microscopy, hot stage optical microscopy, scanning electron microscopy (SEM), electron crystallography and quantitative analysis, particle size analysis (PSA), surface area analysis, solubility studies, and dissolution studies.
- TGA thermal gravimetric analysis
- DSC differential scanning calorimetry
- PXRD single-crystal X-ray diffractometry
- vibrational spectroscopy e.g., IR and Raman spectroscopy
- NMR nuclear magnetic resonance
- optical microscopy e.g., hot stage optical microscopy
- SEM scanning electron microscopy
- SEM scanning electron microscopy
- the terms “about” and “approximately,” when used in this context, indicate that the numeric value or range of values may vary within 30%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1.5%, 1%, 0.5%, or 0.25% of the recited value or range of values.
- the value of a PXRD peak position may vary by up to ⁇ 0.2 degrees two theta while still describing the particular PXRD peak.
- a crystalline that is “pure,” i.e., substantially free of other crystalline or amorphous solid forms, contains less than about 10% by weight of one or more other crystalline or amorphous solid forms, less than about 5% by weight of one or more other crystalline or amorphous solid forms, less than about 3% by weight of one or more other crystalline or amorphous solid forms, or less than about 1% by weight of one or more other crystalline or amorphous solid forms.
- crystalline when used to describe a compound, substance, modification, material, component or product, unless otherwise specified, means that the compound, substance, modification, material, component or product is substantially crystalline as determined by X-ray diffraction. See, e.g., Remington: The Science and Practice of Pharmacy, 21st edition, Lippincott, Williams and Wilkins, Baltimore, Md. (2005); The United States Pharmacopeia, 23 rd ed., 1843-1844 (1995).
- a solid form that is “substantially physically pure” is substantially free from other solid forms.
- a crystal form that is substantially physically pure contains less than about 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.05%, or 0.01% of one or more other solid forms on a weight basis.
- the detection of other solid forms can be accomplished by any method apparent to a person of ordinary skill in the art, including, but not limited to, diffraction analysis, thermal analysis, elemental combustion analysis and/or spectroscopic analysis.
- a solid form that is “substantially chemically pure” is substantially free from other chemical compounds (i.e., chemical impurities).
- a solid form that is substantially chemically pure contains less than about 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.05%, or 0.01% of one or more other chemical compounds on a weight basis.
- the detection of other chemical compounds can be accomplished by any method apparent to a person of ordinary skill in the art, including, but not limited to, methods of chemical analysis, such as, e.g., mass spectrometry analysis, spectroscopic analysis, thermal analysis, elemental combustion analysis and/or chromatographic analysis.
- methods of chemical analysis such as, e.g., mass spectrometry analysis, spectroscopic analysis, thermal analysis, elemental combustion analysis and/or chromatographic analysis.
- a chemical compound, solid form, or composition that is “substantially free” of another chemical compound, solid form, or composition means that the compound, solid form, or composition contains, in certain embodiments, less than about 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.4%, 0.3%, 0.2% 0.1%, 0.05%, or 0.01% by weight of the other compound, solid form, or composition.
- solvate refers to a solid form of a substance which contains solvent.
- hydrate and “hydrated” refer to a solvate wherein the solvent is water.
- Polymorphs of solvates refer to the existence of more than one solid form for a particular solvate composition.
- polymorphs of hydrates refer to the existence of more than one solid form for a particular hydrate composition.
- solvated solvate refers to a solid form of a substance which can be made by removing the solvent from a solvate.
- solvate and solvated can also refer to a solvate of a salt, cocrystal, or molecular complex.
- hydrate and hydrated can also refer to a hydrate of a salt, cocrystal, or molecular complex.
- composition is intended to encompass a product comprising the specified ingredient(s) (and in the specified amount(s), if indicated), as well as any product which results, directly or indirectly, from combination of the specified ingredient(s) in the specified amount(s).
- pharmaceutically acceptable it is meant a diluent, excipient, or carrier in a formulation must be compatible with the other ingredient(s) of the formulation and not deleterious to the recipient thereof.
- solid form refers to a physical form which is not predominantly in a liquid or a gaseous state.
- solid type and “type” are used interchangeably herein with “solid form”.
- solid form refers to Compound 1 refers to a physical form comprising Compound 1 which is not predominantly in a liquid or a gaseous state.
- a solid form may be a crystalline form or a mixture thereof.
- a solid form may be a liquid crystal.
- solid forms comprising Compound 1 includes crystal forms comprising Compound 1.
- the solid form of Compound 1 is Form A, Form B, Form C, Form D, Form E, Form F, Form G, Form H, Form I, the amorphous solid, or a mixture thereof.
- the solid form of Compound 1 is Form A, Form B, Form C, Form D, Form E, Form F, Form G, Form H, Form I, Form J, Form K, Form L, Form M, Form N, the amorphous solid, or a mixture thereof.
- crystalline when used to describe a compound, substance, modification, material, component or product, unless otherwise specified, means that the compound, substance, modification, material, component or product is substantially crystalline as determined by X-ray diffraction. See, e.g., Remington: The Science and Practice of Pharmacy, 21st edition, Lippincott, Williams and Wilkins, Baltimore, Md. (2005); The United States Pharmacopeia, 23 rd ed., 1843-1844 (1995).
- crystal form or “crystalline form” refers to a solid form that is crystalline.
- a crystal form of a substance may be substantially free of amorphous solids and/or other crystal forms.
- a crystal form of a substance may contain less than about 1%, less than about 2%, less than about 3%, less than about 4%, less than about 5%, less than about 6%, less than about 7%, less than about 8%, less than about 9%, less than about 10%, less than about 15%, less than about 20%, less than about 25%, less than about 30%, less than about 35%, less than about 40%, less than about 45%, or less than about 50% by weight of one or more amorphous solids and/or other crystal forms.
- a crystal form of a substance may be physically and/or chemically pure.
- a crystal form of a substance may be about 99%, about 98%, about 97%, about 96%, about 95%, about 94%, about 93%, about 92%, about 91%, or about 90% physically and/or chemically pure.
- amorphous or “amorphous solid form” means that the substance, component, or product in question is not substantially crystalline as determined by X-ray diffraction.
- amorphous solid describes a disordered solid form, i.e., a solid form lacking long range crystalline order.
- an amorphous solid form of a substance may be substantially free of other amorphous solid form and/or crystal forms.
- an amorphous solid form of a substance may contain less than about 1%, less than about 2%, less than about 3%, less than about 4%, less than about 5%, less than about 10%, less than about 15%, less than about 20%, less than about 25%, less than about 30%, less than about 35%, less than about 40%, less than about 45%, or less than about 50% by weight of one or more other amorphous solid forms and/or crystal forms on a weight basis.
- an amorphous solid form of a substance may be physically and/or chemically pure.
- an amorphous solid form of a substance be about 99%, about 98%, about 97%, about 96%, about 95%, about 94%, about 93%, about 92%, about 91%, or about 90% physically and/or chemically pure.
- tautomers refers to isomeric forms of a compound that are in equilibrium with each other.
- concentrations of the isomeric forms will depend on the environment the compound is found in and may be different depending upon, for example, whether the compound is a solid or is in an organic or aqueous solution.
- pyrazoles may exhibit the following isomeric forms, which are referred to as tautomers of each other:
- zwitterion(s) means compound(s) containing both a basic moiety, including but not limited to, for example, pyridine and imidazole; and an acidic moiety including but not limited to, for example, a carboxylic acid.
- treating means an alleviation, in whole or in part, of the disease or disorder, or symptoms associated with the disease or disorder, or slowing, or halting of further progression or worsening of the disease or disorder, or symptoms associated with the disease or disorder.
- the term “preventing” means prevention of the onset, recurrence, or spread of the disease or disorder, or symptoms associated with the disorder or disease, in a patient at risk for developing the disease or disorder.
- the term “therapeutically effective amount” of a compound refers to an amount sufficient to provide a therapeutic benefit in the treatment or management of the disease or to delay or minimize one or more symptoms associated with the disease. Further, a therapeutically effective amount of a compound means that amount of therapeutic agent alone, or in combination with other therapies, provides a therapeutic benefit in the treatment or management of the disease. The term “therapeutically effective amount” can encompass an amount that improves overall therapy, reduces or avoids symptoms or causes of disease, or enhances the therapeutic efficacy of another therapeutic agent.
- the term “subject” or “patient” includes an animal, including, but not limited to, an animal such a cow, monkey, horse, sheep, pig, chicken, turkey, quail, cat, dog, mouse, rat, rabbit or guinea pig, in one embodiment a mammal, in another embodiment a human, in another embodiment a cell from any one of the foregoing animals.
- a subject or patient is a non-human animal, in another embodiment a non-human mammal.
- a subject or patient is a human having or at risk for having an autoimmune or chronic inflammatory disease.
- the autoimmune or chronic inflammatory disease is polymyositis, dermatomyositis, lupus nephritis, rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, psoriasis, amyotrophic lateral sclerosis, autoimmune myositis, systemic lupus, Type 1 diabetes, biliary cirrhosis, bullous pemphigoid, sarcoidosis, Wegener's granulomatosis, ichthyosis, Graves' disease or multiple sclerosis.
- a subject or patient is a human having or at risk for having a neurological disorder.
- the neurological disorder is Rett Syndrome.
- a subject or patient is a human having or at risk for having renal or hepatic impairment.
- a subject or patient is a human having or at risk for having a disease or disorder associated with sphingosine 1-phosphate, including but not limited to multiple sclerosis, relapse-remitting multiple sclerosis, systemic lupus, Type 1 diabetes, amyotrophic lateral sclerosis, refractory rheumatoid arthritis, inflammatory bowel disease, biliary cirrhosis, Crohn's disease, ulcerative colitis, bullous pemphigoid, sarcoidosis, psoriasis, autoimmune myositis, Wegener's granulomatosis, ichthyosis, and Graves' disease.
- a disease or disorder associated with sphingosine 1-phosphate including but not limited to multiple sclerosis, relapse-remitting multiple sclerosis, systemic lupus, Type 1 diabetes, amyotrophic lateral sclerosis, refractory rheumatoid arthritis, inflammatory
- a subject or patient is a human having or at risk for having a disease or disorder associated with the interferon alpha receptor 1, including but not limited to psoriasis, ulcerative colitis, systemic lupus, multiple sclerosis, and rheumatoid arthritis.
- a subject or patient is a human having a disease or disorder mediated by lymphocyte interactions, such as, for example, in transplantation, such as acute or chronic rejection of cell, tissue or organ allo- or xenografts or delayed graft function, graft versus host disease; autoimmune diseases, e.g., rheumatoid arthritis, systemic lupus erythematosus, hashimoto's thyroidis, multiple sclerosis, myasthenia gravis, diabetes type I or II and the disorders associated therewith, vasculitis, pernicious anemia, Sjoegren syndrome, uveitis, psoriasis, Graves ophthalmopathy, alopecia areata and others; allergic diseases, e.g., allergic asthma, atopic dermatitis, allergic rhinitis/conjunctivitis, allergic contact dermatitis; inflammatory diseases optionally with underlying aberrant reactions, e.g., inflammatory mediated by lymphocyte
- cell, tissue or solid organ transplants include, e.g., pancreatic islets, stem cells, bone marrow, corneal tissue, neuronal tissue, heart, lung, combined heart-lung, kidney, liver, bowel, pancreas, trachea or oesophagus.
- solid forms, formulations and methods of use provided herein relate to solid forms (e.g., crystalline forms, amorphous forms, polymorphs or mixtures thereof)) comprising Compound 1:
- Compound 1 can be prepared by methods known in the art. See, e.g., International Patent Application Publication No. WO 2013/113915 A1.
- solid forms comprising Compound 1, or a tautomer thereof.
- the solid form is crystalline.
- the solid form is a single-component solid form.
- the solid form is a hydrate.
- the solid form is an anhydrate.
- the solid form is a solvate.
- the solid form is non-solvated.
- certain solid forms are characterized by physical properties, e.g., stability, solubility and dissolution rate, appropriate for pharmaceutical and therapeutic dosage forms.
- certain solid forms are characterized by physical properties (e.g., density, compressibility, hardness, morphology, cleavage, stickiness, solubility, water uptake, electrical properties, thermal behavior, solid-state reactivity, physical stability, and chemical stability) affecting particular processes (e.g., yield, filtration, washing, drying, milling, mixing, tableting, flowability, dissolution, formulation, and lyophilization) which make certain solid forms suitable for the manufacture of a solid dosage form.
- Such properties can be determined using particular analytical chemical techniques, including solid-state analytical techniques (e.g., X-ray diffraction, microscopy, spectroscopy and thermal analysis), as described herein and known in the art.
- the solid forms comprising Compound 1, or a tautomer thereof, provided herein may be characterized using a number of methods known to a person skilled in the art, including, but not limited to, single crystal X-ray diffraction, X-ray powder diffraction (PXRD), microscopy (e.g., optical microscopy, scanning electron microscopy (SEM)), thermal analysis (e.g., differential scanning calorimetry (DSC), thermal gravimetric analysis (TGA), and hot-stage microscopy), dynamic vapor sorption (DVS), spectroscopy (e.g., infrared, Raman, and nuclear magnetic resonance), high performance liquid chromatography (HPLC).
- the particle size and size distribution of the solid form provided herein may be determined by conventional methods, such as laser light scattering technique.
- the solid forms comprising Compound 1, or a tautomer thereof, provided herein may be characterized using a number of methods known to a person skilled in the art, including, but not limited to, single crystal X-ray diffraction, X-ray powder diffraction (PXRD), microscopy (e.g., optical microscopy, scanning electron microscopy (SEM)), thermal analysis (e.g., differential scanning calorimetry (DSC), thermal gravimetric analysis (TGA), and hot-stage microscopy), dynamic vapor sorption (DVS), spectroscopy (e.g., infrared, Raman, and nuclear magnetic resonance), high performance liquid chromatography (HPLC).
- the particle size and size distribution of the solid form provided herein may be determined by conventional methods, such as laser light scattering technique.
- the purity of the solid forms provided herein may be determined by standard analytical methods, such as thin layer chromatography (TLC), gel electrophoresis, gas chromatography, high performance liquid chromatography (HPLC), and mass spectrometry.
- TLC thin layer chromatography
- HPLC high performance liquid chromatography
- methods for making a solid form comprising Compound 1, or a tautomer thereof comprising 1) obtaining a slurry of Compound 1 in a solvent or solvent system; 2) stirring the slurry for a period of time (e.g., about 72 h) while cycling the temperature (e.g., between about 5° C. and about 40° C.); and 3) collecting solids from the slurry by filtration and optionally drying the collected solids to yield a solid form comprising Compound 1.
- the methods for making a solid form comprising Compound 1 are equilibration experiments, such as slurry experiments.
- the solvent is isopropyl ether, cyclohexane, heptanes, dimethyl carbonate, or water.
- the collected solids are dried using a flow of an inert gas, such as nitrogen or argon.
- the collected solids are dried under vacuum at a certain temperature (e.g., 65° C.).
- the collected solids are dried using a combination of a flow of an inert gas, such as nitrogen or argon, under vacuum at a certain temperature (e.g., 65° C.).
- a solid form comprising Compound 1, or a tautomer thereof comprising 1) dissolving Compound 1 in a solvent or solvent system to yield a solution; 2) filtering the solution if Compound 1 does not dissolve completely; 3) evaporating the supernatant at a certain temperature (e.g., ambient temperature) over a period of time (e.g., 14 days) to yield a solid form comprising Compound 1.
- the evaporation step further comprises evaporating the solution under an inert gas, such as nitrogen or argon.
- the solvent system is dimethylformamide/water (1:2).
- the methods for making a solid form comprising Compound 1 are evaporation experiments.
- a solid form comprising Compound 1, or a tautomer thereof comprising 1) obtaining a solution of Compound 1 in a solvent or solvent system at a first temperature (e.g., about 40° C.); 2) filtering the solution if there is precipitation and isolating the solids; 3) cooling the filtered solution slowly to a second temperature (e.g., about 4° C.) over a period of time (e.g., 7 days); and 5) isolating solids from the solution and optionally drying the isolated solids to yield a solid form comprising Compound 1.
- the solvent system is methyl isobutyl ketone/heptane (1:2).
- the methods for making a solid form comprising Compound 1 are cooling recrystallization experiments.
- a solid form comprising Compound 1, or a tautomer thereof, comprising 1) obtaining a solution of Compound 1 in a solvent or solvent system at a first temperature (e.g., ambient temperature); 2) adding an anti-solvent into the saturated solution at the first temperature; 3) stirring the solution for a period of time (e.g., overnight); 4) cycling the temperature (e.g., between about 20° C.
- a first temperature e.g., ambient temperature
- a first temperature e.g., ambient temperature
- an anti-solvent into the saturated solution at the first temperature
- stirring the solution for a period of time e.g., overnight
- cycling the temperature e.g., between about 20° C.
- the solvent is dimethylformamide and the anti-solvent is water. In certain embodiments, the solvent is 2-propanol and the anti-solvent is water.
- a solid form comprising Compound 1, or a tautomer thereof, comprising 1) obtaining a slurry of Compound 1 in a solvent or solvent system; 2) seeding the slurry with a small amount of a solid form described herein (e.g., Form D or Form I); 3) stirring the slurry for a period of time (e.g., 2 days) while cycling the temperature (e.g., between about 5° C. and 30° C.); and 4) collecting solids from the slurry by centrifugation followed by decanting, washing and drying in a centrifuge evaporator to yield a solid form comprising Compound 1.
- the solvent is water.
- the solvent is nitromethane, acetonitrile, acetonitrile/water (9:1), octane/ethyl acetate (9:1), acetone/water (4:1), water/1-propanol (9:1), acetonitrile/toluene (9:1), isopropyl ether/acetonitrile (1:2), octane/acetone (9:1), acetonitrile/ methyl t-butyl ether (9:1), or acetonitrile/ methyl isobutyl ketone (9:1).
- a solid form comprising Compound 1, or a tautomer thereof, comprising 1) mixing Compound 1 with a solvent or solvent system; 2) sonicating the mixture; 3) filtering the mixture; 4) evaporating the filtrate to dryness; 5) adding solvent to the dried sample to obtain a clear solution; 6) stirring the solution at a certain temperature for a certain time; 7) filtering the mixture; and 8) drying the resulting solid in a vacuum oven to yield a solid form comprising Compound 1.
- the solvent is ethyl methyl ketone.
- the certain temperature is ambient temperature and the certain time is about one day.
- a solid form comprising Compound 1, or a tautomer thereof, comprising 1) drying Compound 1 in a vacuum oven; 2) mixing the dried Compound 1 with a solvent or solvent system; 3) filtering the mixture; 4) evaporating the filtrate until precipitates are visually observed; 5) stirring the resulting mixture at a certain temperature for a certain time; 6) filtering the mixture; and 7) drying the resulting solid in a vacuum oven to yield a solid form comprising Compound 1.
- the solvent is ethyl methyl ketone.
- the certain temperature is ambient temperature and the certain time is about one day.
- a solid form comprising Compound 1, or a tautomer thereof comprising 1) drying a solid form of Compound 1 described herein (e.g., Form K) in a vacuum oven at a certain temperature for a certain time; 2) heating a portion of the dried solid at a certain rate on DSC in a vessel to yield a solid form comprising Compound 1.
- the certain temperature is 35° C. and the certain time is two days.
- the portion of the dried solid is heated to 121° C. at a rate of 10° C./min.
- the portion of the dried solid is heated to 102° C. at a rate of 10° C./min.
- the vessel is a crimped aluminum pan with a pin hole on its lid.
- a solid form comprising Compound 1, or a tautomer thereof comprising 1) mixing a solid form of Compound 1 described herein (e.g., Form E) with a solvent or solvent system; 2) stirring the resulting mixture at a certain temperature for a certain time; 3) filtering the mixture; and 4) drying the resulting solid in a vacuum oven to yield a solid form comprising Compound 1.
- the solvent is water.
- the water is Milli-Q water.
- the certain temperature is ambient temperature and the certain time is five days.
- Form A is Form A.
- Form A is a solid form of Compound 1. In one embodiment, Form A is solvated by isopropyl ether. In one embodiment, Form A is crystalline. In one embodiment, Form A is moderately crystalline.
- a slurry of Compound 1 in a solvent or solvent system comprising: 1) obtaining a slurry of Compound 1 in a solvent or solvent system; 2) stirring the slurry for a period of time (e.g., about 72 h) while cycling the temperature (e.g., between about 5° C. and about 40° C.); and 3) collecting solids from the slurry by filtration and optionally drying the collected solids to yield Form A of Compound 1.
- the solvent is isopropyl ether, cyclohexane, heptanes, dimethyl carbonate, or water.
- the solvent is isopropyl ether.
- Form A having an FT-Raman Spectrum as depicted in FIG. 2 .
- a solid form e.g., Form A of Compound 1, having a DSC thermograph substantially as depicted in FIG. 3 comprising an endothermic event with a peak maximum temperature of about 54° C.
- a solid form e.g., Form A of Compound 1, having a DSC endothermic event with an onset temperature of about 102° C. when heated to 300° C.
- a solid form e.g., Form A of Compound 1, having a TGA thermogram corresponding substantially to the representative TGA thermogram as depicted in FIG. 3 .
- the crystalline form exhibits a TGA thermogram comprising a total mass loss of approximately 6.2% of the total mass of the sample when heated from approximately 25° C. to approximately 150° C.
- the crystalline form loses about 6.2% its total mass when heated from about ambient temperature to about 150° C.
- a solid form provided herein is substantially crystalline, as indicated by, e.g., X-ray powder diffraction measurements.
- a solid form having an X-ray powder diffraction pattern (XRPD) substantially as shown in FIG. 1 e.g., Form A.
- a solid form provided herein has one or more characteristic X-ray powder diffraction peaks at approximately 2.3, 3.9, 6.9, 7.7, 9.2, 9.9, 11.5, 12.1, 14.3, 15.5, 18.2, 19.3, 20.9, 21.7, 23.2, 24.5, or 32.0° 2 ⁇ ( ⁇ 0.2° 2 ⁇ ) or ( ⁇ 0.1° 2 ⁇ ) as depicted in FIG. 1 .
- a solid form provided herein, e.g., Form A has one, two, three, four, or five characteristic X-ray powder diffraction peaks at approximately 2.3, 3.9, 7.7, 11.5, or 20.9° 2 ⁇ ( ⁇ 0.2° 2 ⁇ ).
- the solid form is Form A.
- Form A is substantially pure.
- the substantially pure Form A is substantially free of other solid forms, including but not limited to amorphous solid.
- the substantially pure Form A is substantially free of Form B, Form C, Form D, Form E, Form F, Form G, Form H, or Form I.
- the purity of the substantially pure Form A is no less than about 95%, no less than about 96%, no less than about 97%, no less than about 98%, no less than about 98.5%, no less than about 99%, no less than about 99.5%, or no less than about 99.8%.
- the substantially pure Form A is substantially free of Form J, Form K, Form L, Form M, or Form N.
- Form A is mixed with other solid forms, including but not limited to the amorphous solid.
- Form A is mixed with at least one of Form B, Form C, Form D, Form E, Form F, Form G, Form H, or Form I.
- Form A is mixed with at least one of Form B, Form C, Form D, Form E, Form F, Form G, Form H, Form I, Form J, Form K, Form L, Form M, or Form N.
- Form A comprises a free base of Compound 1. In one embodiment, Form A comprises a free acid of Compound 1. In one embodiment, Form A comprises a zwitterion of Compound 1.
- Form B is Form B.
- Form B is a solid form comprising Compound 1. In one embodiment, Form B is solvated by cyclohexane. In one embodiment, Form B is crystalline. In one embodiment, Form B is moderately crystalline.
- a slurry of Compound 1 in a solvent or solvent system comprising: 1) obtaining a slurry of Compound 1 in a solvent or solvent system; 2) stirring the slurry for a period of time (e.g., about 72 h) while cycling the temperature (e.g., between about 5° C. and about 40° C.); and 3) collecting solids from the slurry by filtration and optionally drying the collected solids to yield Form B of Compound 1.
- the solvent is isopropyl ether, cyclohexane, heptanes, dimethyl carbonate, or water.
- the solvent is cyclohexane.
- Form B having an FT-Raman Spectrum as depicted in FIG. 6 .
- a solid form e.g., Form B of Compound 1, having a DSC thermograph substantially as depicted in FIG. 7 comprising a first endothermic event with an onset temperature of about 40.2° C. and a peak maximum temperature of about 47.4° C.
- a solid form e.g., Form B of Compound 1, having a TGA thermogram corresponding substantially to the representative TGA thermogram as depicted in FIG. 7 .
- the crystalline form exhibits a TGA thermogram comprising a total mass loss of approximately 8.5% of the total mass of the sample when heated from approximately 25° C. to approximately 150° C.
- the crystalline form loses about 8.5% its total mass when heated from about ambient temperature to about 150° C.
- a solid form provided herein e.g., Form B is substantially crystalline, as indicated by, e.g., X-ray powder diffraction measurements.
- a solid form having an X-ray powder diffraction pattern (XRPD) substantially as shown in FIG. 5 e.g., Form B.
- a solid form provided herein e.g., Form B
- a solid form provided herein has one, two, three, four, five, or six characteristic X-ray powder diffraction peaks at approximately 2.3, 2.8, 7.7, 8.4, 11.5, or 20.9° 2 ⁇ ( ⁇ 0.2° 2 ⁇ ).
- the solid form is Form B.
- Form B is substantially pure.
- the substantially pure Form B is substantially free of other solid forms, including but not limited to amorphous solid.
- the substantially pure Form B is substantially free of Form A, Form C, Form D, Form E, Form F, Form G, Form H, or Form I.
- Form B exists in a mixture with Form E.
- the purity of the substantially pure Form B is no less than about 95%, no less than about 96%, no less than about 97%, no less than about 98%, no less than about 98.5%, no less than about 99%, no less than about 99.5%, or no less than about 99.8%.
- the substantially pure Form B is substantially free of Form J, Form K, Form L, Form M, or Form N.
- Form B is mixed with other solid forms, including but not limited to the amorphous solid. In certain embodiments, Form B is mixed with at least one of Form A, Form C, Form D, Form E, Form F, Form G, Form H, or Form I. In certain embodiments, Form B is mixed with at least one of Form A, Form C, Form D, Form E, Form F, Form G, Form H, Form I, Form J, Form K, Form L, Form M, or Form N.
- Form B comprises a free base of Compound 1. In one embodiment, Form B comprises a free acid of Compound 1. In one embodiment, Form B comprises a zwitterion of Compound 1.
- Form C is Form C.
- Form C is a solid form comprising Compound 1. In one embodiment, Form C is solvated by heptane. In one embodiment, Form C is crystalline. In one embodiment, Form C is moderately crystalline.
- a slurry of Compound 1 in a solvent or solvent system comprising: 1) obtaining a slurry of Compound 1 in a solvent or solvent system; 2) stirring the slurry for a period of time (e.g., about 72 h) while cycling the temperature (e.g., between about 5° C. and about 40° C.); and 3) collecting solids from the slurry by filtration and optionally drying the collected solids to yield Form C of Compound 1.
- the solvent is isopropyl ether, cyclohexane, heptane, dimethyl carbonate, or water.
- the solvent is heptane.
- Form C having an FT-Raman Spectrum as depicted in FIG. 10 .
- a solid form e.g., Form C of Compound 1, having a DSC thermograph substantially as depicted in FIG. 11 comprising an endothermic event with an onset temperature of about 101.7° C.
- a solid form e.g., Form C of Compound 1, having a TGA thermograph corresponding substantially to the representative TGA thermograph as depicted in FIG. 11 .
- the crystalline form exhibits a TGA thermogram comprising a total mass loss of approximately 14.3% of the total mass of the sample when heated from approximately 28° C. to approximately 150° C.
- the crystalline form loses about 14.3% of its total mass when heated from about ambient temperature to about 150° C.
- a solid form provided herein is substantially crystalline, as indicated by, e.g., X-ray powder diffraction measurements.
- a solid form having an X-ray powder diffraction pattern (XRPD) substantially as shown in FIG. 9 e.g., Form C.
- a solid form provided herein has one or more characteristic X-ray powder diffraction peaks at approximately 2.2, 3.9, 6.5, 7.7, 8.7, 9.9, 11.5, 14.3, 15.6, 18.3, 19.3, 20.9, 21.8, 23.2, 24.5, and 32.0° 2 ⁇ ( ⁇ 0.2° 2 ⁇ ) or ( ⁇ 0.1° 2 ⁇ ) as depicted in FIG. 9 .
- a solid form provided herein has one, two, three, four, five, or six characteristic X-ray powder diffraction peaks at approximately 2.2, 3.9, 6.5, 7.7, 11.5, or 20.9° 2 ⁇ ( ⁇ 0.2° 2 ⁇ ).
- the solid form is Form C.
- Form C is substantially pure.
- the substantially pure Form C is substantially free of other solid forms, including but not limited to amorphous solid.
- the substantially pure Form C is substantially free of Form A, Form B, Form D, Form E, Form F, Form G, Form H, or Form I.
- the purity of the substantially pure Form C is no less than about 95%, no less than about 96%, no less than about 97%, no less than about 98%, no less than about 98.5%, no less than about 99%, no less than about 99.5%, or no less than about 99.8%.
- the substantially pure Form C is substantially free of Form J, Form K, Form L, Form M, or Form N.
- Form C is mixed with other solid forms, including but not limited to the amorphous solid. In certain embodiments, Form C is mixed with at least one of Form A, Form B, Form D, Form E, Form F, Form G, Form H, or Form I. In certain embodiments, Form C is mixed with at least one of Form A, Form B, Form D, Form E, Form F, Form G, Form H, Form I, Form J, Form K, Form L, Form M, or Form N.
- Form C comprises a free base of Compound 1. In one embodiment, Form C comprises a free acid of Compound 1. In one embodiment, Form C comprises a zwitterion of Compound 1.
- Form D is Form D.
- Form D is a solid form comprising Compound 1. In one embodiment, Form D is non-solvated. In one embodiment, Form D is crystalline. In one embodiment, Form D is moderately crystalline.
- a slurry of Compound 1 in a solvent or solvent system comprising: 1) obtaining a slurry of Compound 1 in a solvent or solvent system; 2) stirring the slurry for a period of time (e.g., about 72 h) while cycling the temperature (e.g., between about 5° C. and about 40° C.); and 3) collecting solids from the slurry by filtration and drying the collected solids to yield Form D of Compound 1.
- the solvent is isopropyl ether, cyclohexane, heptanes, dimethyl carbonate, or water. In a particular embodiment, the solvent is dimethyl carbonate.
- the collected solids are dried using a flow of an inert gas, such as nitrogen or argon. In certain embodiments, the collected solids are dried under vacuum at 65° C. In a particular embodiment, the collected solids are dried using a flow of an inert gas, such as nitrogen or argon, under vacuum at 65° C.
- an inert gas such as nitrogen or argon
- Form D having an FT-Raman Spectrum as depicted in FIG. 14 .
- a solid form e.g., Form D of Compound 1, having a DSC thermogram substantially as depicted in FIG. 15 comprising an endothermic event with an onset temperature of about 96° C. and a peak maximum temperature of about 111° C.
- a solid form e.g., Form D of Compound 1, having a TGA thermogram corresponding substantially to the representative TGA thermogram as depicted in FIG. 15 .
- the crystalline form exhibits a TGA thermogram comprising a total mass loss of approximately 0.4% of the total mass of the sample when heated from approximately 25° C. and 125° C.
- a solid form provided herein is substantially crystalline, as indicated by, e.g., X-ray powder diffraction measurements.
- a solid form having an X-ray powder diffraction pattern (XRPD) substantially as shown in FIG. 13 e.g., Form D.
- XRPD X-ray powder diffraction pattern
- a solid form provided herein, e.g., Form D has one or more characteristic X-ray powder diffraction peaks at approximately 2.8, 3.7, 7.3, 11.0, 14.4, 16.4, 18.3, 20.8, or 22.9° 2 ⁇ ( ⁇ 0.2° 2 ⁇ ) or ( ⁇ 0.1° 2 ⁇ ) as depicted in FIG. 13 .
- a solid form provided herein has one, two, three, four, or five characteristic X-ray powder diffraction peaks at approximately 3.7, 7.3, 11.0, 18.3, or 22.9° 2 ⁇ ( ⁇ 0.2° 2 ⁇ ).
- the solid form is Form D.
- Form D is substantially pure.
- the substantially pure Form D is substantially free of other solid forms, including but not limited to amorphous solid.
- the substantially pure Form D is substantially free of Form A, Form B, Form C, Form E, Form F, Form G, Form H, or Form I.
- the purity of the substantially pure Form D is no less than about 95%, no less than about 96%, no less than about 97%, no less than about 98%, no less than about 98.5%, no less than about 99%, no less than about 99.5%, or no less than about 99.8%.
- the substantially pure Form D is substantially free of Form J, Form K, Form L, Form M, or Form N.
- Form D is mixed with other solid forms, including but not limited to the amorphous solid. In certain embodiments, Form D is mixed with at least one of Form A, Form B, Form C, Form E, Form F, Form G, Form H, or Form I. In certain embodiments, Form D is mixed with at least one of Form A, Form B, Form C, Form E, Form F, Form G, Form H, Form I, Form J, Form K, Form L, Form M, or Form N.
- Form D comprises a free base of Compound 1. In one embodiment, Form D comprises a free acid of Compound 1. In one embodiment, Form D comprises a zwitterion of Compound 1.
- Form E is Form E.
- Form E is a solid form comprising Compound 1. In one embodiment, Form E is non-solvated. In one embodiment, Form E is crystalline.
- methods for making Form E comprising: 1) obtaining a slurry of Compound 1 in a solvent or solvent system; 2) seeding the slurry with a small amount (e.g., 1 mg) of a solid form described herein (e.g., Form D, or Form I) and stirring the slurry for a period of time (e.g., about 48 h) while cycling the temperature (e.g., between about 5° C. and about 30° C.); and 3) collecting solids from the slurry by filtration to yield Form E of Compound 1.
- a slurry of Compound 1 in a solvent or solvent system comprising: 1) obtaining a slurry of Compound 1 in a solvent or solvent system; 2) seeding the slurry with a small amount (e.g., 1 mg) of a solid form described herein (e.g., Form D, or Form I) and stirring the slurry for a period of time (e.g., about 48 h) while cycling the temperature (e.g.,
- the solvent system is selected from the group consisting of nitromethane, acetonitrile, octane/ethyl acetate (9:1), acetonitrile/toluene (9:1), isopropyl ether/acetonitrile (1:2), octane/acetone (9:1), acetonitrile/methyl t-butyl ether (9:1), or acetonitrile/ methyl isobutyl ketone (9:1).
- methods for making Form E comprising: 1) obtaining a slurry of Compound 1 in a solvent or solvent system; 2) seeding the slurry with a small amount (e.g., 1 mg) of a solid form described herein (e.g., Form E,) and stirring the slurry for a period of time (e.g., overnight, or about 48 h) while cycling the temperature (e.g., between about 5° C. and about 40° C.); and 3) collecting solids from the slurry by filtration to yield Form E of Compound 1.
- the method further comprises the step of drying the collected solids under vacuum at 65° C. to yield Form E of Compound 1.
- the collected solids are dried using a flow of an inert gas, such as nitrogen or argon, under vacuum at 65° C.
- the solvent or solvent system is selected from the group consisting of toluene/heptane (1:3), methyl t-butyl ether/hexane (1:9), methyl t-butyl ether/acetonitrile (1:9), and isopropyl ether.
- the solvent is isopropyl ether.
- a slurry of Compound 1 in a solvent or solvent system comprising: 1) obtaining a slurry of Compound 1 in a solvent or solvent system; 2) heating the slurry to a certain temperature (e.g., 40° C.); 3) filtering the hot solution to remove impurities; 4) storing the hot filtrate at 4° C. for a period of time (e.g., 7 days); and 5) collecting solids from the cooled solution by filtration to yield Form E of Compound 1.
- the solvent system is methyl isobutyl ketone/heptane.
- Form E having an FT-Raman Spectrum as depicted in FIG. 18 .
- a solid form e.g., Form E of Compound 1, having a DSC thermograph substantially as depicted in FIG. 19 comprising an endothermic event with an onset temperature of about 106° C.
- a solid form e.g., Form E of Compound 1, having a TGA thermogram corresponding substantially to the representative TGA thermogram as depicted in FIG. 19 .
- the crystalline form exhibits a TGA thermogram comprising a total mass loss of approximately 0.3% of the total mass of the sample when heated from approximately 25° C. to about 125° C.
- a solid form provided herein is substantially crystalline, as indicated by, e.g., X-ray powder diffraction measurements.
- a solid form having an X-ray powder diffraction pattern (XRPD) substantially as shown in FIG. 17 e.g., Form E.
- a solid form provided herein has one or more characteristic X-ray powder diffraction peaks at approximately 3.9, 7.7, 9.9, 11.6, 12.1, 14.3, 15.5, 17.3, 18.2, 19.3, 20.9, 21.7, 23.3, 24.5, 25.3, 32.0° 2 ⁇ ( ⁇ 0.2° 2 ⁇ ) or ( ⁇ 0.1° 2 ⁇ ) as depicted in FIG. 17 .
- a solid form provided herein has one, two, three, four, five or six characteristic X-ray powder diffraction peaks at approximately 3.9, 7.7, 11.6, 14.3, 20.9, 24.5° 2 ⁇ ( ⁇ 0.2° 2 ⁇ ).
- the solid form is Form E.
- Form E is substantially pure.
- the substantially pure Form E is substantially free of other solid forms, including but not limited to amorphous solid.
- the substantially pure Form E is substantially free of Form A, Form B, Form C, Form D, Form F, Form G, Form H, or Form I.
- the purity of the substantially pure Form D is no less than about 95%, no less than about 96%, no less than about 97%, no less than about 98%, no less than about 98.5%, no less than about 99%, no less than about 99.5%, or no less than about 99.8%.
- the substantially pure Form E is substantially free of Form J, Form K, Form L, Form M, or Form N.
- Form E is mixed with other solid forms, including but not limited to the amorphous solid. In certain embodiments, Form E is mixed with at least one of Form A, Form B, Form C, Form D, Form F, Form G, Form H, or Form I. In certain embodiments, Form E is mixed with at least one of Form A, Form B, Form C, Form D, Form F, Form G, Form H, Form I, Form J, Form K, Form L, Form M, or Form N.
- Form E comprises a free base of Compound 1. In one embodiment, Form E comprises a free acid of Compound 1. In one embodiment, Form E comprises a zwitterion of Compound 1.
- Form F is Form F.
- Form F is a solid form comprising Compound 1. In one embodiment, Form F is solvated by dimethyl carbonate. In one embodiment, Form F is crystalline. In one embodiment, Form F is moderately crystalline.
- methods for making Form F comprising: 1) obtaining a slurry of Compound 1 in a solvent, and stirring at 20° C. for 1 h; 2) seeding the slurry with a small amount (e.g., 1 mg) of a solid form described herein (e.g., Form D), 3) stirring the slurry for a period of time (e.g., about 12 h) at 20° C.; and 3) collecting solids from the slurry to yield Form F of Compound 1.
- the solids are collected by centrifugation followed by decanting, washing, and drying in a centrifuge evaporator overnight.
- the solvent is dimethyl carbonate.
- Form F having an FT-Raman Spectrum as depicted in FIG. 22 .
- a solid form e.g., Form F of Compound 1, having a DSC thermograph substantially as depicted in FIG. 23 comprising an endothermic event with an onset temperature at about 48° C. and a peak maximum temperature at about 63° C.
- a solid form e.g., Form F of Compound 1, having a TGA thermograph corresponding substantially to the representative TGA thermograph as depicted in FIG. 23 .
- the crystalline form exhibits a TGA thermograph comprising a total mass loss of approximately 8.9% of the total mass of the sample when heated between approximately 25° C. and approximately 125° C.
- the crystalline loses about 8.9% its total mass when heated from ambient temperature to about 125° C.
- a solid form provided herein is substantially crystalline, as indicated by, e.g., X-ray powder diffraction measurements.
- a solid form having an X-ray powder diffraction pattern (XRPD) substantially as shown in FIG. 21 e.g., Form F.
- a solid form provided herein has one or more characteristic X-ray powder diffraction peaks at approximately 2.5, 3.3, 6.6, 9.9, 10.5, 12.4, 13.2, 14.8, 19.9, 20.4, 21.9, 22.9, 23.5, or 26.6° 2 ⁇ ( ⁇ 0.2° 2 ⁇ ) or ( ⁇ 0.1° 2 ⁇ ) as depicted in FIG. 21 .
- a solid form provided herein has one, two, three, four, five or six characteristic X-ray powder diffraction peaks at approximately 3.3, 9.9, 14.8, 19.9, 20.4, or 23.5° 2 ⁇ ( ⁇ 0.2° 2 ⁇ ).
- the solid form is Form F.
- Form F is substantially pure.
- the substantially pure Form F is substantially free of other solid forms, including but not limited to amorphous solid.
- the substantially pure Form F is substantially free of Form A, Form B, Form C, Form D, Form E, Form G, Form H, or Form I.
- the purity of the substantially pure Form F is no less than about 95%, no less than about 96%, no less than about 97%, no less than about 98%, no less than about 98.5%, no less than about 99%, no less than about 99.5%, or no less than about 99.8%.
- the substantially pure Form F is substantially free of Form J, Form K, Form L, Form M, or Form N.
- Form F is mixed with other solid forms, including but not limited to the amorphous solid. In certain embodiments, Form F is mixed with at least one of Form A, Form B, Form C, Form D, Form E, Form G, Form H, or Form I. In certain embodiments, Form F is mixed with at least one of Form A, Form B, Form C, Form D, Form E, Form G, Form H, Form I, Form J, Form K, Form L, Form M, or Form N.
- Form F comprises a free base of Compound 1. In one embodiment, Form F comprises a free acid of Compound 1. In one embodiment, Form F comprises a zwitterion of Compound 1.
- Form G is Form G.
- Form G is a solid form comprising Compound 1.
- a slurry of Compound 1 in a solvent or solvent system comprising: 1) obtaining a slurry of Compound 1 in a solvent or solvent system; 2) stirring the slurry for a period of time (e.g., about 72 h) while cycling the temperature (e.g., between about 5° C. and about 40° C.); and 3) collecting solids from the slurry by filtration to yield a mixture of Form G and Form D.
- the solvent is isopropyl ether, cyclohexane, heptanes, dimethyl carbonate, or water.
- the solvent is dimethyl carbonate.
- the collected solids are dried using a flow of an inert gas, such as nitrogen or argon.
- Form G is mixed with other solid forms, including but not limited to the amorphous solid. In certain embodiments, Form G is mixed with at least one of Form A, Form B, Form C, Form D, Form E, Form F, Form H, or Form I. In certain embodiments, the substantially pure Form G is substantially free of Form J, Form K, Form L, Form M, or Form N.
- Form G comprises a free base of Compound 1. In one embodiment, Form G comprises a free acid of Compound 1. In one embodiment, Form G comprises a zwitterion of Compound 1. In certain embodiments, Form G is mixed with at least one of Form A, Form B, Form C, Form D, Form E, Form F, Form H, Form I, Form J, Form K, Form L, Form M, or Form N.
- Form H is Form H.
- Form H is a solid form comprising Compound 1. In one embodiment, Form H is solvated by water. In one embodiment, Form H is a hydrate. In one embodiment, Form H is crystalline.
- a slurry of Form E in a solvent or solvent system comprising: 1) obtaining a slurry of Form E in a solvent or solvent system; 2) seeding the slurry with a small amount of a solid form described herein (e.g., Form D or Form I), 3) stirring the slurry for a period of time (e.g., about 48 h) while cycling between two temperatures (e.g., 5° C. and 30° C.); and 3) collecting solids from the slurry and optionally drying to yield Form H of Compound 1.
- the solvent is water.
- the solvent system is a 10% mixture of water in acetonitrile.
- the solvent system is a mixture of 10% 1-propanol in water.
- Form H having an FT-Raman Spectrum as depicted in FIG. 26 .
- a solid form e.g., Form H of Compound 1, having a DSC thermograph substantially as depicted in FIG. 27 comprising an endothermic event with a peak maximum temperature of about 56° C., and another endothermic event with a peak maximum temperature of about 94° C.
- a solid form e.g., Form H of Compound 1, having a TGA thermogram corresponding substantially to the representative TGA thermogram as depicted in FIG. 27 .
- the crystalline form exhibits a TGA thermogram comprising a total mass loss of approximately 7.7% of the total mass of the sample when heated between approximately 25° C. and approximately 80° C.
- the crystalline loses about 7.7% its total mass when heated from ambient temperature to about 80° C.
- a solid form provided herein is substantially crystalline, as indicated by, e.g., X-ray powder diffraction measurements.
- a solid form having an X-ray powder diffraction pattern (XRPD) substantially as shown in FIG. 25 e.g., Form H.
- a solid form provided herein has one or more characteristic X-ray powder diffraction peaks at approximately 3.6, 7.2, 10.8, 11.7, 12.4, 13.6, 14.4, 16.1, 17.8, 18.0, 18.3, 19.2, 19.6, 20.1, 20.7, 21.2, 21.7, 23.1, 23.7, 24.2, 25.3, 27.5, 29.1, or 36.5° 2 ⁇ ( ⁇ 0.2° 2 ⁇ ) or ( ⁇ 0.1° 2 ⁇ ) as depicted in FIG. 25 .
- a solid form provided herein has one, two, three, four, five, six, or seven characteristic X-ray powder diffraction peaks at approximately 3.6, 7.2, 10.8, 17.8, 18.0, 18.3, or 21.7° 2 ⁇ ( ⁇ 0.2° 2 ⁇ ).
- the solid form is Form H.
- Form H is substantially pure.
- the substantially pure Form H is substantially free of other solid forms, including but not limited to amorphous solid.
- the substantially pure Form H is substantially free of Form A, Form B, Form C, Form D, Form E, Form F, Form G, or Form I.
- the purity of the substantially pure Form H is no less than about 95%, no less than about 96%, no less than about 97%, no less than about 98%, no less than about 98.5%, no less than about 99%, no less than about 99.5%, or no less than about 99.8%.
- the substantially pure Form H is substantially free of Form J, Form K, Form L, Form M, or Form N.
- Form H is mixed with other solid forms, including but not limited to the amorphous solid. In certain embodiments, Form H is mixed with at least one of Form A, Form B, Form C, Form D, Form E, Form F, Form G, or Form I. In certain embodiments, Form H is mixed with at least one of Form A, Form B, Form C, Form D, Form E, Form F, Form G, Form I, Form J, Form K, Form L, Form M, or Form N.
- Form H comprises a free base of Compound 1. In one embodiment, Form H comprises a free acid of Compound 1. In one embodiment, Form H comprises a zwitterion of Compound 1.
- Form I is Form I.
- Form I is a solid form comprising Compound 1. In one embodiment, Form I is solvated by water. In one embodiment, Form I is a hydrate. In one embodiment, Form I is crystalline. In one embodiment, Form I is moderately crystalline.
- a solution of Compound 1 in a solvent or a solvent system at a first temperature (e.g., ambient temperature); 2) adding an anti-solvent into the saturated solution at the first temperature; 3) stirring the solution for a period of time (e.g., about 4 days) while cycling the temperature (e.g., between about 20° C. and about 50° C.); and 4) evaporating the solution under a flow of nitrogen gas at a certain temperature (e.g., ambient temperature) over a period of time (e.g., 14 days) to yield Form I of Compound 1.
- the solvent is dimethylformamide and the anti-solvent is water.
- a method of making Form I comprises drying Form H with nitrogen gas bleed for a period of time (e.g., 14 days).
- Form I having an FT-Raman Spectrum as depicted in FIG. 30 .
- a solid form e.g., Form I of Compound 1, having a DSC thermograph substantially as depicted in FIG. 31 comprising an endothermic event with a peak maximum temperature at about 54° C.
- a solid form e.g., Form I of Compound 1, having a DSC endothermic event with an onset temperature at about 82° C. and a peak maximum temperature at about 93° C.
- a solid form e.g., Form I of Compound 1, having a TGA thermogram corresponding substantially to the representative TGA thermogram as depicted in FIG. 31 .
- the crystalline form exhibits a TGA thermogram comprising a total mass loss of approximately 1.6% of the total mass of the sample when heated between approximately 25° C. and approximately 110° C.
- the crystalline loses about 1.6% its total mass when heated from ambient temperature to about 110° C.
- a solid form provided herein is substantially crystalline, as indicated by, e.g., X-ray powder diffraction measurements.
- a solid form having an X-ray powder diffraction pattern (XRPD) substantially as shown in FIG. 29 e.g. Form I.
- XRPD X-ray powder diffraction pattern
- a solid form provided herein, e.g., Form I has one or more characteristic X-ray powder diffraction peaks at approximately 4.0, 8.0, 12.0, 13.5, 17.6, 19.2, 20.1, 21.5, or 32.4° 2 ⁇ ( ⁇ 0.2° 2 ⁇ ) or ( ⁇ 0.1° 2 ⁇ ) as depicted in FIG. 29 .
- a solid form provided herein has one, two, three, four, or five characteristic X-ray powder diffraction peaks at approximately 4.0, 12.0, 17.6, 20.1, or 21.5° 2 ⁇ ( ⁇ 0.2° 2 ⁇ ).
- the solid form is Form I.
- Form I is substantially pure.
- the substantially pure Form I is substantially free of other solid forms, including but not limited to amorphous solid.
- the substantially pure Form I is substantially free of Form A, Form B, Form C, Form D, Form E, Form F, Form G, or Form H.
- the purity of the substantially pure Form I is no less than about 95%, no less than about 96%, no less than about 97%, no less than about 98%, no less than about 98.5%, no less than about 99%, no less than about 99.5%, or no less than about 99.8%.
- the substantially pure Form I is substantially free of Form J, Form K, Form L, Form M, or Form N.
- Form I is mixed with other solid forms, including but not limited to the amorphous solid. In certain embodiments, Form I is mixed with at least one of Form A, Form B, Form C, Form D, Form E, Form F, Form G, or Form H. In certain embodiments, Form I is mixed with at least one of Form A, Form B, Form C, Form D, Form E, Form F, Form G, Form H, Form J, Form K, Form L, Form M, or Form N.
- Form I comprises a free base of Compound 1. In one embodiment, Form I comprises a free acid of Compound 1. In one embodiment, Form I comprises a zwitterion of Compound 1.
- Form J is Form J.
- Form J is a solid form of Compound 1. In one embodiment, Form J is crystalline.
- provided herein are methods for making Form J, comprising 1) mixing Compound 1 with a solvent or solvent system; 2) sonicating the mixture; 3) filtering the mixture; 4) evaporating the filtrate to dryness; 5) adding solvent to the dried sample to obtain a solution; 6) stirring the solution at a certain temperature for a certain time; 7) filtering the mixture; and 8) drying the resulting solid in a vacuum oven to yield Form J of Compound 1.
- the solvent is ethyl methyl ketone.
- the certain temperature is ambient temperature and the certain time is about one day.
- a method for making Form J comprising: 1) mixing an amount of Compound 1 (e.g., about 80 mg) with an amount of ethyl methyl ketone (e.g., 11 mL); 2) sonicating for period of time (e.g., 5 minutes); 3) filtering via 0.2 um PTFE-membraned syringe filter; 4) evaporating the filtrate to dryness under nitrogen purge; 5) adding an amount of ethyl methyl ketone (e.g., 0.6 mL) to the sample; 6) capping the sample and stirring at a speed (e.g., 500 rotations per minute) at a temperature (e.g., ambient temperature) for a period of time (e.g., about a day); 7) collecting solids from the sample by filtration (e.g., via a 0.2 ⁇ m Nylon-membraned centrifuge tube filter) and drying the collected solids in a vacuum
- Form J having a Raman Spectrum as depicted in FIG. 34 .
- a solid form e.g., Form J of Compound 1, having a DSC thermograph substantially as depicted in FIG. 35 comprising an endothermic event with an onset temperature of 143.4° C.
- a solid form e.g., Form J of Compound 1, having a TGA thermogram corresponding substantially to the representative TGA thermogram as depicted in FIG. 35 .
- the crystalline form exhibits a TGA thermogram comprising a total mass loss of approximately 0.1% of the total mass of the sample when heated to 100° C.
- the crystalline form loses about 0.1% its total mass when heated from about ambient temperature to about 100° C.
- a solid form provided herein is substantially crystalline, as indicated by, e.g., X-ray powder diffraction measurements.
- a solid form having an X-ray powder diffraction pattern (XRPD) substantially as shown in FIG. 33 e.g., Form J.
- a solid form provided herein e.g., Form J
- a solid form provided herein, e.g., Form J has one, two, three, four, five, or six characteristic X-ray powder diffraction peaks at approximately 7.9, 11.9, 13.4, 15.7, 17.4, or 20.0° 2 ⁇ ( ⁇ 0.2° 2 ⁇ ).
- the solid form is Form J.
- Form J is substantially pure.
- the substantially pure Form J is substantially free of other solid forms, including but not limited to amorphous solid.
- the substantially pure Form J is substantially free of Form A, Form B, Form C, Form D, Form E, Form F, Form G, Form H, Form I, Form K, Form L, Form M, or Form N.
- the purity of the substantially pure Form J is no less than about 95%, no less than about 96%, no less than about 97%, no less than about 98%, no less than about 98.5%, no less than about 99%, no less than about 99.5%, or no less than about 99.8%.
- Form J is mixed with other solid forms, including but not limited to the amorphous solid. In certain embodiments, Form J is mixed with at least one of Form A, Form B, Form C, Form D, Form E, Form F, Form G, Form H, Form I, Form K, Form L, Form M, or Form N.
- Form J comprises a free base of Compound 1. In one embodiment, Form J comprises a free acid of Compound 1. In one embodiment, Form J comprises a zwitterion of Compound 1.
- Form K is Form K.
- Form K is a solid form of Compound 1. In one embodiment, Form K is crystalline.
- provided herein are methods for making Form K, comprising 1) drying Compound 1 in a vacuum oven; 2) mixing the dried Compound 1 with a solvent or solvent system; 3) filtering the mixture; 4) evaporating the filtrate until precipitates are visually observed; 5) stirring the resulting mixture at a certain temperature for a certain time; 6) filtering the mixture; and 7) drying the resulting solid in a vacuum oven to yield Form K of Compound 1.
- the solvent is ethyl methyl ketone.
- the certain temperature is ambient temperature and the certain time is about one day.
- a method for making Form K comprising: 1) drying an amount of Compound 1 (e.g., about 130 mg) in a vacuum oven at a temperature (e.g., 35° C.) for a period of time (e.g., about 3 hours); 2) adding an amount of ethyl methyl ketone (e.g., 3.5 mL) to the sample; 3) filtering via 0.2 ⁇ m PTFE-membraned syringe filter; 4) evaporating the filtrate under nitrogen purge until precipitates were observed; 5) capping the sample and stirring at a speed (e.g., 500 rotations per minute) at a temperature (e.g., ambient temperature) for a period of time (e.g., about a day); 6) collecting solids from the sample by filtration (e.g., via a 0.2 ⁇ m Nylon-membraned centrifuge tube filter) and drying the collected solids in a vacuum oven at a
- a solid form e.g., Form K of Compound 1, having a DSC thermograph substantially as depicted in FIG. 37 comprising endothermic events with peak maximum temperatures of approximately 98.9° C. and 113.7° C., respectively.
- a solid form e.g., Form K of Compound 1, having a TGA thermogram corresponding substantially to the representative TGA thermogram as depicted in FIG. 37 .
- the crystalline form exhibits a TGA thermogram comprising a total mass loss of approximately 0.1% of the total mass of the sample when heated to 90° C.
- the crystalline form loses about 0.1% its total mass when heated from about ambient temperature to about 90° C.
- a solid form provided herein is substantially crystalline, as indicated by, e.g., X-ray powder diffraction measurements.
- a solid form having an X-ray powder diffraction pattern (XRPD) substantially as shown in FIG. 36 e.g., Form K.
- a solid form provided herein e.g., Form K
- a solid form provided herein, e.g., Form K has one, two, three, four, five, six, or seven characteristic X-ray powder diffraction peaks at approximately 7.3, 8.0, 10.0, 10.9, 12.0, 17.5, or 20.1° 2 ⁇ ( ⁇ 0.2° 2 ⁇ ).
- the solid form is Form K.
- Form K is substantially pure.
- the substantially pure Form K is substantially free of other solid forms, including but not limited to amorphous solid.
- the substantially pure Form K is substantially free of Form A, Form B, Form C, Form D, Form E, Form F, Form G, Form H, Form I, Form J, Form L, Form M, or Form N.
- the purity of the substantially pure Form K is no less than about 95%, no less than about 96%, no less than about 97%, no less than about 98%, no less than about 98.5%, no less than about 99%, no less than about 99.5%, or no less than about 99.8%.
- Form K is mixed with other solid forms, including but not limited to the amorphous solid. In certain embodiments, Form K is mixed with at least one of Form A, Form B, Form C, Form D, Form E, Form F, Form G, Form H, Form I, Form J, Form L, Form M, or Form N.
- Form K comprises a free base of Compound 1. In one embodiment, Form K comprises a free acid of Compound 1. In one embodiment, Form K comprises a zwitterion of Compound 1.
- Form L is Form L.
- Form L is a solid form of Compound 1. In one embodiment, Form L is crystalline.
- a solid form of Compound 1 described herein e.g., Form K
- a vacuum oven at a certain temperature for a certain time
- a portion of the dried solid at a certain rate on DSC in a vessel to yield Form L of Compound 1.
- the certain temperature is 35° C. and the certain time is two days.
- the portion of the dried solid is heated to 121° C. at a rate of 10° C./min.
- the vessel is a crimped aluminum pan with a pin hole on its lid.
- methods for making Form L comprising: 1) drying Form K of Compound 1 in a vacuum oven at a temperature (e.g., 35° C.) for a period of time (e.g., about 2 days); 2) heating the sample to a temperature (e.g., 121° C.) at a rate (e.g., 10° C. per minute) in a crimped aluminum pan with a pin hole on its lid; and 3) collecting the solid residue to yield Form L of Compound 1.
- Form L having a Raman Spectrum as depicted in FIG. 39 .
- a solid form provided herein is substantially crystalline, as indicated by, e.g., X-ray powder diffraction measurements.
- a solid form having an X-ray powder diffraction pattern (XRPD) substantially as shown in FIG. 38 e.g., Form L.
- XRPD X-ray powder diffraction pattern
- a solid form provided herein, e.g., Form L has one or more characteristic X-ray powder diffraction peaks at approximately 11.5, 12.0, 13.4, 15.7, 17.5, 19.0, 19.6, 20.1, 21.0, 21.3, or 23.5° 2 ⁇ ( ⁇ 0.2° 2 ⁇ ) or ( ⁇ 0.1° 2 ⁇ ) as depicted in FIG. 38 .
- a solid form provided herein e.g., Form L
- the solid form is Form L.
- Form L is substantially pure.
- the substantially pure Form L is substantially free of other solid forms, including but not limited to amorphous solid.
- the substantially pure Form L is substantially free of Form A, Form B, Form C, Form D, Form E, Form F, Form G, Form H, Form I, Form J, Form K, Form M, or Form N.
- the purity of the substantially pure Form L is no less than about 95%, no less than about 96%, no less than about 97%, no less than about 98%, no less than about 98.5%, no less than about 99%, no less than about 99.5%, or no less than about 99.8%.
- Form L is mixed with other solid forms, including but not limited to the amorphous solid. In certain embodiments, Form L is mixed with at least one of Form A, Form B, Form C, Form D, Form E, Form F, Form G, Form H, Form I, Form J, Form K, Form M, or Form N.
- Form L comprises a free base of Compound 1. In one embodiment, Form L comprises a free acid of Compound 1. In one embodiment, Form L comprises a zwitterion of Compound 1.
- Form M is Form M.
- Form M is a solid form of Compound 1. In one embodiment, Form M is crystalline.
- a solid form of Compound 1 described herein e.g., Form K
- a vacuum oven at a certain temperature for a certain time
- a portion of the dried solid at a certain rate on DSC in a vessel to yield Form M of Compound 1.
- the certain temperature is 35° C. and the certain time is two days.
- the portion of the dried solid is heated to 102° C. at a rate of 10° C./min.
- the vessel is a crimped aluminum pan with a pin hole on its lid.
- methods for making Form M comprising: 1) drying Form K of Compound 1 in a vacuum oven at a temperature (e.g., 35° C.) for a period of time (e.g., about 2 days); 2) heating the sample to a temperature (e.g., 102° C.) at a rate (e.g., 10° C. per minute) in a crimped aluminum pan with a pin hole on its lid; and 3) collecting the solid residue to yield Form M of Compound 1.
- Form M having a Raman Spectrum as depicted in FIG. 41 .
- a solid form provided herein is substantially crystalline, as indicated by, e.g., X-ray powder diffraction measurements.
- a solid form having an X-ray powder diffraction pattern (XRPD) substantially as shown in FIG. 40 e.g., Form M.
- a solid form provided herein has one or more characteristic X-ray powder diffraction peaks at approximately 7.2, 8.0, 9.5, 10.9, 11.5, 12.0, 13.4, 15.7, 16.4, 17.5, 18.2, 19.0, 19.5, 20.1, 20.7, 21.3, 22.8, or 23.4° 2 ⁇ ( ⁇ 0.2° 2 ⁇ ) or ( ⁇ 0.1° 2 ⁇ ) as depicted in FIG. 40 .
- a solid form provided herein, e.g., Form M has one, two, three, four, five, or six characteristic X-ray powder diffraction peaks at approximately 7.2, 9.5, 12.0, 16.4, 18.2, or 22.8° 2 ⁇ ( ⁇ 0.2° 2 ⁇ ).
- the solid form is Form M.
- Form M is substantially pure.
- the substantially pure Form L is substantially free of other solid forms, including but not limited to amorphous solid.
- the substantially pure Form M is substantially free of Form A, Form B, Form C, Form D, Form E, Form F, Form G, Form H, Form I, Form J, Form K, Form L, or Form N.
- the purity of the substantially pure Form M is no less than about 95%, no less than about 96%, no less than about 97%, no less than about 98%, no less than about 98.5%, no less than about 99%, no less than about 99.5%, or no less than about 99.8%.
- Form M is mixed with other solid forms, including but not limited to the amorphous solid. In certain embodiments, Form M is mixed with at least one of Form A, Form B, Form C, Form D, Form E, Form F, Form G, Form H, Form I, Form J, Form K, Form L, or Form N.
- Form M comprises a free base of Compound 1. In one embodiment, Form M comprises a free acid of Compound 1. In one embodiment, Form M comprises a zwitterion of Compound 1.
- Form N is Form N.
- Form N is a solid form of Compound 1. In one embodiment, Form N is crystalline.
- a solid form of Compound 1 described herein e.g., Form E
- a solvent or solvent system e.g., water or solvent system
- stirring the resulting mixture at a certain temperature for a certain time e.g., a solvent or solvent system
- a filtering the mixture e.g., a solvent or solvent system
- drying the resulting solid in a vacuum oven e.g., a vacuum oven
- the solvent is water.
- the water is Milli-Q water.
- the certain temperature is ambient temperature and the certain time is five days.
- methods for making Form N comprising: 1) mixing an amount of Form E of Compound 1 (e.g., about 8.6 mg) with an amount of water (e.g., 0.12 mL of Milli-Q water); 2) capping the sample and stirring at a speed (e.g., 400 rotations per minute) at a temperature (e.g., ambient temperature) for a period of time (e.g., about 5 days); 3) collecting solids from the sample by filtration (e.g., via a 0.2 ⁇ m Nylon-membraned centrifuge tube filter) and drying the collected solids in a vacuum oven at a temperature (e.g., 35° C.) for a period of time (e.g., about a day) to yield Form N of Compound 1.
- a speed e.g. 400 rotations per minute
- a temperature e.g., ambient temperature
- a period of time e.g., about 5 days
- collecting solids from the sample by filtration (e.g
- Form N having a Raman Spectrum as depicted in FIG. 43 .
- a solid form e.g., Form N of Compound 1, having a DSC thermograph substantially as depicted in FIG. 44 comprising an endothermic event with an onset temperature of approximately 85.7° C.
- a solid form e.g., Form N of Compound 1, having a TGA thermogram corresponding substantially to the representative TGA thermogram as depicted in FIG. 44 .
- the crystalline form exhibits a TGA thermogram comprising a total mass loss of approximately 1.2% of the total mass of the sample when heated to 105.5° C.
- the crystalline form loses about 1.2% of its total mass when heated from about ambient temperature to about 105.5° C.
- a solid form provided herein e.g., Form N is substantially crystalline, as indicated by, e.g., X-ray powder diffraction measurements.
- a solid form having an X-ray powder diffraction pattern (XRPD) substantially as shown in FIG. 42 e.g., Form N).
- a solid form provided herein has one or more characteristic X-ray powder diffraction peaks at approximately 11.6, 12.0, 13.5, 13.8, 14.0, 14.6, 15.8, 16.2, 17.7, 19.2, 19.6, 20.1, 21.6, 21.7, 23.2, 23.7, or 24.1° 2 ⁇ ( ⁇ 0.2° 2 ⁇ ) or ( ⁇ 0.1° 2 ⁇ ) as depicted in FIG. 42 .
- a solid form provided herein, e.g., Form N has one, two, three, four, five, or six characteristic X-ray powder diffraction peaks at approximately 12.0, 13.5, 17.7, 20.1, 21.6, or 23.7° 2 ⁇ ( ⁇ 0.2° 2 ⁇ ).
- the solid form is Form N.
- Form N is substantially pure.
- the substantially pure Form N is substantially free of other solid forms, including but not limited to amorphous solid.
- the substantially pure Form N is substantially free of Form A, Form B, Form C, Form D, Form E, Form F, Form G, Form H, Form I, Form J, Form K, Form L, or Form M.
- the purity of the substantially pure Form N is no less than about 95%, no less than about 96%, no less than about 97%, no less than about 98%, no less than about 98.5%, no less than about 99%, no less than about 99.5%, or no less than about 99.8%.
- Form N is mixed with other solid forms, including but not limited to the amorphous solid. In certain embodiments, Form N is mixed with at least one of Form A, Form B, Form C, Form D, Form E, Form F, Form G, Form H, Form I, Form J, Form K, Form L, or Form M.
- Form N comprises a free base of Compound 1. In one embodiment, Form N comprises a free acid of Compound 1. In one embodiment, Form N comprises a zwitterion of Compound 1.
- the solid forms and the pharmaceutical compositions comprising Compound 1, or a tautomer thereof, provided herein can be used in all the methods provided herein.
- the solid forms and the pharmaceutical compositions comprising Compound 1, or a tautomer thereof, provided herein can be used in the treatment of all diseases, disorders or conditions provided herein.
- a solid form comprising Compound 1, or a tautomer thereof, provided herein or a pharmaceutical composition thereof.
- the autoimmune or chronic inflammatory disorder is polymyositis, dermatomyositis, lupus nephritis, rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, amyotrophic lateral sclerosis, autoimmune myositis, systemic lupus, Type 1 diabetes, biliary cirrhosis, bullous pemphigoid, sarcoidosis, Wegener's granulomatosis, ichthyosis, Graves' disease, or multiple sclerosis.
- the multiple sclerosis is relapsing-remitting multiple sclerosis, primary progressive multiple sclerosis, secondary progressive multiple sclerosis, or relapsing secondary progressive multiple sclerosis.
- the solid form is selected from the group consisting of Form A, Form B, Form C, Form D, Form E, Form F, Form G, Form H, or Form I.
- the solid form is selected from the group consisting of Form J, Form K, Form L, Form M, or Form N.
- kits for treating a subject suffering from or at risk for having a neurological disorder comprising administering to said subject a solid form comprising Compound 1, or a tautomer thereof, provided herein or a pharmaceutical composition thereof.
- the neurological disorder is Rett Syndrome.
- the solid form is selected from the group consisting of Form A, Form B, Form C, Form D, Form E, Form F, Form G, Form H, or Form I.
- the solid form is selected from the group consisting of Form J, Form K, Form L, Form M, or Form N.
- kits for treating a subject suffering from or at risk for renal or hepatic impairment comprising administering to said subject a solid form comprising Compound 1, or a tautomer thereof, provided herein or a pharmaceutical composition thereof.
- the solid form is selected from the group consisting of Form A, Form B, Form C, Form D, Form E, Form F, Form G, Form H, or Form I.
- the solid form is selected from the group consisting of Form J, Form K, Form L, Form M, or Form N.
- provided herein are methods for treating a subject suffering from or at risk for a disease or disorder mediated by lymphocyte interactions, wherein the method comprises administering to said subject a solid form comprising Compound 1, or a tautomer thereof, provided herein or a pharmaceutical composition thereof.
- the disease or disorder mediated by lymphocyte interactions is, for example, in transplantation, acute or chronic rejection of cell, tissue or organ allo- or xenografts or delayed graft function, graft versus host disease; autoimmune diseases, e.g., rheumatoid arthritis, systemic lupus erythematosus, hashimoto's thyroidis, multiple sclerosis, myasthenia gravis, diabetes type I or II and the disorders associated therewith, vasculitis, pernicious anemia, Sjoegren syndrome, uveitis, psoriasis, Graves ophthalmopathy, alopecia areata and others; allergic diseases, e.g., allergic asthma, atopic dermatitis, allergic rhinitis/conjunctivitis, allergic contact dermatitis; inflammatory diseases optionally with underlying aberrant reactions, e.g., inflammatory bowel disease, Crohn's disease or ulcerative colitis, intrinsic
- cell, tissue or solid organ transplants include, e.g., pancreatic islets, stem cells, bone marrow, corneal tissue, neuronal tissue, heart, lung, combined heart-lung, kidney, liver, bowel, pancreas, trachea or oesophagus.
- the solid form is selected from the group consisting of Form A, Form B, Form C, Form D, Form E, Form F, Form G, Form H, or Form I.
- the solid form is selected from the group consisting of Form J, Form K, Form L, Form M, or Form N.
- provided herein are methods for the treatment of a disease or disorder associated with sphingosine 1-phosphate, wherein the method comprises administering to said subject a solid form comprising Compound 1, or a tautomer thereof, provided herein or a pharmaceutical composition thereof.
- the disease or disorder associated with sphingosine 1-phosphate is multiple sclerosis, relapse-remitting multiple sclerosis, systemic lupus, Type 1 diabetes, amyotrophic lateral sclerosis, refractory rheumatoid arthritis, inflammatory bowel disease, biliary cirrhosis, Crohn's disease, ulcerative colitis, bullous pemphigoid, sarcoidosis, psoriasis, autoimmune myositis, Wegener's granulomatosis, ichthyosis, or Graves' disease.
- the solid form is selected from the group consisting of Form A, Form B, Form C, Form D, Form E, Form F, Form G, Form H, or Form I. In one embodiment, the solid form is selected from the group consisting of Form J, Form K, Form L, Form M, or Form N.
- the method comprises administering to said subject a solid form comprising Compound 1, or a tautomer thereof, or a pharmaceutical composition thereof.
- the disease or disorder associated with the interferon alpha receptor is psoriasis, ulcerative colitis, systemic lupus, multiple sclerosis, or rheumatoid arthritis.
- the solid form is selected from the group consisting of Form A, Form B, Form C, Form D, Form E, Form F, Form G, Form H, or Form I.
- the solid form is selected from the group consisting of Form J, Form K, Form L, Form M, or Form N.
- Solid forms comprising Compound 1, or a tautomer thereof, provided herein are useful for the preparation of pharmaceutical compositions, comprising an effective amount of a solid form comprising Compound 1, or a tautomer thereof, and a pharmaceutically acceptable vehicle, carrier, diluent, or excipient, or a mixture thereof.
- the pharmaceutically acceptable carrier is hydroxypropyl methylcellulose.
- the pharmaceutical compositions described herein are suitable for oral, parenteral, mucosal, transdermal or topical administration.
- oral administration also includes buccal, lingual, and sublingual administration.
- Suitable oral dosage forms include, but are not limited to, tablets, fastmelts, chewable tablets, capsules, pills, strips, troches, lozenges, pastilles, cachets, pellets, medicated chewing gum, bulk powders, effervescent or non-effervescent powders or granules, oral mists, solutions, emulsions, suspensions, wafers, sprinkles, elixirs, and syrups.
- the pharmaceutical compositions can contain one or more pharmaceutically acceptable carriers or excipients, including, but not limited to, binders, fillers, diluents, disintegrants, wetting agents, lubricants, glidants, coloring agents, dye-migration inhibitors, sweetening agents, flavoring agents, emulsifying agents, suspending and dispersing agents, preservatives, solvents, non-aqueous liquids, organic acids, and sources of carbon dioxide.
- pharmaceutically acceptable carriers or excipients including, but not limited to, binders, fillers, diluents, disintegrants, wetting agents, lubricants, glidants, coloring agents, dye-migration inhibitors, sweetening agents, flavoring agents, emulsifying agents, suspending and dispersing agents, preservatives, solvents, non-aqueous liquids, organic acids, and sources of carbon dioxide.
- the pharmaceutically acceptable carrier or excipient is selected from the group consisting of lactose (e.g., as lactose monohydrate); microcrystalline cellulose; non-basic polymers (e.g., homopolymers of cross-linked N-vinyl-2-pyrrolidone (crospovidone), hypromellose (hydroxypropylmethyl cellulose), and ethyl cellulose); waxes; colloidal silicon dioxide; stearic acid; hydrogenated vegetable oil; mineral oil; polyethylene glycol (e.g., polyethylene glycol 4000-6000); glyceryl palmitostearate; and glyceryl behenate.
- the pharmaceutically acceptable carrier or excipient is microcrystalline cellulose.
- Binders or granulators impart cohesiveness to a tablet to ensure the tablet remains intact after compression.
- Suitable binders or granulators include, but are not limited to, starches, such as corn starch, potato starch, and pre-gelatinized starch (e.g., STARCH 1500); gelatin; sugars, such as sucrose, glucose, dextrose, molasses, and lactose; natural and synthetic gums, such as acacia, alginic acid, alginates, extract of Irish moss, panwar gum, ghatti gum, mucilage of isabgol husks, carboxymethylcellulose, methylcellulose, polyvinylpyrrolidone (PVP), Veegum, larch arabogalactan, powdered tragacanth, and guar gum; celluloses, such as ethyl cellulose, cellulose acetate, carboxymethyl cellulose calcium, sodium carboxymethyl cellulose, methyl cellulose, hydroxyeth
- Suitable fillers include, but are not limited to, talc, calcium carbonate, microcrystalline cellulose, powdered cellulose, dextrates, kaolin, mannitol, silicic acid, sorbitol, starch, pre-gelatinized starch, and mixtures thereof.
- the amount of a binder or filler in the pharmaceutical compositions provided herein varies upon the type of formulation, and is readily discernible to those of ordinary skill in the art.
- the binder or filler may be present from about 50 to about 99% by weight in the pharmaceutical compositions provided herein.
- Suitable diluents include, but are not limited to, dicalcium phosphate, calcium sulfate, lactose, sorbitol, sucrose, inositol, cellulose, kaolin, mannitol, sodium chloride, dry starch, and powdered sugar.
- Certain diluents, such as mannitol, lactose, sorbitol, sucrose, and inositol when present in sufficient quantity, can impart properties to some compressed tablets that permit disintegration in the mouth by chewing. Such compressed tablets can be used as chewable tablets.
- the amount of a diluent in the pharmaceutical compositions provided herein varies upon the type of formulation, and is readily discernible to those of ordinary skill in the art.
- Suitable disintegrants include, but are not limited to, agar; bentonite; celluloses, such as methylcellulose and carboxymethylcellulose; wood products; natural sponge; cation-exchange resins; alginic acid; gums, such as guar gum and Veegum HV; citrus pulp; cross-linked celluloses, such as croscarmellose; cross-linked polymers, such as crospovidone; cross-linked starches; calcium carbonate; microcrystalline cellulose, such as sodium starch glycolate; polacrilin potassium; starches, such as corn starch, potato starch, tapioca starch, and pre-gelatinized starch; clays; aligns; and mixtures thereof.
- the amount of a disintegrant in the pharmaceutical compositions provided herein varies upon the type of formulation, and is readily discernible to those of ordinary skill in the art.
- the pharmaceutical compositions provided herein may contain from about 0.5% to about 15% or from about 1% to about 5% by weight of a disintegrant.
- Suitable lubricants include, but are not limited to, calcium stearate; magnesium stearate; mineral oil; light mineral oil; glycerin; sorbitol; mannitol; glycols, such as glycerol behenate and polyethylene glycol (PEG); stearic acid; sodium lauryl sulfate; talc; hydrogenated vegetable oil, including peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil, and soybean oil; zinc stearate; ethyl oleate; ethyl laureate; agar; starch; lycopodium; silica or silica gels, such as AEROSIL® 200 (W.R. Grace Co., Baltimore, Md.) and CAB-O-SIL® (Cabot Co. of Boston, Mass.); and mixtures thereof.
- the pharmaceutical compositions provided herein may contain about 0.1% to about 5% by weight of a lubricant.
- Suitable glidants include, but are not limited to, colloidal silicon dioxide, CAB-O-SIL® (Cabot Co. of Boston, Mass.), and asbestos-free talc.
- Suitable coloring agents include, but are not limited to, any of the approved, certified, water soluble FD&C dyes, and water insoluble FD&C dyes suspended on alumina hydrate, and color lakes and mixtures thereof.
- a color lake is the combination by adsorption of a water-soluble dye to a hydrous oxide of a heavy metal, resulting in an insoluble form of the dye.
- Suitable flavoring agents include, but are not limited to, natural flavors extracted from plants, such as fruits, and synthetic blends of compounds which produce a pleasant taste sensation, such as peppermint and methyl salicylate.
- Suitable sweetening agents include, but are not limited to, sucrose, lactose, mannitol, syrups, glycerin, and artificial sweeteners, such as saccharin and aspartame.
- Suitable emulsifying agents include, but are not limited to, gelatin, acacia, tragacanth, bentonite, and surfactants, such as polyoxyethylene sorbitan monooleate (TWEEN® 20), polyoxyethylene sorbitan monooleate 80 (TWEEN® 80), and triethanolamine oleate.
- Suitable suspending and dispersing agents include, but are not limited to, sodium carboxymethylcellulose, pectin, tragacanth, Veegum, acacia, sodium carbomethylcellulose, hydroxypropyl methylcellulose, and polyvinylpyrrolidone.
- Suitable preservatives include, but are not limited to, glycerin, methyl and propylparaben, benzoic acid, sodium benzoate, and alcohol.
- Suitable wetting agents include, but are not limited to, propylene glycol monostearate, sorbitan monooleate, diethylene glycol monolaurate, and polyoxyethylene lauryl ether.
- Suitable solvents include, but are not limited to, glycerin, sorbitol, ethyl alcohol, and syrup.
- Suitable non-aqueous liquids utilized in emulsions include, but are not limited to, mineral oil and cottonseed oil.
- Suitable organic acids include, but are not limited to, citric and tartaric acid.
- Suitable sources of carbon dioxide include, but are not limited to, sodium bicarbonate and sodium carbonate.
- compositions provided herein for oral administration can be provided as compressed tablets, tablet triturates, chewable lozenges, rapidly dissolving tablets, multiple compressed tablets, or enteric-coating tablets, sugar-coated, or film-coated tablets.
- Enteric-coated tablets are compressed tablets coated with substances that resist the action of stomach acid but dissolve or disintegrate in the intestine, thus protecting the active ingredients from the acidic environment of the stomach.
- Enteric-coatings include, but are not limited to, fatty acids, fats, phenyl salicylate, waxes, shellac, ammoniated shellac, and cellulose acetate phthalates.
- Sugar-coated tablets are compressed tablets surrounded by a sugar coating, which may be beneficial in covering up objectionable tastes or odors and in protecting the tablets from oxidation.
- Film-coated tablets are compressed tablets that are covered with a thin layer or film of a water-soluble material.
- Film coatings include, but are not limited to, hydroxyethylcellulose, sodium carboxymethylcellulose, polyethylene glycol 4000, and cellulose acetate phthalate. Film coating imparts the same general characteristics as sugar coating.
- Multiple compressed tablets are compressed tablets made by more than one compression cycle, including layered tablets, and press-coated or dry-coated tablets.
- the oral dosage form comprises one or more of Form A, Form B, Form C, Form D, Form E, Form F, Form G, Form H, Form I, Form J, Form K, Form L, Form M, or Form N.
- the oral dosage form comprises at least 0.001 mg, at least 0.005 mg, at least 0.01 mg, at least 0.05 mg, at least 0.1 mg, at least 0.5 mg, at least 1.0 mg or at least 2.0 mg of Form A, Form B, Form C, Form D, Form E, Form F, Form G, Form H, Form I, Form J, Form K, Form L, Form M, or Form N.
- compositions provided herein can be administered parenterally, for example, by injection, infusion, or implantation techniques, for local or systemic administration.
- Parenteral administration include intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular, intrasynovial, intravesical, and subcutaneous administration.
- compositions provided herein for parenteral administration can be formulated in any dosage forms that are suitable for parenteral administration, including solutions, suspensions, emulsions, micelles, liposomes, microspheres, nanosystems, and solid forms suitable for solutions or suspensions in liquid prior to injection.
- dosage forms can be prepared according to conventional methods known to those skilled in the art of pharmaceutical science (see, Remington: The Science and Practice of Pharmacy, supra).
- compositions intended for parenteral administration can include one or more pharmaceutically acceptable carriers and excipients, including, but not limited to, aqueous vehicles, water-miscible vehicles, non-aqueous vehicles, antimicrobial agents or preservatives against the growth of microorganisms, stabilizers, solubility enhancers, isotonic agents, buffering agents, antioxidants, local anesthetics, suspending and dispersing agents, wetting or emulsifying agents, complexing agents, sequestering or chelating agents, cryoprotectants, lyoprotectants, thickening agents, pH adjusting agents, and inert gases.
- aqueous vehicles water-miscible vehicles
- non-aqueous vehicles non-aqueous vehicles
- antimicrobial agents or preservatives against the growth of microorganisms stabilizers, solubility enhancers, isotonic agents, buffering agents, antioxidants, local anesthetics, suspending and dispersing agents, wetting or emuls
- Suitable aqueous vehicles include, but are not limited to, water, saline, physiological saline or phosphate buffered saline (PBS), sodium chloride injection, Ringers injection, isotonic dextrose injection, sterile water injection, dextrose and lactated Ringers injection.
- Suitable non-aqueous vehicles include, but are not limited to, fixed oils of vegetable origin, castor oil, corn oil, cottonseed oil, olive oil, peanut oil, peppermint oil, safflower oil, sesame oil, soybean oil, hydrogenated vegetable oils, hydrogenated soybean oil, and medium-chain triglycerides of coconut oil, and palm seed oil.
- Suitable water-miscible vehicles include, but are not limited to, ethanol, 1,3-butanediol, liquid polyethylene glycol (e.g., polyethylene glycol 300 and polyethylene glycol 400), propylene glycol, glycerin, N-methyl-2-pyrrolidone, N,N-dimethylacetamide, and dimethyl sulfoxide.
- Suitable antimicrobial agents or preservatives include, but are not limited to, phenols, cresols, mercurials, benzyl alcohol, chlorobutanol, methyl and propyl p-hydroxybenzoates, thimerosal, benzalkonium chloride (e.g., benzethonium chloride), methyl- and propyl-parabens, and sorbic acid.
- Suitable isotonic agents include, but are not limited to, sodium chloride, glycerin, and dextrose.
- Suitable buffering agents include, but are not limited to, phosphate and citrate.
- Suitable antioxidants are those as described herein, including bisulfate and sodium metabisulfite.
- Suitable local anesthetics include, but are not limited to, procaine hydrochloride.
- Suitable suspending and dispersing agents are those as described herein, including sodium carboxymethylcelluose, hydroxypropyl methylcellulose, and polyvinylpyrrolidone.
- Suitable emulsifying agents are those described herein, including polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan monooleate 80, and triethanolamine oleate.
- Suitable sequestering or chelating agents include, but are not limited to EDTA.
- Suitable pH adjusting agents include, but are not limited to, sodium hydroxide, hydrochloric acid, citric acid, and lactic acid.
- Suitable complexing agents include, but are not limited to, cyclodextrins, including ⁇ -cyclodextrin, ⁇ -cyclodextrin, hydroxypropyl- ⁇ -cyclodextrin, sulfobutylether- ⁇ -cyclodextrin, and sulfobutylether 7- ⁇ -cyclodextrin (CAPTISOL®, CyDex, Lenexa, Kans.).
- cyclodextrins including ⁇ -cyclodextrin, ⁇ -cyclodextrin, hydroxypropyl- ⁇ -cyclodextrin, sulfobutylether- ⁇ -cyclodextrin, and sulfobutylether 7- ⁇ -cyclodextrin (CAPTISOL®, CyDex, Lenexa, Kans.).
- the multiple dosage parenteral formulations must contain an antimicrobial agent at bacteriostatic or fungistatic concentrations. All parenteral formulations must be sterile, as known and practiced in the art.
- the pharmaceutical compositions for parenteral administration are provided as ready-to-use sterile solutions.
- the pharmaceutical compositions are provided as sterile dry soluble products, including lyophilized powders and hypodermic tablets, to be reconstituted with a vehicle prior to use.
- the pharmaceutical compositions are provided as ready-to-use sterile suspensions.
- the pharmaceutical compositions are provided as sterile dry insoluble products to be reconstituted with a vehicle prior to use.
- the pharmaceutical compositions are provided as ready-to-use sterile emulsions.
- compositions provided herein for parenteral administration can be formulated as immediate or modified release dosage forms, including delayed-, sustained, pulsed-, controlled, targeted-, and programmed-release forms.
- compositions provided herein for parenteral administration can be formulated as a suspension, solid, semi-solid, or thixotropic liquid, for administration as an implanted depot.
- the pharmaceutical compositions provided herein are dispersed in a solid inner matrix, which is surrounded by an outer polymeric membrane that is insoluble in body fluids but allows the active ingredient in the pharmaceutical compositions diffuse through.
- Suitable inner matrixes include, but are not limited to, polymethylmethacrylate, polybutyl-methacrylate, plasticized or unplasticized polyvinylchloride, plasticized nylon, plasticized polyethylene terephthalate, natural rubber, polyisoprene, polyisobutylene, polybutadiene, polyethylene, ethylene-vinyl acetate copolymers, silicone rubbers, polydimethylsiloxanes, silicone carbonate copolymers, hydrophilic polymers, such as hydrogels of esters of acrylic and methacrylic acid, collagen, cross-linked polyvinyl alcohol, and cross-linked partially hydrolyzed polyvinyl acetate.
- Suitable outer polymeric membranes include but are not limited to, polyethylene, polypropylene, ethylene/propylene copolymers, ethylene/ethyl acrylate copolymers, ethylene/vinyl acetate copolymers, silicone rubbers, polydimethyl siloxanes, neoprene rubber, chlorinated polyethylene, polyvinylchloride, vinyl chloride copolymers with vinyl acetate, vinylidene chloride, ethylene and propylene, ionomer polyethylene terephthalate, butyl rubber epichlorohydrin rubbers, ethylene/vinyl alcohol copolymer, ethylene/vinyl acetate/vinyl alcohol terpolymer, and ethylene/vinyloxyethanol copolymer.
- Powder X-ray diffraction (PXRD) patterns were obtained using a PANalytical X'Pert Pro diffractometer using Ni-filtered Cu Ka (45 kV/40 mA) radiation and a step size of 0.02° 2 ⁇ and X'celerator Real Time Multi-Strip (RTMS) detector.
- Configuration on the incidental beam side is a fixed divergence slit)(0.25°), 0.04 radian Soller slits, anti-scatter slit)(0.25°), and 10 mm beam mask.
- Configuration on the diffracted beam side is a fixed divergence slit)(0.25°) and 0.04 radian Soller slit. Samples were mounted flat on zero-background Si wafers and covered with Kapton film to comply with safety policies.
- FT-Raman spectra were collected with a Nicolet NXR9650 or NXR 960 spectrometer (Thermo Electron) equipped with 1064 nm Nd:YVO 4 excitation laser, InGaAs and liquid-N 2 cooled Ge detectors, and a MicroStage. Spectra were acquired at 4 cm ⁇ 1 resolution, 64 scans, using Happ-Genzel apodization function and 2-level zero-filling.
- DSC Differential Scanning calorimetry
- Polarized-light microscopy (PLM) photomicrographs were collected using an Olympus BX60 polarized-light microscope equipped with an Olympus DP70 camera.
- thermograms were obtained with a TA Instruments Q500 thermogravimetric analyzer under 40 mL/min N2 purge at 15° C./min in Al pans.
- TGA-IR Thermogravimetric Analysis with IR Off-Gas Detection
- TA Instruments Q5000 thermogravimetric analyzer interfaced to a Nicolet 6700 FT-IR spectrometer (Thermo Electron) equipped with an external TGA-IR module with a gas flow cell and DTGS detector.
- TGA was conducted with 60 mL/min N2 flow and heating rate of 15° C./min in Al pans.
- IR spectra were collected at 4 cm ⁇ 1 resolution and 32 scans at each time point.
- Powder X-ray diffraction (PXRD) patterns were obtained on a Rigaku SmartLab Guidance diffractometer with Cu-Ka radiation and D/teX Ultra detector. The powder samples were deposited on a zero-background polished silicon sample holder and were spun during measurement. Measurements were performed as follows: 40 kV/44 mA tube power, 0.02° 2 ⁇ step size, 5° 2 ⁇ /min scan rate, and 3-40° 2 ⁇ scan range. Data were processed using Rigaku PDXL2 software.
- Raman spectra were collected using a Raman Work Station (Kaiser Optical Systems, Inc, Ann Arbor, Mich.) with Holograms software. Data was acquired using 785 nm excitation laser with 300 mW in a reflection mode, 4 cm ⁇ 1 resolution through a 10 ⁇ objective with 10 accumulations. Data were processed using Grams/AI software (Thermo Fisher Scientific Inc). Data may also be acquired using 785 nm excitation laser with 300 mW in a reflection mode, 4 cm ⁇ 1 resolution through a 10 ⁇ objective.
- DSC Differential Scanning calorimetry
- thermograms were obtained with a TA Instruments Q5000 thermogravimetric analyzer under 40 mL/min N 2 purge at 10° C./min in Al pans.
- Form A has an FT-Raman Spectrum as depicted in FIG. 2 .
- Form A has a DSC thermograph substantially as depicted in FIG. 3 , comprising an endothermic event with a peak maximum temperature of about 54° C., and a second endotherm with an onset temperature of about 102° C.
- Form A has a TGA thermograph as depicted in FIG. 3 , comprising a total mass loss of approximately 6.2% of the total mass of the sample when heated to 150° C.
- Form B has an FT-Raman Spectrum as depicted in FIG. 6 .
- Form B has a DSC thermograph substantially as depicted in FIG. 7 , comprising a first endothermic event with an onset temperature of about 40.2° C. and a peak maximum temperature of about 47.7° C.
- Form B has a TGA thermograph as depicted in FIG. 7 , comprising a total mass loss of approximately 8.5% of the total mass of the sample when heated from approximately 25° C. and 150° C.
- Form C has an FT-Raman Spectrum as depicted in FIG. 10 .
- Form C has a DSC thermograph substantially as depicted in FIG. 11 , comprising an endothermic event with an onset temperature of about 101.7° C.
- Form B has a TGA thermograph as depicted in FIG. 11 , comprising a total mass loss of approximately 14.3% of the total mass of the sample when heated to about 150° C.
- Form D has an FT-Raman Spectrum as depicted in FIG. 14 .
- Form D has a DSC thermograph substantially as depicted in FIG. 15 , comprising an endothermic event with an onset temperature of about 96° C. and a peak maximum temperature of about 111° C.
- Form D has a TGA thermograph as depicted in FIG. 15 , comprising a total mass loss of approximately 0.4% of the total mass of the sample when heated from approximately 25° C. to 125° C.
- Form E has an FT-Raman Spectrum as depicted in FIG. 18 .
- Form E has a DSC thermograph substantially as depicted in FIG. 19 , comprising a possible melting endotherm with an onset temperature of about 106° C.
- Form E has a TGA thermograph as depicted in FIG. 19 , comprising a total mass loss of approximately 0.3% of the total mass of the sample when heated from approximately 25° C. to about 125° C.
- Form F has an FT-Raman Spectrum as depicted in FIG. 22 .
- Form F has a DSC thermograph substantially as depicted in FIG. 23 , comprising an endothermic event with an onset temperature of about 48° C. and a peak maximum temperature of about 63° C.
- Form F has a TGA thermograph as depicted in FIG. 23 , comprising a total mass loss of approximately 8.9% of the total mass of the sample when heated from approximately 25° C. to about 125° C.
- Form E was suspended in a 10% mixture of water in acetonitrile and seeded with a small amount of Form D (1 mg) or Form I (1 mg) and the suspension was allowed to stir at ambient temperature overnight. The resulting mixture was then stirred while cycling the temperature between 5° C. and 30° C. over a period of 48 h. The resulting mixture was filtered to yield Form H of Compound 1.
- Form E was suspended in a 10% mixture of water in 1-propanol and seeded with a small amount of Form D (1 mg) or Form I (1 mg) and the suspension was allowed to stir at ambient temperature overnight. The resulting mixture was then stirred while cycling the temperature between 5° C. and 30° C. over a period of 48 h. The resulting mixture was filtered to yield Form H of Compound 1.
- Form H has an FT-Raman Spectrum as depicted in FIG. 26 .
- Form H has a DSC thermograph substantially as depicted in FIG. 27 , comprising an endothermic event with a peak maximum temperature of about 56° C. and a second endothermic event with a peak maximum temperature of about 94° C.
- Form H has a TGA thermograph as depicted in FIG. 27 , comprising a total mass loss of approximately 7.7% of the total mass of the sample when heated from approximately 25° C. and 80° C.
- Form H of Compound 1 is dried under vacuum with nitrogen gas bleed at 65° C. overnight or two days to yield Form I of Compound 1.
- Form I has an FT-Raman Spectrum as depicted in FIG. 30 .
- Form I has a DSC thermograph substantially as depicted in FIG. 31 , comprising an endothermic event with an onset temperature of about 82° C. and a peak maximum temperature of about 93° C.
- DSC analysis showed a possible dehydration endotherm between 25° C. and 80° C.
- Form I has a TGA thermograph as depicted in FIG. 31 , comprising a total mass loss of approximately 1.6% of the total mass of the sample when heated from approximately 25° C. to about 110° C.
- Form J has a Raman Spectrum as depicted in FIG. 34 .
- Form J has a DSC thermograph substantially as depicted in FIG. 35 , comprising an endothermic peak with onset temperature of 143.4° C.
- Form J has a TGA thermograph as depicted in FIG. 35 , comprising a total mass loss of approximately 0.1% of the total mass of the sample when heated to 100° C.
- Compound 1 (130 mg) was dried in a vacuum oven at 35° C. for 3 hours, then mixed with ethyl methyl ketone (3.5 mL). The sample was filtered via 0.2 ⁇ m PTFE-membraned syringe filter. The filtrate was evaporated in fume hood under nitrogen purge until precipitates were visually observed. The sample was capped and stirred at 500 rotations per minute at ambient temperature for about a day. The solids were isolated via 0.2 ⁇ m Nylon-membraned centrifuge tube filter and further dried in vacuum oven at 35° C. for about a day to yield Form J of Compound 1.
- Form K has a DSC thermograph substantially as depicted in FIG. 37 , comprising endothermic peaks with peak maximum temperatures of approximately 98.9° C. and 113.7° C., respectively.
- Form K has a TGA thermograph as depicted in FIG. 37 , comprising a total mass loss of approximately 0.1% of the total mass of the sample when heated to 90° C.
- Form K of Compound 1 was dried in vacuum oven at 35° C. for two days. A portion of the sample was heated to 121° C. at 10° C./min on DSC in a crimped pan with a pin hole on its lid. The solid residue was recovered as Form L of Compound 1.
- Form L has a Raman Spectrum as depicted in FIG. 39 .
- a list of X-Ray diffraction peaks for Form L is provided below in Table 11.
- Form K of Compound 1 was dried in vacuum oven at 35° C. for two days. A portion of the sample was heated to 102° C. at 10° C./min on DSC in a crimped pan with a pin hole on its lid. The solid residue was recovered as Form M of Compound 1.
- Form M has a Raman Spectrum as depicted in FIG. 41 .
- a list of X-Ray diffraction peaks for Form M is provided below in Table 12.
- Form E of Compound 1 (8.6 mg) was mixed with Milli-Q water (0.12 mL) in a clear glass vial. The sample was capped and stirred at 400 rotations per minute at ambient temperature for 5 days. The solids were isolated via 0.2 ⁇ m Nylon-membraned centrifuge tube filter, and dried in vacuum oven at 35° C. for one day to obtain Form N of Compound 1.
- Form N has a Raman Spectrum as depicted in FIG. 43 .
- Form N has a DSC thermograph substantially as depicted in FIG. 44 , comprising an endothermic peak with onset temperature of approximately 85.7° C.
- Form N has a TGA thermograph as depicted in FIG. 44 , comprising a total mass loss of approximately 1.2% of the total mass of the sample when heated to 105.5° C.
- a weighed sample of each of Form A, Form B, Form C, Form D, Form E, Form F, Form H, and Form I is treated with aliquots of the test solvent at ambient temperature or elevated temperature.
- Complete dissolution of the test material is determined by visual inspection. Solubility is estimated based on the total solvent used to provide complete dissolution of the sample. The actual solubility may be greater than the value calculated because of the use of solvent aliquots that were too large or due to a slow rate of dissolution.
- a weighed sample of each of Form J, Form K, Form L, Form M, or Form N is treated with aliquots of the test solvent at ambient temperature or elevated temperature.
- Complete dissolution of the test material is determined by visual inspection. Solubility is estimated based on the total solvent used to provide complete dissolution of the sample. The actual solubility may be greater than the value calculated because of the use of solvent aliquots that were too large or due to a slow rate of dissolution.
- Stability of each of Form A, Form B, Form C, Form D, Form E, Form F, Form H, and Form I is determined by exposing the sample to a 40° C./75% relative humidity (RH) environment for four weeks or 11% RH at ambient temperature for four days.
- RH relative humidity
- stability of each of Form J, Form K, Form L, Form M, or Form N is determined by exposing the sample to a 40° C./75% relative humidity (RH) environment for four weeks or 11% RH at ambient temperature for four days.
- RH relative humidity
- the compounds are useful in the treatment of a variety of S1P1 receptor-mediated clinical conditions, including autoimmune/inflammatory diseases; rheumatoid arthritis; lupus; insulin dependent diabetes (Type I); non-insulin dependent diabetes (Type II); multiple sclerosis; psoriasis; ulcerative colitis; inflammatory bowel disease; Crohn's disease; acute and chronic lymphocytic leukemias and lymphomas. Therefore, the compounds of the invention may be assayed for their ability to modulate the S1P1 receptor activity. See Colandrea, Biorg. Med. Chem. Lett. 2006, 16(11):2905-2908.
- the solid forms described herein are evaluated using a [ 35 S]-GTPgammaS binding assay to monitor dose-dependent selectivity against S1P1 receptors.
- the assay is completed with sample solid forms subjected to an eight-point, four-fold dose response curve with starting concentration of 10 ⁇ M.
- Selectivity is determined upon initial addition of solid forms followed by an incubation period. Following compound incubation, bounded [ 35 S]-GTPgammaS is determined by filtration and scintillation counting. Percentage activation and inhibition values are determined relative to the reference agonist at S1P1.
- solid forms described herein are evaluated using a [ 35 S]-GTPgammaS binding assay to monitor dose-dependent selectivity against S1P1 receptors.
- the assay is completed with sample solid forms subjected to an eight-point, four-fold dose response curve with starting concentration of 10 ⁇ M.
- Selectivity is determined upon initial addition of solid forms followed by an incubation period. Following compound incubation, bounded [ 35 S]-GTPgammaS is determined by filtration and scintillation counting. Percentage activation and inhibition values are determined relative to the reference agonist at S1P1.
- modulators of the S1P1 receptor also have accelerating lymphocyte homing properties. These properties may be measured using a blood lymphocyte depletion assay.
- the solid forms described herein e.g., Form A, Form B, Form C, Form D, Form E, Form F, Form H, and Form I
- the solid forms described herein are administered orally by gavage to rats.
- Tail blood for hematological monitoring is obtained on day 1 to give the baseline individual values, and at 2, 6, 24, 48 and 72 hours after application.
- the change in peripheral blood lymphocytes is measured across different doses of the solid forms.
- solid forms described herein are administered orally by gavage to rats.
- Tail blood for hematological monitoring is obtained on day 1 to give the baseline individual values, and at 2, 6, 24, 48 and 72 hours after application.
- the change in peripheral blood lymphocytes is measured across different doses of the solid forms.
- the stability of each of Form A, Form B, Form C, Form D, Form E, Form F, Form H, and Form I is determined according to standard procedures known in the art. For example, stability of each of Form A, Form B, Form C, Form D, Form E, Form F, Form H, and Form I is established by an in vitro assay.
- An in vitro hepatic microsome stability assay measures the stability of one or more subject compounds when reacting with mouse, rat or human microsomes.
- each of Form J, Form K, Form L, Form M, and Form N is determined according to standard procedures known in the art.
- stability of each of Form J, Form K, Form L, Form M, and Form N is established by an in vitro assay.
- An in vitro hepatic microsome stability assay measures the stability of one or more subject compounds when reacting with mouse, rat or human microsomes.
- Incubations with liver microsomes are conducted in a final volume of 0.1 mL per incubation time point. 10 ⁇ M of the subject compound from a stock solution in DMSO (final DMSO concentration of 0.1%) is incubated at 37° C. from 0-60 min with pooled microsomal protein (1.0 mg/mL), suspended in incubation buffer (0.1 M potassium phosphate, pH 7.4, 5 mM MgCl 2 , and 0.1 mM EDTA). The microsomal reaction is initiated by the addition of NADPH (3 mM final concentration). Incubations with (a) no protein or (b) no NADPH serve as controls. Reactions are terminated by the addition of 0.2 mL of stop solution (acetonitrile).
- the samples are vortex-mixed for 30 sec and then centrifuged at 10,000 ⁇ g for 10 min.
- the supernatant is dried using a Labconco CentriVap concentrator and the dry residue reconstituted in water, transferred to an HPLC glass vial and analyzed by HPLC-UV. The disappearance of the subject compound is used to evaluate the in vitro metabolism thereof.
Abstract
Description
- This application claims the benefit of U.S. Provisional Application No. 62/591,880, filed on Nov. 29, 2017, and U.S. Provisional Application No. 62/469,150, filed on Mar. 9, 2017, each of which is incorporated herein by reference in its entirety.
- Provided herein are solid forms comprising (E)-1-(4-(1-(((4-cyclohexyl-3-(trifluoromethyl)benzyl)oxy)imino)ethyl)-2-ethylbenzyl)azetidine-3-carboxylic acid, or a tautomer thereof. Pharmaceutical compositions comprising such solid forms and methods of use of such solid forms for treating, preventing, and managing various disorders are also provided herein.
- When the immune system functions normally, it produces a response intended to protect against harmful or foreign substances such as bacteria, parasites, and cancerous cells. Autoimmune diseases arise when the immune system attacks one or more of the body's normal constituents as if they were a foreign substance. These attacks cause inflammation and tissue damage that may lead to autoimmune disorders. There are more than 80 diseases that occur as a result of the body's autoimmune response to various harmful or foreign substances, affecting more than 23.5 million people in the United States. Some of the most common types of autoimmune or chronic inflammatory diseases include Graves' disease,
Type 1 diabetes, multiple sclerosis, inflammatory bowel disease, systemic lupus, polymyositis, dermatomyositis, lupus nephritis, rheumatoid arthritis, and psoriasis. - Multiple Sclerosis (“MS”) is an autoimmune disease of the central nervous system, characterized by degeneration of the protective sheath (“myelin”) that covers nerve fibers in the brain and spinal cord. More than 2.5 million people in the world suffer from MS, and it is the most common neurologic, disabling disease in young adults. Diagnosis is generally made between 15 and 50 years of age, with symptoms either occurring in recurring, isolated attacks (i.e., relapsing forms) or symptoms increasing over time (i.e., progressive forms). Permanent neurological dysfunction can result from incomplete recovery from acute relapses or as a consequence of slow progression of disability.
- There is a need in the art for novel drug products for the treatment of MS and other autoimmune diseases of the central nervous systems. Alternative solid forms of pharmaceutical compounds have emerged as a possible approach to modulate or enhance the physical and chemical properties of drug products. The identification and selection of a solid form of a pharmaceutical compound are complex, given that a change in solid form may affect a variety of physical and chemical properties, which may provide benefits or drawbacks in processing, formulation, stability, bioavailability, storage, handling (e.g., shipping), among other important pharmaceutical characteristics. Useful pharmaceutical solid forms include crystalline solids and amorphous solids, depending on the product and its mode of administration. Amorphous solids are characterized by a lack of long-range structural order, whereas crystalline solids are characterized by structural periodicity. The desired class of pharmaceutical solid depends upon the specific application; amorphous solids are sometimes selected on the basis of, e.g., an enhanced dissolution profile, while crystalline solids may be desirable for properties such as, e.g., physical or chemical stability (see, e.g., S. R. Vippagunta et al., Adv. Drug. Deliv. Rev., (2001) 48:3-26; L. Yu, Adv. Drug. Deliv. Rev., (2001) 48:27-42).
- Notably, it is not possible to predict a priori if crystalline forms of a compound even exist, let alone how to successfully prepare them (see, e.g., Braga and Grepioni, 2005, “Making crystals from crystals: a green route to crystal engineering and polymorphism,” Chem. Commun.:3635-3645 (with respect to crystal engineering, if instructions are not very precise and/or if other external factors affect the process, the result can be unpredictable); Jones et al., 2006, Pharmaceutical Cocrystals: An Emerging Approach to Physical Property Enhancement,” MRS Bulletin 31:875-879 (at present it is not generally possible to computationally predict the number of observable polymorphs of even the simplest molecules); Price, 2004, “The computational prediction of pharmaceutical crystal structures and polymorphism,” Advanced Drug Delivery Reviews 56:301-319 (“Price”); and Bernstein, 2004, “Crystal Structure Prediction and Polymorphism,” ACA Transactions 39:14-23 (a great deal still needs to be learned and done before one can state with any degree of confidence the ability to predict a crystal structure, much less polymorphic forms)).
- The variety of possible solid forms creates potential diversity in physical and chemical properties for a given pharmaceutical compound. The discovery and selection of solid forms are of great importance in the development of an effective, stable and marketable pharmaceutical product.
- Provided herein are solid forms comprising Compound 1 (e.g., crystalline forms, amorphous forms, polymorphs or mixtures thereof):
- having the name (E)-1-(4-(1-(((4-cyclohexyl-3-(trifluoromethyl)benzyl)oxy)imino)ethyl)-2-ethylbenzyl)azetidine-3-carboxylic acid, including tautomers thereof. Also provided herein are methods of preparing, isolating, and characterizing the solid forms.
- In one embodiment, described herein is a solid
form comprising Compound 1, or a tautomer thereof: - which has an X-ray powder diffraction pattern comprising three or more characteristic peaks at approximately 2.3, 3.9, 7.7, 11.5, or 20.9° 2θ. In a certain embodiment, the solid form has an X-ray powder diffraction pattern comprising four or more characteristic peaks at approximately 2.3, 3.9, 7.7, 11.5, or 20.9° 2θ. In a certain embodiment, the solid form has an X-ray powder diffraction pattern comprising five or more characteristic peaks at approximately 2.3, 3.9, 7.7, 11.5, or 20.9° 2θ. In a certain embodiment, the solid form has an X-ray powder diffraction pattern substantially as shown in
FIG. 1 . In a certain embodiment, the solid form has a DSC thermogram comprising an endothermic event with a peak maximum temperature of about 54° C. and another endothermic event with an onset temperature of about 102° C. In a certain embodiment, the solid form is solvated by isopropyl ether. - In another embodiment, described herein is a solid
form comprising Compound 1, or a tautomer thereof: - which has an X-ray powder diffraction pattern comprising three or more characteristic peaks at approximately 2.3, 2.8, 7.7, 8.4, 11.5, or 20.9° 2θ. In a certain embodiment, the solid form has an X-ray powder diffraction pattern comprising four or more characteristic peaks at approximately 2.3, 2.8, 7.7, 8.4, 11.5, or 20.9° 2θ. In a certain embodiment, the solid form has an X-ray powder diffraction pattern comprising five or more characteristic peaks at approximately 2.3, 2.8, 7.7, 8.4, 11.5, or 20.9° 2θ. In a certain embodiment, the solid form has an X-ray powder diffraction pattern comprising six characteristic peaks at approximately 2.3, 2.8, 7.7, 8.4, 11.5, or 20.9° 2θ. In a certain embodiment, the solid form has an X-ray powder diffraction pattern substantially as shown in
FIG. 5 . In a certain embodiment, the solid form has a DSC thermograph comprising a first endothermic event with an onset temperature of about 40.2° C. and a peak maximum temperature of about 47.7° C. In a certain embodiment, the solid form is solvated by cyclohexane. - In another embodiment, provided herein is a solid
form comprising Compound 1, or a tautomer thereof: - which has an X-ray powder diffraction pattern comprising three or more characteristic peaks at approximately 2.2, 3.9, 6.5, 7.7, 11.5, or 20.9° 2θ. In a certain embodiment, the solid form has an X-ray powder diffraction pattern comprising four or more characteristic peaks at approximately 2.2, 3.9, 6.5, 7.7, 11.5, or 20.9° 2θ. In a certain embodiment, the solid form has an X-ray powder diffraction pattern comprising five or more characteristic peaks at approximately 2.2, 3.9, 6.5, 7.7, 11.5, or 20.9° 2θ. In a certain embodiment, the solid form has an X-ray powder diffraction pattern comprising six characteristic peaks at approximately 2.2, 3.9, 6.5, 7.7, 11.5, or 20.9° 2θ. In a certain embodiment, the solid form has an X-ray powder diffraction pattern substantially as shown in
FIG. 9 . In a certain embodiment, the solid form has a DSC thermogram comprising an endothermic event with an onset temperature of about 101.7° C. In a certain embodiment, the solid form is solvated by heptane. - In another embodiment, provided herein is a solid
form comprising Compound 1, or a tautomer thereof: - which has an X-ray powder diffraction pattern comprising three or more characteristic peaks at approximately 3.7, 7.3, 11.0, 18.3, or 22.9° 2θ. In a certain embodiment, wherein the solid form has an X-ray powder diffraction pattern comprising four or more characteristic peaks at approximately 3.7, 7.3, 11.0, 18.3, or 22.9° 2θ. In a certain embodiment, the solid form has an X-ray powder diffraction pattern comprising five characteristic peaks at approximately 3.7, 7.3, 11.0, 18.3, or 22.9° 2θ. In a certain embodiment, the solid form has an X-ray powder diffraction pattern substantially as shown in
FIG. 13 . In a certain embodiment, the solid form has a DSC thermogram comprising an endothermic event with an onset temperature of about 96° C. and a peak maximum temperature of about 111° C. In a certain embodiment, the solid form is non-solvated. - In another embodiment, provided herein is a solid form comprising Compound 1, or a tautomer thereof:
- which has an X-ray powder diffraction pattern comprising three or more characteristic peaks at approximately 3.9, 7.7, 11.6, 14.3, 20.9, or 24.5° 2θ. In a certain embodiment, the solid form has an X-ray powder diffraction pattern comprising four or more characteristic peaks at approximately 3.9, 7.7, 11.6, 14.3, 20.9, or 24.5° 2θ. In a certain embodiment, the solid form has an X-ray powder diffraction pattern comprising five or more characteristic peaks at approximately 3.9, 7.7, 11.6, 14.3, 20.9, or 24.5° 2θ. In a certain embodiment, the solid form has an X-ray powder diffraction pattern comprising six characteristic peaks at approximately 3.9, 7.7, 11.6, 14.3, 20.9, or 24.5° 2θ. In a certain embodiment, the solid form has an X-ray powder diffraction pattern substantially as shown in
FIG. 17 . In a certain embodiment, the solid form has a DSC thermogram comprising an endothermic event with an onset temperature of about 106° C. In a certain embodiment, the solid form is non-solvated. - In another embodiment, provided herein is a solid form comprising Compound 1, or a tautomer thereof:
- which has an X-ray powder diffraction pattern comprising three or more characteristic peaks at approximately 3.3, 9.9, 14.8, 19.9, 20.4, or 23.5° 2θ. In a certain embodiment, the solid form has an X-ray powder diffraction pattern comprising four or more characteristic peaks at approximately 3.3, 9.9, 14.8, 19.9, 20.4, or 23.5° 2θ. In a certain embodiment, the solid form has an X-ray powder diffraction pattern comprising five or more characteristic peaks at approximately 3.3, 9.9, 14.8, 19.9, 20.4, or 23.5° 2θ. In a certain embodiment, the solid form has an X-ray powder diffraction pattern comprising six characteristic peaks at approximately 3.3, 9.9, 14.8, 19.9, 20.4, or 23.5° 2θ. In a certain embodiment, the solid form has an X-ray powder diffraction pattern substantially as shown in
FIG. 21 . In a certain embodiment, the solid form has a DSC thermogram comprising an endothermic event with an onset temperature of about 48° C. and a peak maximum temperature of about 63° C. In a certain embodiment, the solid form is solvated by dimethyl carbonate. - In another embodiment, provided herein is a solid form comprising Compound 1, or a tautomer thereof:
- which has an X-ray powder diffraction pattern comprising three or more characteristic peaks at approximately 3.6, 7.2, 10.8, 17.8, 18.0, 18.3, or 21.7° 2θ. In a certain embodiment, the solid form has an X-ray powder diffraction pattern comprising four or more characteristic peaks at approximately 3.6, 7.2, 10.8, 17.8, 18.0, 18.3, or 21.7° 2θ. In a certain embodiment, the solid form has an X-ray powder diffraction pattern comprising five or more characteristic peaks at approximately 3.6, 7.2, 10.8, 17.8, 18.0, 18.3, or 21.7° 2θ. In a certain embodiment, the solid form has an X-ray powder diffraction pattern comprising six or more characteristic peaks at approximately 3.6, 7.2, 10.8, 17.8, 18.0, 18.3, or 21.7° 2θ. In a certain embodiment, the solid form has an X-ray powder diffraction pattern comprising seven characteristic peaks at approximately 3.6, 7.2, 10.8, 17.8, 18.0, 18.3, or 21.7° 2θ. In a certain embodiment, the solid form has an X-ray powder diffraction pattern substantially as shown in
FIG. 25 . In a certain embodiment, the solid form has a DSC thermogram comprising an endothermic event with a peak maximum temperature of about 56° C. and a second endothermic event with a peak maximum temperature of about 94° C. In a certain embodiment, the solid form is hydrated. - In another embodiment, provided herein is a solid form comprising Compound 1, or a tautomer thereof:
- which has an X-ray powder diffraction pattern comprising three or more characteristic peaks at approximately 4.0, 12.0, 17.6, 20.1 or 21.5° 2θ. In a certain embodiment, the solid form has an X-ray powder diffraction pattern comprising four or more characteristic peaks at approximately 4.0, 12.0, 17.6, 20.1 or 21.5° 2θ. In a certain embodiment, the solid form an X-ray powder diffraction pattern comprising five characteristic peaks at approximately 4.0, 12.0, 17.6, 20.1 or 21.5° 2θ. In a certain embodiment, the solid form has an X-ray powder diffraction pattern substantially as shown in
FIG. 29 . In a certain embodiment, the solid form has a DSC thermogram comprising an endothermic event with a peak maximum temperature of about 54° C. and a second endothermic event with an onset temperature of about 82° C. and a peak maximum temperature of about 93° C. In a certain embodiment, the solid form is hydrated. - In another embodiment, provided herein are pharmaceutical compositions comprising one or more of the solid forms described herein. In certain embodiments, the solid form is no less than 95% pure. In certain embodiments, the pharmaceutical composition further comprises a second solid form described herein. In certain embodiments, the pharmaceutical composition further comprises an amorphous form of
Compound 1. In certain embodiments, the pharmaceutical composition further comprises a pharmaceutically acceptable excipient or carrier. In certain embodiments, the pharmaceutical composition is a single unit dosage form. In certain embodiments, the pharmaceutical composition is a tablet. In certain embodiments, the pharmaceutical composition is a capsule. - In another embodiment, provided herein is a method of treating multiple sclerosis, wherein the method comprises administering to a patient in need thereof a therapeutically effective amount of a solid form described herein. In another embodiment, provided herein is a method of treating multiple sclerosis, wherein the method comprises administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition described herein.
- In another embodiment, provided herein is a method of treating psoriasis, wherein the method comprises administering to a patient in need thereof a therapeutically effective amount of a solid form described herein. In another embodiment, provided herein is a method of treating psoriasis, wherein the method comprises administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical formulation described herein.
- In another embodiment, provided herein is a method of treating polymyositis, wherein the method comprises administering to a patient in need thereof a therapeutically effective amount of a solid form described herein. In another embodiment, provided herein is a method of treating polymyositis, wherein the method comprises administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical formulation described herein.
- In another embodiment, provided herein is a method of making a solid form comprising Compound 1, or a tautomer thereof:
- which has an X-ray powder diffraction pattern comprising at least three characteristic peaks at approximately 2.3, 3.9, 7.7, 11.5, or 20.9° 2θ, comprising:
-
- a) obtaining a slurry of
Compound 1 in isopropyl ether; - b) stirring the slurry for about 72 h while cycling the temperature between about 5° C. and about 40° C.; and
- c) collecting the solids from the slurry by filtration.
- a) obtaining a slurry of
- In another embodiment, provided herein is a method of making a solid form comprising Compound 1, or a tautomer thereof:
- which has an X-ray powder diffraction pattern comprising at least three characteristic peaks at approximately 2.3, 2.8, 7.7, 8.4, 11.5, or 20.9° 2θ, comprising:
-
- a) obtaining a slurry of
Compound 1 in cyclohexane; - b) stirring the slurry for about 72 h while cycling the temperature between about 5° C. and about 40° C.; and
- c) collecting the solids from the slurry by filtration.
- a) obtaining a slurry of
- In another embodiment, provided herein is a method of making a solid form comprising Compound 1, or a tautomer thereof:
- which has an X-ray powder diffraction pattern comprising at least three characteristic peaks at approximately 2.2, 3.9, 6.5, 7.7, 11.5, or 20.9° 2θ, comprising:
-
- a) obtaining a slurry of
Compound 1 in heptane; - b) stirring the slurry for about 72 h while cycling the temperature between about 5° C. and about 40° C.; and
- c) collecting the solids from the slurry by filtration.
- a) obtaining a slurry of
- In another embodiment, provided herein is a method of making a solid form comprising Compound 1, or a tautomer thereof:
- which has an X-ray powder diffraction pattern comprising at least three characteristic peaks at approximately 3.7, 7.3, 11.0, 18.3, or 22.9° 20, comprising:
-
- a) obtaining a slurry of
Compound 1 in dimethyl carbonate; and - b) stirring the slurry for about 72 h while cycling the temperature between about 5° C. and about 40° C.
- c) collecting the solids from the slurry by filtration; and
- d) drying the solids with a flow of inert gas under vacuum at 65° C.
- a) obtaining a slurry of
- In another embodiment, provided herein is a method of making a solid form comprising Compound 1, or a tautomer thereof:
- which has an X-ray powder diffraction pattern comprising at least three characteristic peaks at approximately 3.9, 7.7, 11.6, 14.3, 20.9, or 24.5° 2θ, comprising:
-
- a) obtaining a solution of
Compound 1 in isopropyl ether; - b) seeding the solution with a small amount of Form E described herein;
- c) stirring the solution overnight or about 48 h while cycling the temperature between about 5° C. and about 40° C.; and
- d) collecting the solids from the slurry by filtration; and
- e) drying the solids with a flow of inert gas under vacuum at 65° C.
- a) obtaining a solution of
- In another embodiment, provided herein is a method of making a solid form comprising Compound 1, or a tautomer thereof:
- which has an X-ray powder diffraction pattern comprising characteristic peaks at approximately 3.3, 9.9, 14.8, 19.9, 20.4, or 23.5° 2θ, comprising:
-
- a) obtaining a slurry of
Compound 1 in dimethyl carbonate; - b) seeding the slurry with a small amount of Form D described herein;
- c) stirring the slurry for about 12 h at 20° C.; and
- d) collecting the solids from the slurry by centrifugation followed by decanting and drying.
- a) obtaining a slurry of
- In another embodiment, provided herein is a method of making a solid form comprising Compound 1, or a tautomer thereof:
- which has an X-ray powder diffraction pattern comprising at least three characteristic peaks at approximately 3.6, 7.2, 10.8, 17.8, 18.0, 18.3, or 21.7° 2θ, comprising:
-
- a) obtaining a slurry of Form E of
Compound 1 in dimethyl carbonate; - b) seeding the slurry with a small amount of Form D or Form I described herein;
- c) stirring the slurry for about 48 h while cycling the temperature between about 5° C. and about 30° C.; and
- d) collecting the solids from the slurry by filtration.
- a) obtaining a slurry of Form E of
- In another embodiment, provided herein is a method of making a solid form comprising Compound 1, or a tautomer thereof:
- which has an X-ray powder diffraction pattern comprising at least three characteristic peaks at approximately 4.0, 12.0, 17.6, 20.1 or 21.5° 2θ, comprising:
-
- a) obtaining a saturated solution of
Compound 1 in dimethylformamide; - b) adding water into the saturated solution at an ambient temperature;
- c) stirring the slurry for about 4 days while cycling the temperature between about 20° C. and about 50° C.; and
- d) evaporating the mixture under a flow of nitrogen gas at ambient temperature over 14 days.
- a) obtaining a saturated solution of
- In another embodiment, provided herein is a solid form comprising Compound 1, or a tautomer thereof:
- which has an X-ray powder diffraction pattern comprising three or more characteristic peaks at approximately 7.9, 11.9, 13.4, 15.7, 17.4, or 20.0° 2θ. In certain embodiments, the solid form has an X-ray powder diffraction pattern comprising four or more characteristic peaks at approximately 7.9, 11.9, 13.4, 15.7, 17.4, or 20.0° 2θ. In certain embodiments, the solid form has an X-ray powder diffraction pattern comprising five or more characteristic peaks at approximately 7.9, 11.9, 13.4, 15.7, 17.4, or 20.0° 2θ. In certain embodiments, the solid form has an X-ray powder diffraction pattern comprising six or more characteristic peaks at approximately 7.9, 11.9, 13.4, 15.7, 17.4, or 20.0° 2θ. In certain embodiments, the solid form has an X-ray powder diffraction pattern substantially as shown in
FIG. 33 . In certain embodiments, the solid form has a DSC thermogram comprising an endothermic event with an onset temperature of 143.4° C. - In another embodiment, provided herein is a solid form comprising Compound 1, or a tautomer thereof:
- which has an X-ray powder diffraction pattern comprising three or more characteristic peaks at approximately 7.3, 8.0, 10.0, 10.9, 12.0, 17.5, or 20.1° 2θ. In certain embodiments, the solid form has an X-ray powder diffraction pattern comprising four or more characteristic peaks at approximately 7.3, 8.0, 10.0, 10.9, 12.0, 17.5, or 20.1° 2θ. In certain embodiments, the solid form has an X-ray powder diffraction pattern comprising five or more characteristic peaks at approximately 7.3, 8.0, 10.0, 10.9, 12.0, 17.5, or 20.1° 2θ. In certain embodiments, the solid form has an X-ray powder diffraction pattern comprising six or more characteristic peaks at approximately 7.3, 8.0, 10.0, 10.9, 12.0, 17.5, or 20.1° 2θ. In certain embodiments, the solid form has an X-ray powder diffraction pattern substantially as shown in
FIG. 36 . In certain embodiments, the solid form has a DSC thermogram comprising endothermic events with peak maximum temperatures of approximately 98.9° C. and 113.7° C., respectively. - In another embodiment, provided herein is a solid form comprising Compound 1, or a tautomer thereof:
- which has an X-ray powder diffraction pattern comprising three or more characteristic peaks at approximately 11.5, 12.0, 13.4, 17.5, 20.1, or 21.3° 2θ. In certain embodiments, the solid form has an X-ray powder diffraction pattern comprising four or more characteristic peaks at approximately 11.5, 12.0, 13.4, 17.5, 20.1, or 21.3° 2θ. In certain embodiments, the solid form has an X-ray powder diffraction pattern comprising five or more characteristic peaks at approximately 11.5, 12.0, 13.4, 17.5, 20.1, or 21.3° 2θ. In certain embodiments, the solid form has an X-ray powder diffraction pattern comprising six or more characteristic peaks at approximately 11.5, 12.0, 13.4, 17.5, 20.1, or 21.3° 2θ. In certain embodiments, the solid form has an X-ray powder diffraction pattern substantially as shown in
FIG. 38 . - In another embodiment, provided herein is a solid form comprising Compound 1, or a tautomer thereof:
- which has an X-ray powder diffraction pattern comprising three or more characteristic peaks at approximately 7.2, 9.5, 12.0, 16.4, 18.2, or 22.8° 2θ. In certain embodiments, the solid form has an X-ray powder diffraction pattern comprising four or more characteristic peaks at approximately 7.2, 9.5, 12.0, 16.4, 18.2, or 22.8° 2θ. In certain embodiments, the solid form has an X-ray powder diffraction pattern comprising five or more characteristic peaks at approximately 7.2, 9.5, 12.0, 16.4, 18.2, or 22.8° 2θ. In certain embodiments, the solid form has an X-ray powder diffraction pattern comprising six or more characteristic peaks at approximately 7.2, 9.5, 12.0, 16.4, 18.2, or 22.8° 2θ. In certain embodiments, the solid form has an X-ray powder diffraction pattern substantially as shown in
FIG. 40 . - In certain embodiments, provided herein is a solid form comprising Compound 1, or a tautomer thereof:
- which has an X-ray powder diffraction pattern comprising three or more characteristic peaks at approximately 12.0, 13.5, 17.7, 20.1, 21.6, or 23.7° 2θ. In certain embodiments, the solid form has an X-ray powder diffraction pattern comprising four or more characteristic peaks at approximately 12.0, 13.5, 17.7, 20.1, 21.6, or 23.7° 2θ. In certain embodiments, the solid form has an X-ray powder diffraction pattern comprising five or more characteristic peaks at approximately 12.0, 13.5, 17.7, 20.1, 21.6, or 23.7° 2θ. In certain embodiments, the solid form has an X-ray powder diffraction pattern comprising six or more characteristic peaks at approximately 12.0, 13.5, 17.7, 20.1, 21.6, or 23.7° 2θ. In certain embodiments, the solid form has an X-ray powder diffraction pattern substantially as shown in
FIG. 42 . In certain embodiments, the solid form has a DSC thermogram comprising an endothermic event with an onset temperature of approximately 85.7° C. - In another embodiment, provided herein is a method of making a solid form comprising Compound 1, or a tautomer thereof:
- which has an X-ray powder diffraction pattern comprising at least three characteristic peaks at approximately 7.9, 11.9, 13.4, 15.7, 17.4, or 20.0° 2θ, comprising:
-
- a)
mixing Compound 1 with ethyl methyl ketone; - b) sonicating for 5 minutes;
- c) filtering via 0.2 μm PTFE-membraned syringe filter;
- d) evaporating the filtrate to dryness under nitrogen purge;
- e) adding ethyl methyl ketone to the sample;
- f) capping the sample and stirring at 500 rotations per minute for about a day; and
- g) collecting solids from the sample by filtration and drying the collected solids in a vacuum oven at 35° C. for about a day.
- a)
- In another embodiment, provided herein is a method of making a solid form comprising Compound 1, or a tautomer thereof:
- which has an X-ray powder diffraction pattern comprising at least three characteristic peaks at approximately 7.3, 8.0, 10.0, 10.9, 12.0, 17.5, or 20.1° 2θ, comprising:
-
- a)
drying Compound 1 in a vacuum oven at 35° C. for 3 hours; - b) adding ethyl methyl ketone to the sample;
- c) filtering via 0.2 um PTFE-membraned syringe filter;
- d) evaporating the filtrate under nitrogen purge until precipitates were observed;
- e) capping the sample and stirring at 500 rotations per minute for about a day; and
- f) collecting solids from the sample by filtration and drying the collected solids in a vacuum oven at 35° C. for about a day.
- a)
- In another embodiment, provided herein is a method of making a solid form comprising Compound 1, or a tautomer thereof:
- which has an X-ray powder diffraction pattern comprising at least three characteristic peaks at approximately 11.5, 12.0, 13.4, 17.5, 20.1, or 21.3° 2θ, comprising:
-
- a) drying Form K of
Compound 1 in a vacuum oven at 35° C. for about two days; and - b) heating the sample to 121° C. at 10° C. per minute in a crimped pan with a pin hole on its lid.
- a) drying Form K of
- In another embodiment, provided herein is a method of making a solid form comprising Compound 1, or a tautomer thereof:
- which has an X-ray powder diffraction pattern comprising at least three characteristic peaks at approximately 7.2, 9.5, 12.0, 16.4, 18.2, or 22.8° 2θ, comprising:
-
- a) drying Form K of
Compound 1 in a vacuum oven at 35° C. for about two days; and - b) heating the sample to 102° C. at 10° C. per minute in a crimped pan with a pin hole on its lid.
- a) drying Form K of
- In another embodiment, provided herein is a method of making a solid form comprising Compound 1, or a tautomer thereof:
- which has an X-ray powder diffraction pattern comprising at least three characteristic peaks at approximately 12.0, 13.5, 17.7, 20.1, 21.6, or 23.7° 2θ, comprising:
-
- a) mixing Form E of
Compound 1 with Milli-Q water; - b) capping the sample and stirring at 400 rotations per minute for about 5 days; and
- c) collecting solids from the sample by filtration and drying the collected solids in a vacuum oven at 35° C. for about a day.
- a) mixing Form E of
-
FIG. 1 depicts a PXRD pattern of Form A ofCompound 1. -
FIG. 2 depicts an FT-Raman spectrum of Form A ofCompound 1. -
FIG. 3 depicts differential scanning calorimetry/thermal gravimetric analysis of Form A ofCompound 1. -
FIG. 4 depicts polarized-light microscopy of Form A ofCompound 1. -
FIG. 5 depicts a PXRD pattern of Form B ofCompound 1. -
FIG. 6 depicts an FT-Raman spectrum of Form B ofCompound 1. -
FIG. 7 depicts differential scanning calorimetry/thermal gravimetric analysis of Form B ofCompound 1. -
FIG. 8 depicts polarized-light microscopy of Form B ofCompound 1. -
FIG. 9 depicts a PXRD pattern of Form C ofCompound 1. -
FIG. 10 depicts an FT-Raman spectrum of Form C ofCompound 1. -
FIG. 11 depicts differential scanning calorimetry/thermal gravimetric analysis of Form C ofCompound 1. -
FIG. 12 depicts polarized-light microscopy of Form C ofCompound 1. -
FIG. 13 depicts a PXRD pattern of Form D ofCompound 1. -
FIG. 14 depicts an FT-Raman spectrum of Form D ofCompound 1. -
FIG. 15 depicts differential scanning calorimetry/thermal gravimetric analysis of Form D ofCompound 1. -
FIG. 16 depicts polarized-light microscopy of Form D ofCompound 1. -
FIG. 17 depicts a PXRD pattern of Form E ofCompound 1. -
FIG. 18 depicts an FT-Raman spectrum of Form E ofCompound 1. -
FIG. 19 depicts differential scanning calorimetry/thermal gravimetric analysis of Form E ofCompound 1. -
FIG. 20 depicts polarized-light microscopy of Form E ofCompound 1. -
FIG. 21 depicts a PXRD pattern of Form F ofCompound 1. -
FIG. 22 depicts an FT-Raman spectrum of Form F ofCompound 1. -
FIG. 23 depicts differential scanning calorimetry/thermal gravimetric analysis of Form F ofCompound 1. -
FIG. 24 depicts polarized-light microscopy of Form F ofCompound 1. -
FIG. 25 depicts a PXRD pattern of Form H ofCompound 1. -
FIG. 26 depicts an FT-Raman spectrum of Form H ofCompound 1. -
FIG. 27 depicts differential scanning calorimetry/thermal gravimetric analysis of Form H ofCompound 1. -
FIG. 28 depicts polarized-light microscopy of Form H ofCompound 1. -
FIG. 29 depicts a PXRD pattern of Form I ofCompound 1. -
FIG. 30 depicts an FT-Raman spectrum of Form I ofCompound 1. -
FIG. 31 depicts differential scanning calorimetry/thermal gravimetric analysis of Form I ofCompound 1. -
FIG. 32 depicts polarized-light microscopy of Form I ofCompound 1. -
FIG. 33 depicts a PXRD pattern of Form J ofCompound 1. -
FIG. 34 depicts a Raman spectrum of Form J ofCompound 1. -
FIG. 35 depicts differential scanning calorimetry/thermal gravimetric analysis of Form J ofCompound 1. -
FIG. 36 depicts a PXRD pattern of Form K ofCompound 1. -
FIG. 37 depicts differential scanning calorimetry/thermal gravimetric analysis of Form K ofCompound 1. -
FIG. 38 depicts a PXRD pattern of Form L ofCompound 1. -
FIG. 39 depicts a Raman spectrum of Form L ofCompound 1. -
FIG. 40 depicts a PXRD pattern of Form M ofCompound 1. -
FIG. 41 depicts a Raman spectrum of Form M ofCompound 1. -
FIG. 42 depicts a PXRD pattern of Form N ofCompound 1. -
FIG. 43 depicts a Raman spectrum of Form N ofCompound 1. -
FIG. 44 depicts differential scanning calorimetry/thermal gravimetric analysis of Form N ofCompound 1. - 5.1 Definitions
- As used herein, and unless otherwise specified, the terms “about” and “approximately,” when used in connection with doses, amounts, or weight percents of ingredients of a composition or a dosage form, mean a dose, amount, or weight percent that is recognized by one of ordinary skill in the art to provide a pharmacological effect equivalent to that obtained from the specified dose, amount, or weight percent. In certain embodiments, the terms “about” and “approximately,” when used in this context, contemplate a dose, amount, or weight percent within 30%, within 20%, within 15%, within 10%, or within 5%, of the specified dose, amount, or weight percent.
- As used herein, and unless otherwise specified, the terms “about” and “approximately,” when used in connection with a numeric value or range of values which is provided to characterize a particular solid form, e.g., a specific temperature or temperature range, such as, for example, that describes a melting, dehydration, desolvation, or glass transition temperature; a mass change, such as, for example, a mass change as a function of temperature or humidity; a solvent or water content, in terms of, for example, mass or a percentage; or a peak position, such as, for example, in analysis by, for example, infrared (IR) or Raman spectroscopy or X-ray powder diffractometry (PXRD); indicate that the value or range of values may deviate to an extent deemed reasonable to one of ordinary skill in the art while still describing the solid form. Techniques for characterizing crystal forms and amorphous forms include, but are not limited to, thermal gravimetric analysis (TGA), differential scanning calorimetry (DSC), PXRD, single-crystal X-ray diffractometry, vibrational spectroscopy, e.g., IR and Raman spectroscopy, solid-state and solution nuclear magnetic resonance (NMR) spectroscopy, optical microscopy, hot stage optical microscopy, scanning electron microscopy (SEM), electron crystallography and quantitative analysis, particle size analysis (PSA), surface area analysis, solubility studies, and dissolution studies. In certain embodiments, the terms “about” and “approximately,” when used in this context, indicate that the numeric value or range of values may vary within 30%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1.5%, 1%, 0.5%, or 0.25% of the recited value or range of values. For example, in some embodiments, the value of a PXRD peak position may vary by up to ±0.2 degrees two theta while still describing the particular PXRD peak.
- As used herein, and unless otherwise specified, a crystalline that is “pure,” i.e., substantially free of other crystalline or amorphous solid forms, contains less than about 10% by weight of one or more other crystalline or amorphous solid forms, less than about 5% by weight of one or more other crystalline or amorphous solid forms, less than about 3% by weight of one or more other crystalline or amorphous solid forms, or less than about 1% by weight of one or more other crystalline or amorphous solid forms.
- As used herein and unless otherwise specified, the term “crystalline” when used to describe a compound, substance, modification, material, component or product, unless otherwise specified, means that the compound, substance, modification, material, component or product is substantially crystalline as determined by X-ray diffraction. See, e.g., Remington: The Science and Practice of Pharmacy, 21st edition, Lippincott, Williams and Wilkins, Baltimore, Md. (2005); The United States Pharmacopeia, 23rd ed., 1843-1844 (1995).
- As used herein, and unless otherwise specified, a solid form that is “substantially physically pure” is substantially free from other solid forms. In certain embodiments, a crystal form that is substantially physically pure contains less than about 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.05%, or 0.01% of one or more other solid forms on a weight basis. The detection of other solid forms can be accomplished by any method apparent to a person of ordinary skill in the art, including, but not limited to, diffraction analysis, thermal analysis, elemental combustion analysis and/or spectroscopic analysis.
- As used herein, and unless otherwise specified, a solid form that is “substantially chemically pure” is substantially free from other chemical compounds (i.e., chemical impurities). In certain embodiments, a solid form that is substantially chemically pure contains less than about 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.05%, or 0.01% of one or more other chemical compounds on a weight basis. The detection of other chemical compounds can be accomplished by any method apparent to a person of ordinary skill in the art, including, but not limited to, methods of chemical analysis, such as, e.g., mass spectrometry analysis, spectroscopic analysis, thermal analysis, elemental combustion analysis and/or chromatographic analysis.
- As used herein, and unless otherwise indicated, a chemical compound, solid form, or composition that is “substantially free” of another chemical compound, solid form, or composition means that the compound, solid form, or composition contains, in certain embodiments, less than about 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.4%, 0.3%, 0.2% 0.1%, 0.05%, or 0.01% by weight of the other compound, solid form, or composition.
- Unless otherwise specified, the terms “solvate” and “solvated,” refer to a solid form of a substance which contains solvent. The terms “hydrate” and “hydrated” refer to a solvate wherein the solvent is water. “Polymorphs of solvates” refer to the existence of more than one solid form for a particular solvate composition. Similarly, “polymorphs of hydrates” refer to the existence of more than one solid form for a particular hydrate composition.
- As used herein, and unless otherwise indicated, the term “desolvated solvate” refers to a solid form of a substance which can be made by removing the solvent from a solvate. The terms “solvate” and “solvated,” as used herein, can also refer to a solvate of a salt, cocrystal, or molecular complex. The terms “hydrate” and “hydrated,” as used herein, can also refer to a hydrate of a salt, cocrystal, or molecular complex.
- As used herein, and unless otherwise indicated, the term “composition” is intended to encompass a product comprising the specified ingredient(s) (and in the specified amount(s), if indicated), as well as any product which results, directly or indirectly, from combination of the specified ingredient(s) in the specified amount(s). By “pharmaceutically acceptable,” it is meant a diluent, excipient, or carrier in a formulation must be compatible with the other ingredient(s) of the formulation and not deleterious to the recipient thereof.
- As used herein, and unless otherwise indicated, the term “solid form” refers to a physical form which is not predominantly in a liquid or a gaseous state. The terms “solid type” and “type” are used interchangeably herein with “solid form”. As used herein and unless otherwise specified, the term “solid form,” refers to
Compound 1, refers to a physicalform comprising Compound 1 which is not predominantly in a liquid or a gaseous state. A solid form may be a crystalline form or a mixture thereof. In certain embodiments, a solid form may be a liquid crystal. In certain embodiments, the term “solidforms comprising Compound 1” includes crystalforms comprising Compound 1. In certain embodiments, the solid form ofCompound 1 is Form A, Form B, Form C, Form D, Form E, Form F, Form G, Form H, Form I, the amorphous solid, or a mixture thereof. In certain embodiments, the solid form ofCompound 1 is Form A, Form B, Form C, Form D, Form E, Form F, Form G, Form H, Form I, Form J, Form K, Form L, Form M, Form N, the amorphous solid, or a mixture thereof. - As used herein and unless otherwise specified, the term “crystalline” when used to describe a compound, substance, modification, material, component or product, unless otherwise specified, means that the compound, substance, modification, material, component or product is substantially crystalline as determined by X-ray diffraction. See, e.g., Remington: The Science and Practice of Pharmacy, 21st edition, Lippincott, Williams and Wilkins, Baltimore, Md. (2005); The United States Pharmacopeia, 23rd ed., 1843-1844 (1995).
- As used herein and unless otherwise specified the term “crystal form” or “crystalline form” refers to a solid form that is crystalline. In certain embodiments, a crystal form of a substance may be substantially free of amorphous solids and/or other crystal forms. In certain embodiments, a crystal form of a substance may contain less than about 1%, less than about 2%, less than about 3%, less than about 4%, less than about 5%, less than about 6%, less than about 7%, less than about 8%, less than about 9%, less than about 10%, less than about 15%, less than about 20%, less than about 25%, less than about 30%, less than about 35%, less than about 40%, less than about 45%, or less than about 50% by weight of one or more amorphous solids and/or other crystal forms. In certain embodiments, a crystal form of a substance may be physically and/or chemically pure. In certain embodiments, a crystal form of a substance may be about 99%, about 98%, about 97%, about 96%, about 95%, about 94%, about 93%, about 92%, about 91%, or about 90% physically and/or chemically pure.
- As used herein and unless otherwise specified, the term “amorphous” or “amorphous solid form” means that the substance, component, or product in question is not substantially crystalline as determined by X-ray diffraction. In particular, the term “amorphous solid” describes a disordered solid form, i.e., a solid form lacking long range crystalline order. In certain embodiments, an amorphous solid form of a substance may be substantially free of other amorphous solid form and/or crystal forms. In certain embodiments, an amorphous solid form of a substance may contain less than about 1%, less than about 2%, less than about 3%, less than about 4%, less than about 5%, less than about 10%, less than about 15%, less than about 20%, less than about 25%, less than about 30%, less than about 35%, less than about 40%, less than about 45%, or less than about 50% by weight of one or more other amorphous solid forms and/or crystal forms on a weight basis. In certain embodiments, an amorphous solid form of a substance may be physically and/or chemically pure. In certain embodiments, an amorphous solid form of a substance be about 99%, about 98%, about 97%, about 96%, about 95%, about 94%, about 93%, about 92%, about 91%, or about 90% physically and/or chemically pure.
- As used herein, and unless otherwise indicated, the term “tautomers” refers to isomeric forms of a compound that are in equilibrium with each other. The concentrations of the isomeric forms will depend on the environment the compound is found in and may be different depending upon, for example, whether the compound is a solid or is in an organic or aqueous solution. For example, in aqueous solution, pyrazoles may exhibit the following isomeric forms, which are referred to as tautomers of each other:
- As readily understood by one skilled in the art, a wide variety of functional groups and other structures may exhibit tautomerism and all tautomers of
Compound 1 are within the scope of the present invention. - As used herein, and unless otherwise indicated, the term “zwitterion(s)” means compound(s) containing both a basic moiety, including but not limited to, for example, pyridine and imidazole; and an acidic moiety including but not limited to, for example, a carboxylic acid.
- As used herein, and unless otherwise indicated, the term “treating” means an alleviation, in whole or in part, of the disease or disorder, or symptoms associated with the disease or disorder, or slowing, or halting of further progression or worsening of the disease or disorder, or symptoms associated with the disease or disorder.
- As used herein, and unless otherwise indicated, the term “preventing” means prevention of the onset, recurrence, or spread of the disease or disorder, or symptoms associated with the disorder or disease, in a patient at risk for developing the disease or disorder.
- As used herein, and unless otherwise specified, the term “therapeutically effective amount” of a compound refers to an amount sufficient to provide a therapeutic benefit in the treatment or management of the disease or to delay or minimize one or more symptoms associated with the disease. Further, a therapeutically effective amount of a compound means that amount of therapeutic agent alone, or in combination with other therapies, provides a therapeutic benefit in the treatment or management of the disease. The term “therapeutically effective amount” can encompass an amount that improves overall therapy, reduces or avoids symptoms or causes of disease, or enhances the therapeutic efficacy of another therapeutic agent.
- As used herein, and unless otherwise indicated, the term “subject” or “patient” includes an animal, including, but not limited to, an animal such a cow, monkey, horse, sheep, pig, chicken, turkey, quail, cat, dog, mouse, rat, rabbit or guinea pig, in one embodiment a mammal, in another embodiment a human, in another embodiment a cell from any one of the foregoing animals. In one embodiment, a subject or patient is a non-human animal, in another embodiment a non-human mammal. In another embodiment, a subject or patient is a human having or at risk for having an autoimmune or chronic inflammatory disease. In certain embodiments, the autoimmune or chronic inflammatory disease is polymyositis, dermatomyositis, lupus nephritis, rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, psoriasis, amyotrophic lateral sclerosis, autoimmune myositis, systemic lupus,
Type 1 diabetes, biliary cirrhosis, bullous pemphigoid, sarcoidosis, Wegener's granulomatosis, ichthyosis, Graves' disease or multiple sclerosis. In certain embodiments, provided herein are methods for treating a subject suffering from or at risk for having relapsing-remitting multiple sclerosis, primary progressive multiple sclerosis, secondary progressive multiple sclerosis, and relapsing secondary progressive multiple sclerosis. In certain embodiments, a subject or patient is a human having or at risk for having a neurological disorder. In certain embodiments, the neurological disorder is Rett Syndrome. In certain embodiments, a subject or patient is a human having or at risk for having renal or hepatic impairment. In certain embodiments, a subject or patient is a human having or at risk for having a disease or disorder associated with sphingosine 1-phosphate, including but not limited to multiple sclerosis, relapse-remitting multiple sclerosis, systemic lupus,Type 1 diabetes, amyotrophic lateral sclerosis, refractory rheumatoid arthritis, inflammatory bowel disease, biliary cirrhosis, Crohn's disease, ulcerative colitis, bullous pemphigoid, sarcoidosis, psoriasis, autoimmune myositis, Wegener's granulomatosis, ichthyosis, and Graves' disease. In certain embodiments, a subject or patient is a human having or at risk for having a disease or disorder associated with theinterferon alpha receptor 1, including but not limited to psoriasis, ulcerative colitis, systemic lupus, multiple sclerosis, and rheumatoid arthritis. In certain embodiments, a subject or patient is a human having a disease or disorder mediated by lymphocyte interactions, such as, for example, in transplantation, such as acute or chronic rejection of cell, tissue or organ allo- or xenografts or delayed graft function, graft versus host disease; autoimmune diseases, e.g., rheumatoid arthritis, systemic lupus erythematosus, hashimoto's thyroidis, multiple sclerosis, myasthenia gravis, diabetes type I or II and the disorders associated therewith, vasculitis, pernicious anemia, Sjoegren syndrome, uveitis, psoriasis, Graves ophthalmopathy, alopecia areata and others; allergic diseases, e.g., allergic asthma, atopic dermatitis, allergic rhinitis/conjunctivitis, allergic contact dermatitis; inflammatory diseases optionally with underlying aberrant reactions, e.g., inflammatory bowel disease, Crohn's disease or ulcerative colitis, intrinsic asthma, inflammatory lung injury, inflammatory liver injury, inflammatory glomerular injury, atherosclerosis, osteoarthritis, irritant contact dermatitis and further eczematous dermatitises, seborrhoeic dermatitis, cutaneous manifestations of immunologically-mediated disorders, inflammatory eye disease, keratoconjunctivitis, inflammatory myopathy; myocarditis or hepatitis; ischemia/reperfusion injury, e.g., myocardial infarction, stroke, gut ischemia, renal failure or hemorrhage shock, traumatic shock; T cell lymphomas or T cell leukemias; infectious diseases, e.g., toxic shock (e.g., superantigen induced), septic shock, adult respiratory distress syndrome or viral infections, e.g., AIDS, viral hepatitis, chronic bacterial infection; muscle diseases, e.g., polymyositis; or senile dementia. Examples of cell, tissue or solid organ transplants include, e.g., pancreatic islets, stem cells, bone marrow, corneal tissue, neuronal tissue, heart, lung, combined heart-lung, kidney, liver, bowel, pancreas, trachea or oesophagus. - Unless otherwise specified, to the extent that there is a discrepancy between a depicted chemical structure of a compound provided herein and a chemical name of a compound provided herein, the chemical structure shall control.
- 5.2
Compound 1 - The solid forms, formulations and methods of use provided herein relate to solid forms (e.g., crystalline forms, amorphous forms, polymorphs or mixtures thereof)) comprising Compound 1:
- having the name (E)-1-(4-(1-(((4-cyclohexyl-3-(trifluoromethyl)benzyl)oxy)imino)ethyl)-2-ethylbenzyl)azetidine-3-carboxylic acid, including tautomers thereof.
Compound 1 can be prepared by methods known in the art. See, e.g., International Patent Application Publication No. WO 2013/113915 A1. - It should be noted that if there is a discrepancy between a depicted structure and a name given that structure, the depicted structure is to be accorded more weight. In addition, if the stereochemistry of a structure or a portion of a structure is not indicated with, for example, bold or dashed lines, the structure or portion of the structure is to be interpreted as encompassing all stereoisomers of it.
- 5.3 Solid Forms of
Compound 1 - In certain embodiments, provided herein are solid
forms comprising Compound 1, or a tautomer thereof. In certain embodiments, the solid form is crystalline. In certain embodiments, the solid form is a single-component solid form. In certain embodiments, the solid form is a hydrate. In certain embodiments, the solid form is an anhydrate. In certain embodiments, the solid form is a solvate. In certain embodiments, the solid form is non-solvated. - While not intending to be bound by any particular theory, certain solid forms are characterized by physical properties, e.g., stability, solubility and dissolution rate, appropriate for pharmaceutical and therapeutic dosage forms. Moreover, while not wishing to be bound by any particular theory, certain solid forms are characterized by physical properties (e.g., density, compressibility, hardness, morphology, cleavage, stickiness, solubility, water uptake, electrical properties, thermal behavior, solid-state reactivity, physical stability, and chemical stability) affecting particular processes (e.g., yield, filtration, washing, drying, milling, mixing, tableting, flowability, dissolution, formulation, and lyophilization) which make certain solid forms suitable for the manufacture of a solid dosage form. Such properties can be determined using particular analytical chemical techniques, including solid-state analytical techniques (e.g., X-ray diffraction, microscopy, spectroscopy and thermal analysis), as described herein and known in the art.
- The solid
forms comprising Compound 1, or a tautomer thereof, provided herein (e.g., Form A, Form B, Form C, Form D, Form E, Form F, Form G, Form H, and Form I) may be characterized using a number of methods known to a person skilled in the art, including, but not limited to, single crystal X-ray diffraction, X-ray powder diffraction (PXRD), microscopy (e.g., optical microscopy, scanning electron microscopy (SEM)), thermal analysis (e.g., differential scanning calorimetry (DSC), thermal gravimetric analysis (TGA), and hot-stage microscopy), dynamic vapor sorption (DVS), spectroscopy (e.g., infrared, Raman, and nuclear magnetic resonance), high performance liquid chromatography (HPLC). The particle size and size distribution of the solid form provided herein may be determined by conventional methods, such as laser light scattering technique. - The solid
forms comprising Compound 1, or a tautomer thereof, provided herein (e.g., Form A, Form B, Form C, Form D, Form E, Form F, Form G, Form H, Form I, Form J, Form K, Form L, Form M, and Form N) may be characterized using a number of methods known to a person skilled in the art, including, but not limited to, single crystal X-ray diffraction, X-ray powder diffraction (PXRD), microscopy (e.g., optical microscopy, scanning electron microscopy (SEM)), thermal analysis (e.g., differential scanning calorimetry (DSC), thermal gravimetric analysis (TGA), and hot-stage microscopy), dynamic vapor sorption (DVS), spectroscopy (e.g., infrared, Raman, and nuclear magnetic resonance), high performance liquid chromatography (HPLC). The particle size and size distribution of the solid form provided herein may be determined by conventional methods, such as laser light scattering technique. - The purity of the solid forms provided herein may be determined by standard analytical methods, such as thin layer chromatography (TLC), gel electrophoresis, gas chromatography, high performance liquid chromatography (HPLC), and mass spectrometry.
- It should be understood that the numerical values of the peaks of an X-ray powder diffraction pattern may vary slightly from one machine to another or from one sample to another, and so the values quoted are not to be construed as absolute, but with an allowable variability, such as ±0.2° 2θ or ±0.1° 2θ (see, United States Pharmacopoeia, page 2228 (2003)).
- (a) Methods of Preparing Solid
Forms Comprising Compound 1 - In certain embodiments, provided herein are methods for making a solid
form comprising Compound 1, or a tautomer thereof, comprising 1) obtaining a slurry ofCompound 1 in a solvent or solvent system; 2) stirring the slurry for a period of time (e.g., about 72 h) while cycling the temperature (e.g., between about 5° C. and about 40° C.); and 3) collecting solids from the slurry by filtration and optionally drying the collected solids to yield a solidform comprising Compound 1. In certain embodiments, the methods for making a solidform comprising Compound 1 are equilibration experiments, such as slurry experiments. In certain embodiments, the solvent is isopropyl ether, cyclohexane, heptanes, dimethyl carbonate, or water. In certain embodiments, the collected solids are dried using a flow of an inert gas, such as nitrogen or argon. In certain embodiments, the collected solids are dried under vacuum at a certain temperature (e.g., 65° C.). In a particular embodiment, the collected solids are dried using a combination of a flow of an inert gas, such as nitrogen or argon, under vacuum at a certain temperature (e.g., 65° C.). - In certain embodiments, provided herein are methods for making a solid
form comprising Compound 1, or a tautomer thereof, comprising 1) dissolvingCompound 1 in a solvent or solvent system to yield a solution; 2) filtering the solution ifCompound 1 does not dissolve completely; 3) evaporating the supernatant at a certain temperature (e.g., ambient temperature) over a period of time (e.g., 14 days) to yield a solidform comprising Compound 1. In certain embodiments, the evaporation step further comprises evaporating the solution under an inert gas, such as nitrogen or argon. In certain embodiments, the solvent system is dimethylformamide/water (1:2). In certain embodiments, the methods for making a solidform comprising Compound 1 are evaporation experiments. - In certain embodiments, provided herein are methods for making a solid
form comprising Compound 1, or a tautomer thereof, comprising 1) obtaining a solution ofCompound 1 in a solvent or solvent system at a first temperature (e.g., about 40° C.); 2) filtering the solution if there is precipitation and isolating the solids; 3) cooling the filtered solution slowly to a second temperature (e.g., about 4° C.) over a period of time (e.g., 7 days); and 5) isolating solids from the solution and optionally drying the isolated solids to yield a solidform comprising Compound 1. In certain embodiments, the solvent system is methyl isobutyl ketone/heptane (1:2). In certain embodiments, the methods for making a solidform comprising Compound 1 are cooling recrystallization experiments. - In certain embodiments, provided herein are methods for making a solid
form comprising Compound 1, or a tautomer thereof, comprising 1) obtaining a solution ofCompound 1 in a solvent or solvent system at a first temperature (e.g., ambient temperature); 2) adding an anti-solvent into the saturated solution at the first temperature; 3) stirring the solution for a period of time (e.g., overnight); 4) cycling the temperature (e.g., between about 20° C. and about 50° C.) for a period of time (e.g., 4 days); 5) collecting a solid and isolating the solids; 6) evaporating the remaining solution, oil or gum under a flow of nitrogen gas at a certain temperature (e.g., ambient temperature) over a period of time (e.g., 14 days) to yield a solidform comprising Compound 1. In certain embodiments, the solvent is dimethylformamide and the anti-solvent is water. In certain embodiments, the solvent is 2-propanol and the anti-solvent is water. - In certain embodiments, provided herein are methods for making a solid
form comprising Compound 1, or a tautomer thereof, comprising 1) obtaining a slurry ofCompound 1 in a solvent or solvent system; 2) seeding the slurry with a small amount of a solid form described herein (e.g., Form D or Form I); 3) stirring the slurry for a period of time (e.g., 2 days) while cycling the temperature (e.g., between about 5° C. and 30° C.); and 4) collecting solids from the slurry by centrifugation followed by decanting, washing and drying in a centrifuge evaporator to yield a solidform comprising Compound 1. In certain embodiments, the solvent is water. In certain embodiments, the solvent is nitromethane, acetonitrile, acetonitrile/water (9:1), octane/ethyl acetate (9:1), acetone/water (4:1), water/1-propanol (9:1), acetonitrile/toluene (9:1), isopropyl ether/acetonitrile (1:2), octane/acetone (9:1), acetonitrile/ methyl t-butyl ether (9:1), or acetonitrile/ methyl isobutyl ketone (9:1). - In certain embodiments, provided herein are methods for making a solid
form comprising Compound 1, or a tautomer thereof, comprising 1)mixing Compound 1 with a solvent or solvent system; 2) sonicating the mixture; 3) filtering the mixture; 4) evaporating the filtrate to dryness; 5) adding solvent to the dried sample to obtain a clear solution; 6) stirring the solution at a certain temperature for a certain time; 7) filtering the mixture; and 8) drying the resulting solid in a vacuum oven to yield a solidform comprising Compound 1. In certain embodiments, the solvent is ethyl methyl ketone. In certain embodiments, the certain temperature is ambient temperature and the certain time is about one day. - In certain embodiments, provided herein are methods for making a solid
form comprising Compound 1, or a tautomer thereof, comprising 1) dryingCompound 1 in a vacuum oven; 2) mixing the driedCompound 1 with a solvent or solvent system; 3) filtering the mixture; 4) evaporating the filtrate until precipitates are visually observed; 5) stirring the resulting mixture at a certain temperature for a certain time; 6) filtering the mixture; and 7) drying the resulting solid in a vacuum oven to yield a solidform comprising Compound 1. In certain embodiments, the solvent is ethyl methyl ketone. In certain embodiments, the certain temperature is ambient temperature and the certain time is about one day. - In certain embodiments, provided herein are methods for making a solid
form comprising Compound 1, or a tautomer thereof, comprising 1) drying a solid form ofCompound 1 described herein (e.g., Form K) in a vacuum oven at a certain temperature for a certain time; 2) heating a portion of the dried solid at a certain rate on DSC in a vessel to yield a solidform comprising Compound 1. In certain embodiments, the certain temperature is 35° C. and the certain time is two days. In certain embodiments, the portion of the dried solid is heated to 121° C. at a rate of 10° C./min. In certain embodiments, the portion of the dried solid is heated to 102° C. at a rate of 10° C./min. In certain embodiments, the vessel is a crimped aluminum pan with a pin hole on its lid. - In certain embodiments, provided herein are methods for making a solid
form comprising Compound 1, or a tautomer thereof, comprising 1) mixing a solid form ofCompound 1 described herein (e.g., Form E) with a solvent or solvent system; 2) stirring the resulting mixture at a certain temperature for a certain time; 3) filtering the mixture; and 4) drying the resulting solid in a vacuum oven to yield a solidform comprising Compound 1. In certain embodiments, the solvent is water. In some embodiments, the water is Milli-Q water. In certain embodiments, the certain temperature is ambient temperature and the certain time is five days. - (b) Form A
- In certain embodiments, provided herein is Form A.
- In one embodiment, Form A is a solid form of
Compound 1. In one embodiment, Form A is solvated by isopropyl ether. In one embodiment, Form A is crystalline. In one embodiment, Form A is moderately crystalline. - In certain embodiments, provided herein are methods for making Form A, comprising: 1) obtaining a slurry of
Compound 1 in a solvent or solvent system; 2) stirring the slurry for a period of time (e.g., about 72 h) while cycling the temperature (e.g., between about 5° C. and about 40° C.); and 3) collecting solids from the slurry by filtration and optionally drying the collected solids to yield Form A ofCompound 1. In certain embodiments, the solvent is isopropyl ether, cyclohexane, heptanes, dimethyl carbonate, or water. In a particular embodiment, the solvent is isopropyl ether. - In one embodiment, provided herein is Form A having an FT-Raman Spectrum as depicted in
FIG. 2 . - In one embodiment, provided herein is a solid form, e.g., Form A of
Compound 1, having a DSC thermograph substantially as depicted inFIG. 3 comprising an endothermic event with a peak maximum temperature of about 54° C. In one embodiment, provided herein is a solid form, e.g., Form A ofCompound 1, having a DSC endothermic event with an onset temperature of about 102° C. when heated to 300° C. - In one embodiment, provided herein is a solid form, e.g., Form A of
Compound 1, having a TGA thermogram corresponding substantially to the representative TGA thermogram as depicted inFIG. 3 . In certain embodiments, the crystalline form exhibits a TGA thermogram comprising a total mass loss of approximately 6.2% of the total mass of the sample when heated from approximately 25° C. to approximately 150° C. Thus, in certain embodiments, the crystalline form loses about 6.2% its total mass when heated from about ambient temperature to about 150° C. - In certain embodiments, a solid form provided herein, e.g., Form A, is substantially crystalline, as indicated by, e.g., X-ray powder diffraction measurements. In one embodiment, provided herein is a solid form having an X-ray powder diffraction pattern (XRPD) substantially as shown in
FIG. 1 (e.g., Form A). In one embodiment, a solid form provided herein, e.g., Form A, has one or more characteristic X-ray powder diffraction peaks at approximately 2.3, 3.9, 6.9, 7.7, 9.2, 9.9, 11.5, 12.1, 14.3, 15.5, 18.2, 19.3, 20.9, 21.7, 23.2, 24.5, or 32.0° 2θ (±0.2° 2θ) or (±0.1° 2θ) as depicted inFIG. 1 . In a specific embodiment, a solid form provided herein, e.g., Form A, has one, two, three, four, or five characteristic X-ray powder diffraction peaks at approximately 2.3, 3.9, 7.7, 11.5, or 20.9° 2θ (±0.2° 2θ). In certain embodiments, the solid form is Form A. - In still another embodiment, Form A is substantially pure. In certain embodiments, the substantially pure Form A is substantially free of other solid forms, including but not limited to amorphous solid. In certain embodiments, the substantially pure Form A is substantially free of Form B, Form C, Form D, Form E, Form F, Form G, Form H, or Form I. In certain embodiments, the purity of the substantially pure Form A is no less than about 95%, no less than about 96%, no less than about 97%, no less than about 98%, no less than about 98.5%, no less than about 99%, no less than about 99.5%, or no less than about 99.8%. In certain embodiments, the substantially pure Form A is substantially free of Form J, Form K, Form L, Form M, or Form N.
- In certain embodiments, Form A is mixed with other solid forms, including but not limited to the amorphous solid. In certain embodiments, Form A is mixed with at least one of Form B, Form C, Form D, Form E, Form F, Form G, Form H, or Form I. In certain embodiments, Form A is mixed with at least one of Form B, Form C, Form D, Form E, Form F, Form G, Form H, Form I, Form J, Form K, Form L, Form M, or Form N.
- In one embodiment, Form A comprises a free base of
Compound 1. In one embodiment, Form A comprises a free acid ofCompound 1. In one embodiment, Form A comprises a zwitterion ofCompound 1. - (c) Form B
- In certain embodiments, provided herein is Form B.
- In one embodiment, Form B is a solid
form comprising Compound 1. In one embodiment, Form B is solvated by cyclohexane. In one embodiment, Form B is crystalline. In one embodiment, Form B is moderately crystalline. - In certain embodiments, provided herein are methods for making Form B, comprising: 1) obtaining a slurry of
Compound 1 in a solvent or solvent system; 2) stirring the slurry for a period of time (e.g., about 72 h) while cycling the temperature (e.g., between about 5° C. and about 40° C.); and 3) collecting solids from the slurry by filtration and optionally drying the collected solids to yield Form B ofCompound 1. In certain embodiments, the solvent is isopropyl ether, cyclohexane, heptanes, dimethyl carbonate, or water. In a particular embodiment, the solvent is cyclohexane. - In one embodiment, provided herein is Form B having an FT-Raman Spectrum as depicted in
FIG. 6 . - In one embodiment, provided herein is a solid form, e.g., Form B of
Compound 1, having a DSC thermograph substantially as depicted inFIG. 7 comprising a first endothermic event with an onset temperature of about 40.2° C. and a peak maximum temperature of about 47.4° C. - In one embodiment, provided herein is a solid form, e.g., Form B of
Compound 1, having a TGA thermogram corresponding substantially to the representative TGA thermogram as depicted inFIG. 7 . In certain embodiments, the crystalline form exhibits a TGA thermogram comprising a total mass loss of approximately 8.5% of the total mass of the sample when heated from approximately 25° C. to approximately 150° C. Thus, in certain embodiments, the crystalline form loses about 8.5% its total mass when heated from about ambient temperature to about 150° C. - In certain embodiments, a solid form provided herein, e.g., Form B is substantially crystalline, as indicated by, e.g., X-ray powder diffraction measurements. In one embodiment, provided herein is a solid form having an X-ray powder diffraction pattern (XRPD) substantially as shown in
FIG. 5 (e.g., Form B). In one embodiment, a solid form provided herein, e.g., Form B, has one or more characteristic X-ray powder diffraction peaks at approximately 2.3, 2.8, 3.8, 5.6, 7.0, 7.7, 8.4, 9.3, 11.5, 14.0, 14.3, 15.5, 18.2, 19.3, 20.9, 21.7, 22.5, 23.2, 24.6, or 32.0° 2θ (±0.2° 2θ) or (±0.1° 2θ) as depicted inFIG. 5 . In a specific embodiment, a solid form provided herein has one, two, three, four, five, or six characteristic X-ray powder diffraction peaks at approximately 2.3, 2.8, 7.7, 8.4, 11.5, or 20.9° 2θ (±0.2° 2θ). In certain embodiments, the solid form is Form B. - In still another embodiment, Form B is substantially pure. In certain embodiments, the substantially pure Form B is substantially free of other solid forms, including but not limited to amorphous solid. In certain embodiments, the substantially pure Form B is substantially free of Form A, Form C, Form D, Form E, Form F, Form G, Form H, or Form I. In a particular embodiment, Form B exists in a mixture with Form E. In certain embodiments, the purity of the substantially pure Form B is no less than about 95%, no less than about 96%, no less than about 97%, no less than about 98%, no less than about 98.5%, no less than about 99%, no less than about 99.5%, or no less than about 99.8%. In certain embodiments, the substantially pure Form B is substantially free of Form J, Form K, Form L, Form M, or Form N.
- In certain embodiments, Form B is mixed with other solid forms, including but not limited to the amorphous solid. In certain embodiments, Form B is mixed with at least one of Form A, Form C, Form D, Form E, Form F, Form G, Form H, or Form I. In certain embodiments, Form B is mixed with at least one of Form A, Form C, Form D, Form E, Form F, Form G, Form H, Form I, Form J, Form K, Form L, Form M, or Form N.
- In one embodiment, Form B comprises a free base of
Compound 1. In one embodiment, Form B comprises a free acid ofCompound 1. In one embodiment, Form B comprises a zwitterion ofCompound 1. - (d) Form C
- In certain embodiments, provided herein is Form C.
- In one embodiment, Form C is a solid
form comprising Compound 1. In one embodiment, Form C is solvated by heptane. In one embodiment, Form C is crystalline. In one embodiment, Form C is moderately crystalline. - In certain embodiments, provided herein are methods for making Form C, comprising: 1) obtaining a slurry of
Compound 1 in a solvent or solvent system; 2) stirring the slurry for a period of time (e.g., about 72 h) while cycling the temperature (e.g., between about 5° C. and about 40° C.); and 3) collecting solids from the slurry by filtration and optionally drying the collected solids to yield Form C ofCompound 1. In certain embodiments, the solvent is isopropyl ether, cyclohexane, heptane, dimethyl carbonate, or water. In a particular embodiment, the solvent is heptane. - In one embodiment, provided herein is Form C having an FT-Raman Spectrum as depicted in
FIG. 10 . - In one embodiment, provided herein is a solid form, e.g., Form C of
Compound 1, having a DSC thermograph substantially as depicted inFIG. 11 comprising an endothermic event with an onset temperature of about 101.7° C. - In one embodiment, provided herein is a solid form, e.g., Form C of
Compound 1, having a TGA thermograph corresponding substantially to the representative TGA thermograph as depicted inFIG. 11 . In certain embodiments, the crystalline form exhibits a TGA thermogram comprising a total mass loss of approximately 14.3% of the total mass of the sample when heated from approximately 28° C. to approximately 150° C. Thus, in certain embodiments, the crystalline form loses about 14.3% of its total mass when heated from about ambient temperature to about 150° C. - In certain embodiments, a solid form provided herein, e.g., Form C, is substantially crystalline, as indicated by, e.g., X-ray powder diffraction measurements. In one embodiment, provided herein is a solid form having an X-ray powder diffraction pattern (XRPD) substantially as shown in
FIG. 9 (e.g., Form C). In one embodiment, a solid form provided herein, e.g., Form C, has one or more characteristic X-ray powder diffraction peaks at approximately 2.2, 3.9, 6.5, 7.7, 8.7, 9.9, 11.5, 14.3, 15.6, 18.3, 19.3, 20.9, 21.8, 23.2, 24.5, and 32.0° 2θ (±0.2° 2θ) or (±0.1° 2θ) as depicted inFIG. 9 . In a specific embodiment, a solid form provided herein has one, two, three, four, five, or six characteristic X-ray powder diffraction peaks at approximately 2.2, 3.9, 6.5, 7.7, 11.5, or 20.9° 2θ (±0.2° 2θ). In certain embodiments, the solid form is Form C. - In still another embodiment, Form C is substantially pure. In certain embodiments, the substantially pure Form C is substantially free of other solid forms, including but not limited to amorphous solid. In certain embodiments, the substantially pure Form C is substantially free of Form A, Form B, Form D, Form E, Form F, Form G, Form H, or Form I. In certain embodiments, the purity of the substantially pure Form C is no less than about 95%, no less than about 96%, no less than about 97%, no less than about 98%, no less than about 98.5%, no less than about 99%, no less than about 99.5%, or no less than about 99.8%. In certain embodiments, the substantially pure Form C is substantially free of Form J, Form K, Form L, Form M, or Form N.
- In certain embodiments, Form C is mixed with other solid forms, including but not limited to the amorphous solid. In certain embodiments, Form C is mixed with at least one of Form A, Form B, Form D, Form E, Form F, Form G, Form H, or Form I. In certain embodiments, Form C is mixed with at least one of Form A, Form B, Form D, Form E, Form F, Form G, Form H, Form I, Form J, Form K, Form L, Form M, or Form N.
- In one embodiment, Form C comprises a free base of
Compound 1. In one embodiment, Form C comprises a free acid ofCompound 1. In one embodiment, Form C comprises a zwitterion ofCompound 1. - (e) Form D
- In certain embodiments, provided herein is Form D.
- In one embodiment, Form D is a solid
form comprising Compound 1. In one embodiment, Form D is non-solvated. In one embodiment, Form D is crystalline. In one embodiment, Form D is moderately crystalline. - In certain embodiments, provided herein are methods for making Form D, comprising: 1) obtaining a slurry of
Compound 1 in a solvent or solvent system; 2) stirring the slurry for a period of time (e.g., about 72 h) while cycling the temperature (e.g., between about 5° C. and about 40° C.); and 3) collecting solids from the slurry by filtration and drying the collected solids to yield Form D ofCompound 1. In certain embodiments, the solvent is isopropyl ether, cyclohexane, heptanes, dimethyl carbonate, or water. In a particular embodiment, the solvent is dimethyl carbonate. In certain embodiments, the collected solids are dried using a flow of an inert gas, such as nitrogen or argon. In certain embodiments, the collected solids are dried under vacuum at 65° C. In a particular embodiment, the collected solids are dried using a flow of an inert gas, such as nitrogen or argon, under vacuum at 65° C. - In one embodiment, provided herein is Form D having an FT-Raman Spectrum as depicted in
FIG. 14 . - In one embodiment, provided herein is a solid form, e.g., Form D of
Compound 1, having a DSC thermogram substantially as depicted inFIG. 15 comprising an endothermic event with an onset temperature of about 96° C. and a peak maximum temperature of about 111° C. - In one embodiment, provided herein is a solid form, e.g., Form D of
Compound 1, having a TGA thermogram corresponding substantially to the representative TGA thermogram as depicted inFIG. 15 . In certain embodiments, the crystalline form exhibits a TGA thermogram comprising a total mass loss of approximately 0.4% of the total mass of the sample when heated from approximately 25° C. and 125° C. - In certain embodiments, a solid form provided herein, e.g., Form D, is substantially crystalline, as indicated by, e.g., X-ray powder diffraction measurements. In one embodiment, provided herein is a solid form having an X-ray powder diffraction pattern (XRPD) substantially as shown in
FIG. 13 (e.g., Form D). In one embodiment, a solid form provided herein, e.g., Form D, has one or more characteristic X-ray powder diffraction peaks at approximately 2.8, 3.7, 7.3, 11.0, 14.4, 16.4, 18.3, 20.8, or 22.9° 2θ (±0.2° 2θ) or (±0.1° 2θ) as depicted inFIG. 13 . In a specific embodiment, a solid form provided herein has one, two, three, four, or five characteristic X-ray powder diffraction peaks at approximately 3.7, 7.3, 11.0, 18.3, or 22.9° 2θ (±0.2° 2θ). In certain embodiments, the solid form is Form D. - In still another embodiment, Form D is substantially pure. In certain embodiments, the substantially pure Form D is substantially free of other solid forms, including but not limited to amorphous solid. In certain embodiments, the substantially pure Form D is substantially free of Form A, Form B, Form C, Form E, Form F, Form G, Form H, or Form I. In certain embodiments, the purity of the substantially pure Form D is no less than about 95%, no less than about 96%, no less than about 97%, no less than about 98%, no less than about 98.5%, no less than about 99%, no less than about 99.5%, or no less than about 99.8%. In certain embodiments, the substantially pure Form D is substantially free of Form J, Form K, Form L, Form M, or Form N.
- In certain embodiments, Form D is mixed with other solid forms, including but not limited to the amorphous solid. In certain embodiments, Form D is mixed with at least one of Form A, Form B, Form C, Form E, Form F, Form G, Form H, or Form I. In certain embodiments, Form D is mixed with at least one of Form A, Form B, Form C, Form E, Form F, Form G, Form H, Form I, Form J, Form K, Form L, Form M, or Form N.
- In one embodiment, Form D comprises a free base of
Compound 1. In one embodiment, Form D comprises a free acid ofCompound 1. In one embodiment, Form D comprises a zwitterion ofCompound 1. - (f) Form E
- In certain embodiments, provided herein is Form E.
- In one embodiment, Form E is a solid
form comprising Compound 1. In one embodiment, Form E is non-solvated. In one embodiment, Form E is crystalline. - In certain embodiments, provided herein are methods for making Form E, comprising: 1) obtaining a slurry of
Compound 1 in a solvent or solvent system; 2) seeding the slurry with a small amount (e.g., 1 mg) of a solid form described herein (e.g., Form D, or Form I) and stirring the slurry for a period of time (e.g., about 48 h) while cycling the temperature (e.g., between about 5° C. and about 30° C.); and 3) collecting solids from the slurry by filtration to yield Form E ofCompound 1. In one embodiment, the solvent system is selected from the group consisting of nitromethane, acetonitrile, octane/ethyl acetate (9:1), acetonitrile/toluene (9:1), isopropyl ether/acetonitrile (1:2), octane/acetone (9:1), acetonitrile/methyl t-butyl ether (9:1), or acetonitrile/ methyl isobutyl ketone (9:1). - In certain embodiments, provided herein are methods for making Form E, comprising: 1) obtaining a slurry of
Compound 1 in a solvent or solvent system; 2) seeding the slurry with a small amount (e.g., 1 mg) of a solid form described herein (e.g., Form E,) and stirring the slurry for a period of time (e.g., overnight, or about 48 h) while cycling the temperature (e.g., between about 5° C. and about 40° C.); and 3) collecting solids from the slurry by filtration to yield Form E ofCompound 1. In one embodiment, the method further comprises the step of drying the collected solids under vacuum at 65° C. to yield Form E ofCompound 1. In a particular embodiment, the collected solids are dried using a flow of an inert gas, such as nitrogen or argon, under vacuum at 65° C. In one embodiment, the solvent or solvent system is selected from the group consisting of toluene/heptane (1:3), methyl t-butyl ether/hexane (1:9), methyl t-butyl ether/acetonitrile (1:9), and isopropyl ether. In a preferred embodiment, the solvent is isopropyl ether. - In certain other embodiments, provided herein are methods for making Form E, comprising: 1) obtaining a slurry of
Compound 1 in a solvent or solvent system; 2) heating the slurry to a certain temperature (e.g., 40° C.); 3) filtering the hot solution to remove impurities; 4) storing the hot filtrate at 4° C. for a period of time (e.g., 7 days); and 5) collecting solids from the cooled solution by filtration to yield Form E ofCompound 1. In one embodiment, the solvent system is methyl isobutyl ketone/heptane. - In one embodiment, provided herein is Form E having an FT-Raman Spectrum as depicted in
FIG. 18 . - In one embodiment, provided herein is a solid form, e.g., Form E of
Compound 1, having a DSC thermograph substantially as depicted inFIG. 19 comprising an endothermic event with an onset temperature of about 106° C. - In one embodiment, provided herein is a solid form, e.g., Form E of
Compound 1, having a TGA thermogram corresponding substantially to the representative TGA thermogram as depicted inFIG. 19 . In certain embodiments, the crystalline form exhibits a TGA thermogram comprising a total mass loss of approximately 0.3% of the total mass of the sample when heated from approximately 25° C. to about 125° C. - In certain embodiments, a solid form provided herein, e.g., Form E, is substantially crystalline, as indicated by, e.g., X-ray powder diffraction measurements. In one embodiment, provided herein is a solid form having an X-ray powder diffraction pattern (XRPD) substantially as shown in
FIG. 17 (e.g., Form E). In one embodiment, a solid form provided herein, e.g., Form E, has one or more characteristic X-ray powder diffraction peaks at approximately 3.9, 7.7, 9.9, 11.6, 12.1, 14.3, 15.5, 17.3, 18.2, 19.3, 20.9, 21.7, 23.3, 24.5, 25.3, 32.0° 2θ (±0.2° 2θ) or (±0.1° 2θ) as depicted inFIG. 17 . In a specific embodiment, a solid form provided herein has one, two, three, four, five or six characteristic X-ray powder diffraction peaks at approximately 3.9, 7.7, 11.6, 14.3, 20.9, 24.5° 2θ (±0.2° 2θ). In certain embodiments, the solid form is Form E. - In still another embodiment, Form E is substantially pure. In certain embodiments, the substantially pure Form E is substantially free of other solid forms, including but not limited to amorphous solid. In certain embodiments, the substantially pure Form E is substantially free of Form A, Form B, Form C, Form D, Form F, Form G, Form H, or Form I. In certain embodiments, the purity of the substantially pure Form D is no less than about 95%, no less than about 96%, no less than about 97%, no less than about 98%, no less than about 98.5%, no less than about 99%, no less than about 99.5%, or no less than about 99.8%. In certain embodiments, the substantially pure Form E is substantially free of Form J, Form K, Form L, Form M, or Form N.
- In certain embodiments, Form E is mixed with other solid forms, including but not limited to the amorphous solid. In certain embodiments, Form E is mixed with at least one of Form A, Form B, Form C, Form D, Form F, Form G, Form H, or Form I. In certain embodiments, Form E is mixed with at least one of Form A, Form B, Form C, Form D, Form F, Form G, Form H, Form I, Form J, Form K, Form L, Form M, or Form N.
- In one embodiment, Form E comprises a free base of
Compound 1. In one embodiment, Form E comprises a free acid ofCompound 1. In one embodiment, Form E comprises a zwitterion ofCompound 1. - (g) Form F
- In certain embodiments, provided herein is Form F.
- In one embodiment, Form F is a solid
form comprising Compound 1. In one embodiment, Form F is solvated by dimethyl carbonate. In one embodiment, Form F is crystalline. In one embodiment, Form F is moderately crystalline. - In certain embodiments, provided herein are methods for making Form F, comprising: 1) obtaining a slurry of
Compound 1 in a solvent, and stirring at 20° C. for 1 h; 2) seeding the slurry with a small amount (e.g., 1 mg) of a solid form described herein (e.g., Form D), 3) stirring the slurry for a period of time (e.g., about 12 h) at 20° C.; and 3) collecting solids from the slurry to yield Form F ofCompound 1. In one embodiment, the solids are collected by centrifugation followed by decanting, washing, and drying in a centrifuge evaporator overnight. In one embodiment, the solvent is dimethyl carbonate. - In one embodiment, provided herein is Form F having an FT-Raman Spectrum as depicted in
FIG. 22 . - In one embodiment, provided herein is a solid form, e.g., Form F of
Compound 1, having a DSC thermograph substantially as depicted inFIG. 23 comprising an endothermic event with an onset temperature at about 48° C. and a peak maximum temperature at about 63° C. - In one embodiment, provided herein is a solid form, e.g., Form F of
Compound 1, having a TGA thermograph corresponding substantially to the representative TGA thermograph as depicted inFIG. 23 . In certain embodiments, the crystalline form exhibits a TGA thermograph comprising a total mass loss of approximately 8.9% of the total mass of the sample when heated between approximately 25° C. and approximately 125° C. Thus, in certain embodiments, the crystalline loses about 8.9% its total mass when heated from ambient temperature to about 125° C. - In certain embodiments, a solid form provided herein, e.g., Form F, is substantially crystalline, as indicated by, e.g., X-ray powder diffraction measurements. In one embodiment, provided herein is a solid form having an X-ray powder diffraction pattern (XRPD) substantially as shown in
FIG. 21 (e.g., Form F). In one embodiment, a solid form provided herein, e.g., Form F, has one or more characteristic X-ray powder diffraction peaks at approximately 2.5, 3.3, 6.6, 9.9, 10.5, 12.4, 13.2, 14.8, 19.9, 20.4, 21.9, 22.9, 23.5, or 26.6° 2θ (±0.2° 2θ) or (±0.1° 2θ) as depicted inFIG. 21 . In a specific embodiment, a solid form provided herein has one, two, three, four, five or six characteristic X-ray powder diffraction peaks at approximately 3.3, 9.9, 14.8, 19.9, 20.4, or 23.5° 2θ (±0.2° 2θ). In certain embodiments, the solid form is Form F. - In still another embodiment, Form F is substantially pure. In certain embodiments, the substantially pure Form F is substantially free of other solid forms, including but not limited to amorphous solid. In certain embodiments, the substantially pure Form F is substantially free of Form A, Form B, Form C, Form D, Form E, Form G, Form H, or Form I. In certain embodiments, the purity of the substantially pure Form F is no less than about 95%, no less than about 96%, no less than about 97%, no less than about 98%, no less than about 98.5%, no less than about 99%, no less than about 99.5%, or no less than about 99.8%. In certain embodiments, the substantially pure Form F is substantially free of Form J, Form K, Form L, Form M, or Form N.
- In certain embodiments, Form F is mixed with other solid forms, including but not limited to the amorphous solid. In certain embodiments, Form F is mixed with at least one of Form A, Form B, Form C, Form D, Form E, Form G, Form H, or Form I. In certain embodiments, Form F is mixed with at least one of Form A, Form B, Form C, Form D, Form E, Form G, Form H, Form I, Form J, Form K, Form L, Form M, or Form N.
- In one embodiment, Form F comprises a free base of
Compound 1. In one embodiment, Form F comprises a free acid ofCompound 1. In one embodiment, Form F comprises a zwitterion ofCompound 1. - (h) Form G
- In certain embodiments, provided herein is Form G.
- In one embodiment, Form G is a solid
form comprising Compound 1. - In certain embodiments, provided herein are methods for making Form G, comprising: 1) obtaining a slurry of
Compound 1 in a solvent or solvent system; 2) stirring the slurry for a period of time (e.g., about 72 h) while cycling the temperature (e.g., between about 5° C. and about 40° C.); and 3) collecting solids from the slurry by filtration to yield a mixture of Form G and Form D. In certain embodiments, the solvent is isopropyl ether, cyclohexane, heptanes, dimethyl carbonate, or water. In a particular embodiment, the solvent is dimethyl carbonate. In certain embodiments, the collected solids are dried using a flow of an inert gas, such as nitrogen or argon. - In certain embodiments, Form G is mixed with other solid forms, including but not limited to the amorphous solid. In certain embodiments, Form G is mixed with at least one of Form A, Form B, Form C, Form D, Form E, Form F, Form H, or Form I. In certain embodiments, the substantially pure Form G is substantially free of Form J, Form K, Form L, Form M, or Form N.
- In one embodiment, Form G comprises a free base of
Compound 1. In one embodiment, Form G comprises a free acid ofCompound 1. In one embodiment, Form G comprises a zwitterion ofCompound 1. In certain embodiments, Form G is mixed with at least one of Form A, Form B, Form C, Form D, Form E, Form F, Form H, Form I, Form J, Form K, Form L, Form M, or Form N. - (i) Form H
- In certain embodiments, provided herein is Form H.
- In one embodiment, Form H is a solid
form comprising Compound 1. In one embodiment, Form H is solvated by water. In one embodiment, Form H is a hydrate. In one embodiment, Form H is crystalline. - In certain embodiments, provided herein are methods for making Form H, comprising: 1) obtaining a slurry of Form E in a solvent or solvent system; 2) seeding the slurry with a small amount of a solid form described herein (e.g., Form D or Form I), 3) stirring the slurry for a period of time (e.g., about 48 h) while cycling between two temperatures (e.g., 5° C. and 30° C.); and 3) collecting solids from the slurry and optionally drying to yield Form H of
Compound 1. In certain embodiments, the solvent is water. In certain embodiments, the solvent system is a 10% mixture of water in acetonitrile. In certain embodiments, the solvent system is a mixture of 10% 1-propanol in water. - In one embodiment, provided herein is Form H having an FT-Raman Spectrum as depicted in
FIG. 26 . - In one embodiment, provided herein is a solid form, e.g., Form H of
Compound 1, having a DSC thermograph substantially as depicted inFIG. 27 comprising an endothermic event with a peak maximum temperature of about 56° C., and another endothermic event with a peak maximum temperature of about 94° C. - In one embodiment, provided herein is a solid form, e.g., Form H of
Compound 1, having a TGA thermogram corresponding substantially to the representative TGA thermogram as depicted inFIG. 27 . In certain embodiments, the crystalline form exhibits a TGA thermogram comprising a total mass loss of approximately 7.7% of the total mass of the sample when heated between approximately 25° C. and approximately 80° C. Thus, in certain embodiments, the crystalline loses about 7.7% its total mass when heated from ambient temperature to about 80° C. - In certain embodiments, a solid form provided herein, e.g., Form H, is substantially crystalline, as indicated by, e.g., X-ray powder diffraction measurements. In one embodiment, provided herein is a solid form having an X-ray powder diffraction pattern (XRPD) substantially as shown in
FIG. 25 (e.g., Form H). In one embodiment, a solid form provided herein, e.g., Form H, has one or more characteristic X-ray powder diffraction peaks at approximately 3.6, 7.2, 10.8, 11.7, 12.4, 13.6, 14.4, 16.1, 17.8, 18.0, 18.3, 19.2, 19.6, 20.1, 20.7, 21.2, 21.7, 23.1, 23.7, 24.2, 25.3, 27.5, 29.1, or 36.5° 2θ (±0.2° 2θ) or (±0.1° 2θ) as depicted inFIG. 25 . In a specific embodiment, a solid form provided herein has one, two, three, four, five, six, or seven characteristic X-ray powder diffraction peaks at approximately 3.6, 7.2, 10.8, 17.8, 18.0, 18.3, or 21.7° 2θ (±0.2° 2θ). In certain embodiments, the solid form is Form H. - In still another embodiment, Form H is substantially pure. In certain embodiments, the substantially pure Form H is substantially free of other solid forms, including but not limited to amorphous solid. In certain embodiments, the substantially pure Form H is substantially free of Form A, Form B, Form C, Form D, Form E, Form F, Form G, or Form I. In certain embodiments, the purity of the substantially pure Form H is no less than about 95%, no less than about 96%, no less than about 97%, no less than about 98%, no less than about 98.5%, no less than about 99%, no less than about 99.5%, or no less than about 99.8%. In certain embodiments, the substantially pure Form H is substantially free of Form J, Form K, Form L, Form M, or Form N.
- In certain embodiments, Form H is mixed with other solid forms, including but not limited to the amorphous solid. In certain embodiments, Form H is mixed with at least one of Form A, Form B, Form C, Form D, Form E, Form F, Form G, or Form I. In certain embodiments, Form H is mixed with at least one of Form A, Form B, Form C, Form D, Form E, Form F, Form G, Form I, Form J, Form K, Form L, Form M, or Form N.
- In one embodiment, Form H comprises a free base of
Compound 1. In one embodiment, Form H comprises a free acid ofCompound 1. In one embodiment, Form H comprises a zwitterion ofCompound 1. - (j) Form I
- In certain embodiments, provided herein is Form I.
- In one embodiment, Form I is a solid
form comprising Compound 1. In one embodiment, Form I is solvated by water. In one embodiment, Form I is a hydrate. In one embodiment, Form I is crystalline. In one embodiment, Form I is moderately crystalline. - In certain embodiments, provided herein are methods for making Form I, comprising: 1) obtaining a solution of
Compound 1 in a solvent or a solvent system at a first temperature (e.g., ambient temperature); 2) adding an anti-solvent into the saturated solution at the first temperature; 3) stirring the solution for a period of time (e.g., about 4 days) while cycling the temperature (e.g., between about 20° C. and about 50° C.); and 4) evaporating the solution under a flow of nitrogen gas at a certain temperature (e.g., ambient temperature) over a period of time (e.g., 14 days) to yield Form I ofCompound 1. In certain embodiments, the solvent is dimethylformamide and the anti-solvent is water. - In certain embodiments, a method of making Form I comprises drying Form H with nitrogen gas bleed for a period of time (e.g., 14 days).
- In one embodiment, provided herein is Form I having an FT-Raman Spectrum as depicted in
FIG. 30 . - In one embodiment, provided herein is a solid form, e.g., Form I of
Compound 1, having a DSC thermograph substantially as depicted inFIG. 31 comprising an endothermic event with a peak maximum temperature at about 54° C. In one embodiment, provided herein is a solid form, e.g., Form I ofCompound 1, having a DSC endothermic event with an onset temperature at about 82° C. and a peak maximum temperature at about 93° C. - In one embodiment, provided herein is a solid form, e.g., Form I of
Compound 1, having a TGA thermogram corresponding substantially to the representative TGA thermogram as depicted inFIG. 31 . In certain embodiments, the crystalline form exhibits a TGA thermogram comprising a total mass loss of approximately 1.6% of the total mass of the sample when heated between approximately 25° C. and approximately 110° C. Thus, in certain embodiments, the crystalline loses about 1.6% its total mass when heated from ambient temperature to about 110° C. - In certain embodiments, a solid form provided herein, e.g., Form I, is substantially crystalline, as indicated by, e.g., X-ray powder diffraction measurements. In one embodiment, provided herein is a solid form having an X-ray powder diffraction pattern (XRPD) substantially as shown in
FIG. 29 (e.g. Form I). In one embodiment, a solid form provided herein, e.g., Form I, has one or more characteristic X-ray powder diffraction peaks at approximately 4.0, 8.0, 12.0, 13.5, 17.6, 19.2, 20.1, 21.5, or 32.4° 2θ (±0.2° 2θ) or (±0.1° 2θ) as depicted inFIG. 29 . In a specific embodiment, a solid form provided herein has one, two, three, four, or five characteristic X-ray powder diffraction peaks at approximately 4.0, 12.0, 17.6, 20.1, or 21.5° 2θ (±0.2° 2θ). In certain embodiments, the solid form is Form I. - In still another embodiment, Form I is substantially pure. In certain embodiments, the substantially pure Form I is substantially free of other solid forms, including but not limited to amorphous solid. In certain embodiments, the substantially pure Form I is substantially free of Form A, Form B, Form C, Form D, Form E, Form F, Form G, or Form H. In certain embodiments, the purity of the substantially pure Form I is no less than about 95%, no less than about 96%, no less than about 97%, no less than about 98%, no less than about 98.5%, no less than about 99%, no less than about 99.5%, or no less than about 99.8%. In certain embodiments, the substantially pure Form I is substantially free of Form J, Form K, Form L, Form M, or Form N.
- In certain embodiments, Form I is mixed with other solid forms, including but not limited to the amorphous solid. In certain embodiments, Form I is mixed with at least one of Form A, Form B, Form C, Form D, Form E, Form F, Form G, or Form H. In certain embodiments, Form I is mixed with at least one of Form A, Form B, Form C, Form D, Form E, Form F, Form G, Form H, Form J, Form K, Form L, Form M, or Form N.
- In one embodiment, Form I comprises a free base of
Compound 1. In one embodiment, Form I comprises a free acid ofCompound 1. In one embodiment, Form I comprises a zwitterion ofCompound 1. - (k) Form J
- In certain embodiments, provided herein is Form J.
- In one embodiment, Form J is a solid form of
Compound 1. In one embodiment, Form J is crystalline. - In certain embodiments, provided herein are methods for making Form J, comprising 1)
mixing Compound 1 with a solvent or solvent system; 2) sonicating the mixture; 3) filtering the mixture; 4) evaporating the filtrate to dryness; 5) adding solvent to the dried sample to obtain a solution; 6) stirring the solution at a certain temperature for a certain time; 7) filtering the mixture; and 8) drying the resulting solid in a vacuum oven to yield Form J ofCompound 1. In certain embodiments, the solvent is ethyl methyl ketone. In certain embodiments, the certain temperature is ambient temperature and the certain time is about one day. - In certain embodiments, provided herein are methods for making Form J, comprising: 1) mixing an amount of Compound 1 (e.g., about 80 mg) with an amount of ethyl methyl ketone (e.g., 11 mL); 2) sonicating for period of time (e.g., 5 minutes); 3) filtering via 0.2 um PTFE-membraned syringe filter; 4) evaporating the filtrate to dryness under nitrogen purge; 5) adding an amount of ethyl methyl ketone (e.g., 0.6 mL) to the sample; 6) capping the sample and stirring at a speed (e.g., 500 rotations per minute) at a temperature (e.g., ambient temperature) for a period of time (e.g., about a day); 7) collecting solids from the sample by filtration (e.g., via a 0.2 μm Nylon-membraned centrifuge tube filter) and drying the collected solids in a vacuum oven at a temperature (e.g., 35° C.) for a period of time (e.g., about a day) to yield Form J of
Compound 1. - In one embodiment, provided herein is Form J having a Raman Spectrum as depicted in
FIG. 34 . - In one embodiment, provided herein is a solid form, e.g., Form J of
Compound 1, having a DSC thermograph substantially as depicted inFIG. 35 comprising an endothermic event with an onset temperature of 143.4° C. - In one embodiment, provided herein is a solid form, e.g., Form J of
Compound 1, having a TGA thermogram corresponding substantially to the representative TGA thermogram as depicted inFIG. 35 . In certain embodiments, the crystalline form exhibits a TGA thermogram comprising a total mass loss of approximately 0.1% of the total mass of the sample when heated to 100° C. Thus, in certain embodiments, the crystalline form loses about 0.1% its total mass when heated from about ambient temperature to about 100° C. - In certain embodiments, a solid form provided herein, e.g., Form J, is substantially crystalline, as indicated by, e.g., X-ray powder diffraction measurements. In one embodiment, provided herein is a solid form having an X-ray powder diffraction pattern (XRPD) substantially as shown in
FIG. 33 (e.g., Form J). In one embodiment, a solid form provided herein, e.g., Form J, has one or more characteristic X-ray powder diffraction peaks at approximately 7.9, 11.5, 11.9, 13.4, 13.8, 14.0, 15.7, 17.4, 18.9, 19.6, 20.0, 21.0, 21.4, or 23.5° 2θ (±0.2° 2θ) or (±0.1° 2θ) as depicted inFIG. 33 . In a specific embodiment, a solid form provided herein, e.g., Form J, has one, two, three, four, five, or six characteristic X-ray powder diffraction peaks at approximately 7.9, 11.9, 13.4, 15.7, 17.4, or 20.0° 2θ (±0.2° 2θ). In certain embodiments, the solid form is Form J. - In still another embodiment, Form J is substantially pure. In certain embodiments, the substantially pure Form J is substantially free of other solid forms, including but not limited to amorphous solid. In certain embodiments, the substantially pure Form J is substantially free of Form A, Form B, Form C, Form D, Form E, Form F, Form G, Form H, Form I, Form K, Form L, Form M, or Form N. In certain embodiments, the purity of the substantially pure Form J is no less than about 95%, no less than about 96%, no less than about 97%, no less than about 98%, no less than about 98.5%, no less than about 99%, no less than about 99.5%, or no less than about 99.8%.
- In certain embodiments, Form J is mixed with other solid forms, including but not limited to the amorphous solid. In certain embodiments, Form J is mixed with at least one of Form A, Form B, Form C, Form D, Form E, Form F, Form G, Form H, Form I, Form K, Form L, Form M, or Form N.
- In one embodiment, Form J comprises a free base of
Compound 1. In one embodiment, Form J comprises a free acid ofCompound 1. In one embodiment, Form J comprises a zwitterion ofCompound 1. - (1) Form K
- In certain embodiments, provided herein is Form K.
- In one embodiment, Form K is a solid form of
Compound 1. In one embodiment, Form K is crystalline. - In certain embodiments, provided herein are methods for making Form K, comprising 1) drying
Compound 1 in a vacuum oven; 2) mixing the driedCompound 1 with a solvent or solvent system; 3) filtering the mixture; 4) evaporating the filtrate until precipitates are visually observed; 5) stirring the resulting mixture at a certain temperature for a certain time; 6) filtering the mixture; and 7) drying the resulting solid in a vacuum oven to yield Form K ofCompound 1. In certain embodiments, the solvent is ethyl methyl ketone. In certain embodiments, the certain temperature is ambient temperature and the certain time is about one day. - In certain embodiments, provided herein are methods for making Form K, comprising: 1) drying an amount of Compound 1 (e.g., about 130 mg) in a vacuum oven at a temperature (e.g., 35° C.) for a period of time (e.g., about 3 hours); 2) adding an amount of ethyl methyl ketone (e.g., 3.5 mL) to the sample; 3) filtering via 0.2 μm PTFE-membraned syringe filter; 4) evaporating the filtrate under nitrogen purge until precipitates were observed; 5) capping the sample and stirring at a speed (e.g., 500 rotations per minute) at a temperature (e.g., ambient temperature) for a period of time (e.g., about a day); 6) collecting solids from the sample by filtration (e.g., via a 0.2 μm Nylon-membraned centrifuge tube filter) and drying the collected solids in a vacuum oven at a temperature (e.g., 35° C.) for a period of time (e.g., about a day). to yield Form K of
Compound 1. - In one embodiment, provided herein is a solid form, e.g., Form K of
Compound 1, having a DSC thermograph substantially as depicted inFIG. 37 comprising endothermic events with peak maximum temperatures of approximately 98.9° C. and 113.7° C., respectively. - In one embodiment, provided herein is a solid form, e.g., Form K of
Compound 1, having a TGA thermogram corresponding substantially to the representative TGA thermogram as depicted inFIG. 37 . In certain embodiments, the crystalline form exhibits a TGA thermogram comprising a total mass loss of approximately 0.1% of the total mass of the sample when heated to 90° C. Thus, in certain embodiments, the crystalline form loses about 0.1% its total mass when heated from about ambient temperature to about 90° C. - In certain embodiments, a solid form provided herein, e.g., Form K, is substantially crystalline, as indicated by, e.g., X-ray powder diffraction measurements. In one embodiment, provided herein is a solid form having an X-ray powder diffraction pattern (XRPD) substantially as shown in
FIG. 36 (e.g., Form K). In one embodiment, a solid form provided herein, e.g., Form K, has one or more characteristic X-ray powder diffraction peaks at approximately 7.3, 8.0, 10.0, 10.9, 11.5, 12.0, 13.4, 14.1, 15.7, 17.5, 19.0, 20.1, 21.3, or 23.5° 2θ (±0.2° 2θ) or (±0.1° 2θ) as depicted inFIG. 36 . In a specific embodiment, a solid form provided herein, e.g., Form K, has one, two, three, four, five, six, or seven characteristic X-ray powder diffraction peaks at approximately 7.3, 8.0, 10.0, 10.9, 12.0, 17.5, or 20.1° 2θ (±0.2° 2θ). In certain embodiments, the solid form is Form K. - In still another embodiment, Form K is substantially pure. In certain embodiments, the substantially pure Form K is substantially free of other solid forms, including but not limited to amorphous solid. In certain embodiments, the substantially pure Form K is substantially free of Form A, Form B, Form C, Form D, Form E, Form F, Form G, Form H, Form I, Form J, Form L, Form M, or Form N. In certain embodiments, the purity of the substantially pure Form K is no less than about 95%, no less than about 96%, no less than about 97%, no less than about 98%, no less than about 98.5%, no less than about 99%, no less than about 99.5%, or no less than about 99.8%.
- In certain embodiments, Form K is mixed with other solid forms, including but not limited to the amorphous solid. In certain embodiments, Form K is mixed with at least one of Form A, Form B, Form C, Form D, Form E, Form F, Form G, Form H, Form I, Form J, Form L, Form M, or Form N.
- In one embodiment, Form K comprises a free base of
Compound 1. In one embodiment, Form K comprises a free acid ofCompound 1. In one embodiment, Form K comprises a zwitterion ofCompound 1. - (m) Form L
- In certain embodiments, provided herein is Form L.
- In one embodiment, Form L is a solid form of
Compound 1. In one embodiment, Form L is crystalline. - In certain embodiments, provided herein are methods for making Form L, comprising 1) drying a solid form of
Compound 1 described herein (e.g., Form K) in a vacuum oven at a certain temperature for a certain time; 2) heating a portion of the dried solid at a certain rate on DSC in a vessel to yield Form L ofCompound 1. In certain embodiments, the certain temperature is 35° C. and the certain time is two days. In certain embodiments, the portion of the dried solid is heated to 121° C. at a rate of 10° C./min. In certain embodiments, the vessel is a crimped aluminum pan with a pin hole on its lid. - In certain embodiments, provided herein are methods for making Form L, comprising: 1) drying Form K of
Compound 1 in a vacuum oven at a temperature (e.g., 35° C.) for a period of time (e.g., about 2 days); 2) heating the sample to a temperature (e.g., 121° C.) at a rate (e.g., 10° C. per minute) in a crimped aluminum pan with a pin hole on its lid; and 3) collecting the solid residue to yield Form L ofCompound 1. - In one embodiment, provided herein is Form L having a Raman Spectrum as depicted in
FIG. 39 . - In certain embodiments, a solid form provided herein, e.g., Form L, is substantially crystalline, as indicated by, e.g., X-ray powder diffraction measurements. In one embodiment, provided herein is a solid form having an X-ray powder diffraction pattern (XRPD) substantially as shown in
FIG. 38 (e.g., Form L). In one embodiment, a solid form provided herein, e.g., Form L, has one or more characteristic X-ray powder diffraction peaks at approximately 11.5, 12.0, 13.4, 15.7, 17.5, 19.0, 19.6, 20.1, 21.0, 21.3, or 23.5° 2θ (±0.2° 2θ) or (±0.1° 2θ) as depicted inFIG. 38 . In a specific embodiment, a solid form provided herein, e.g., Form L, has one, two, three, four, five, or six characteristic X-ray powder diffraction peaks at approximately 11.5, 12.0, 13.4, 17.5, 20.1, or 21.3° 2θ (±0.2° 2θ). In certain embodiments, the solid form is Form L. - In still another embodiment, Form L is substantially pure. In certain embodiments, the substantially pure Form L is substantially free of other solid forms, including but not limited to amorphous solid. In certain embodiments, the substantially pure Form L is substantially free of Form A, Form B, Form C, Form D, Form E, Form F, Form G, Form H, Form I, Form J, Form K, Form M, or Form N. In certain embodiments, the purity of the substantially pure Form L is no less than about 95%, no less than about 96%, no less than about 97%, no less than about 98%, no less than about 98.5%, no less than about 99%, no less than about 99.5%, or no less than about 99.8%.
- In certain embodiments, Form L is mixed with other solid forms, including but not limited to the amorphous solid. In certain embodiments, Form L is mixed with at least one of Form A, Form B, Form C, Form D, Form E, Form F, Form G, Form H, Form I, Form J, Form K, Form M, or Form N.
- In one embodiment, Form L comprises a free base of
Compound 1. In one embodiment, Form L comprises a free acid ofCompound 1. In one embodiment, Form L comprises a zwitterion ofCompound 1. - (n) Form M
- In certain embodiments, provided herein is Form M.
- In one embodiment, Form M is a solid form of
Compound 1. In one embodiment, Form M is crystalline. - In certain embodiments, provided herein are methods for making Form M, comprising 1) drying a solid form of
Compound 1 described herein (e.g., Form K) in a vacuum oven at a certain temperature for a certain time; 2) heating a portion of the dried solid at a certain rate on DSC in a vessel to yield Form M ofCompound 1. In certain embodiments, the certain temperature is 35° C. and the certain time is two days. In certain embodiments, the portion of the dried solid is heated to 102° C. at a rate of 10° C./min. In certain embodiments, the vessel is a crimped aluminum pan with a pin hole on its lid. - In certain embodiments, provided herein are methods for making Form M, comprising: 1) drying Form K of
Compound 1 in a vacuum oven at a temperature (e.g., 35° C.) for a period of time (e.g., about 2 days); 2) heating the sample to a temperature (e.g., 102° C.) at a rate (e.g., 10° C. per minute) in a crimped aluminum pan with a pin hole on its lid; and 3) collecting the solid residue to yield Form M ofCompound 1. - In one embodiment, provided herein is Form M having a Raman Spectrum as depicted in
FIG. 41 . - In certain embodiments, a solid form provided herein, e.g., Form M, is substantially crystalline, as indicated by, e.g., X-ray powder diffraction measurements. In one embodiment, provided herein is a solid form having an X-ray powder diffraction pattern (XRPD) substantially as shown in
FIG. 40 (e.g., Form M). In one embodiment, a solid form provided herein, e.g., Form M, has one or more characteristic X-ray powder diffraction peaks at approximately 7.2, 8.0, 9.5, 10.9, 11.5, 12.0, 13.4, 15.7, 16.4, 17.5, 18.2, 19.0, 19.5, 20.1, 20.7, 21.3, 22.8, or 23.4° 2θ (±0.2° 2θ) or (±0.1° 2θ) as depicted inFIG. 40 . In a specific embodiment, a solid form provided herein, e.g., Form M, has one, two, three, four, five, or six characteristic X-ray powder diffraction peaks at approximately 7.2, 9.5, 12.0, 16.4, 18.2, or 22.8° 2θ (±0.2° 2θ). In certain embodiments, the solid form is Form M. - In still another embodiment, Form M is substantially pure. In certain embodiments, the substantially pure Form L is substantially free of other solid forms, including but not limited to amorphous solid. In certain embodiments, the substantially pure Form M is substantially free of Form A, Form B, Form C, Form D, Form E, Form F, Form G, Form H, Form I, Form J, Form K, Form L, or Form N. In certain embodiments, the purity of the substantially pure Form M is no less than about 95%, no less than about 96%, no less than about 97%, no less than about 98%, no less than about 98.5%, no less than about 99%, no less than about 99.5%, or no less than about 99.8%.
- In certain embodiments, Form M is mixed with other solid forms, including but not limited to the amorphous solid. In certain embodiments, Form M is mixed with at least one of Form A, Form B, Form C, Form D, Form E, Form F, Form G, Form H, Form I, Form J, Form K, Form L, or Form N.
- In one embodiment, Form M comprises a free base of
Compound 1. In one embodiment, Form M comprises a free acid ofCompound 1. In one embodiment, Form M comprises a zwitterion ofCompound 1. - (o) Form N
- In certain embodiments, provided herein is Form N.
- In one embodiment, Form N is a solid form of
Compound 1. In one embodiment, Form N is crystalline. - In certain embodiments, provided herein are methods for making Form N, comprising 1) mixing a solid form of
Compound 1 described herein (e.g., Form E) with a solvent or solvent system; 2) stirring the resulting mixture at a certain temperature for a certain time; 3) filtering the mixture; and 4) drying the resulting solid in a vacuum oven to yield Form N ofCompound 1. In certain embodiments, the solvent is water. In some embodiments, the water is Milli-Q water. In certain embodiments, the certain temperature is ambient temperature and the certain time is five days. - In certain embodiments, provided herein are methods for making Form N, comprising: 1) mixing an amount of Form E of Compound 1 (e.g., about 8.6 mg) with an amount of water (e.g., 0.12 mL of Milli-Q water); 2) capping the sample and stirring at a speed (e.g., 400 rotations per minute) at a temperature (e.g., ambient temperature) for a period of time (e.g., about 5 days); 3) collecting solids from the sample by filtration (e.g., via a 0.2 μm Nylon-membraned centrifuge tube filter) and drying the collected solids in a vacuum oven at a temperature (e.g., 35° C.) for a period of time (e.g., about a day) to yield Form N of
Compound 1. - In one embodiment, provided herein is Form N having a Raman Spectrum as depicted in
FIG. 43 . - In one embodiment, provided herein is a solid form, e.g., Form N of
Compound 1, having a DSC thermograph substantially as depicted inFIG. 44 comprising an endothermic event with an onset temperature of approximately 85.7° C. - In one embodiment, provided herein is a solid form, e.g., Form N of
Compound 1, having a TGA thermogram corresponding substantially to the representative TGA thermogram as depicted inFIG. 44 . In certain embodiments, the crystalline form exhibits a TGA thermogram comprising a total mass loss of approximately 1.2% of the total mass of the sample when heated to 105.5° C. Thus, in certain embodiments, the crystalline form loses about 1.2% of its total mass when heated from about ambient temperature to about 105.5° C. - In certain embodiments, a solid form provided herein, e.g., Form N is substantially crystalline, as indicated by, e.g., X-ray powder diffraction measurements. In one embodiment, provided herein is a solid form having an X-ray powder diffraction pattern (XRPD) substantially as shown in
FIG. 42 (e.g., Form N). In one embodiment, a solid form provided herein, e.g., Form N, has one or more characteristic X-ray powder diffraction peaks at approximately 11.6, 12.0, 13.5, 13.8, 14.0, 14.6, 15.8, 16.2, 17.7, 19.2, 19.6, 20.1, 21.6, 21.7, 23.2, 23.7, or 24.1° 2θ (±0.2° 2θ) or (±0.1° 2θ) as depicted inFIG. 42 . In a specific embodiment, a solid form provided herein, e.g., Form N, has one, two, three, four, five, or six characteristic X-ray powder diffraction peaks at approximately 12.0, 13.5, 17.7, 20.1, 21.6, or 23.7° 2θ (±0.2° 2θ). In certain embodiments, the solid form is Form N. - In still another embodiment, Form N is substantially pure. In certain embodiments, the substantially pure Form N is substantially free of other solid forms, including but not limited to amorphous solid. In certain embodiments, the substantially pure Form N is substantially free of Form A, Form B, Form C, Form D, Form E, Form F, Form G, Form H, Form I, Form J, Form K, Form L, or Form M. In certain embodiments, the purity of the substantially pure Form N is no less than about 95%, no less than about 96%, no less than about 97%, no less than about 98%, no less than about 98.5%, no less than about 99%, no less than about 99.5%, or no less than about 99.8%.
- In certain embodiments, Form N is mixed with other solid forms, including but not limited to the amorphous solid. In certain embodiments, Form N is mixed with at least one of Form A, Form B, Form C, Form D, Form E, Form F, Form G, Form H, Form I, Form J, Form K, Form L, or Form M.
- In one embodiment, Form N comprises a free base of
Compound 1. In one embodiment, Form N comprises a free acid ofCompound 1. In one embodiment, Form N comprises a zwitterion ofCompound 1. - 5.4 Methods of Use
- The solid forms and the pharmaceutical
compositions comprising Compound 1, or a tautomer thereof, provided herein can be used in all the methods provided herein. The solid forms and the pharmaceuticalcompositions comprising Compound 1, or a tautomer thereof, provided herein can be used in the treatment of all diseases, disorders or conditions provided herein. - Provided herein are methods for treating a subject suffering from or at risk for having an autoimmune disease or chronic inflammatory disorder, wherein the method comprises administering to said subject a solid
form comprising Compound 1, or a tautomer thereof, provided herein or a pharmaceutical composition thereof. In certain embodiments, the autoimmune or chronic inflammatory disorder is polymyositis, dermatomyositis, lupus nephritis, rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, amyotrophic lateral sclerosis, autoimmune myositis, systemic lupus,Type 1 diabetes, biliary cirrhosis, bullous pemphigoid, sarcoidosis, Wegener's granulomatosis, ichthyosis, Graves' disease, or multiple sclerosis. In a preferred embodiment, the multiple sclerosis is relapsing-remitting multiple sclerosis, primary progressive multiple sclerosis, secondary progressive multiple sclerosis, or relapsing secondary progressive multiple sclerosis. In one embodiment, the solid form is selected from the group consisting of Form A, Form B, Form C, Form D, Form E, Form F, Form G, Form H, or Form I. In one embodiment, the solid form is selected from the group consisting of Form J, Form K, Form L, Form M, or Form N. - In another embodiment, provided herein are methods for treating a subject suffering from or at risk for having a neurological disorder, wherein the method comprises administering to said subject a solid
form comprising Compound 1, or a tautomer thereof, provided herein or a pharmaceutical composition thereof. In one embodiment, the neurological disorder is Rett Syndrome. In one embodiment, the solid form is selected from the group consisting of Form A, Form B, Form C, Form D, Form E, Form F, Form G, Form H, or Form I. In one embodiment, the solid form is selected from the group consisting of Form J, Form K, Form L, Form M, or Form N. - In another embodiment, provided herein are methods for treating a subject suffering from or at risk for renal or hepatic impairment, wherein the method comprises administering to said subject a solid
form comprising Compound 1, or a tautomer thereof, provided herein or a pharmaceutical composition thereof. In one embodiment, the solid form is selected from the group consisting of Form A, Form B, Form C, Form D, Form E, Form F, Form G, Form H, or Form I. In one embodiment, the solid form is selected from the group consisting of Form J, Form K, Form L, Form M, or Form N. - In another embodiment, provided herein are methods for treating a subject suffering from or at risk for a disease or disorder mediated by lymphocyte interactions, wherein the method comprises administering to said subject a solid
form comprising Compound 1, or a tautomer thereof, provided herein or a pharmaceutical composition thereof. In certain embodiments, the disease or disorder mediated by lymphocyte interactions is, for example, in transplantation, acute or chronic rejection of cell, tissue or organ allo- or xenografts or delayed graft function, graft versus host disease; autoimmune diseases, e.g., rheumatoid arthritis, systemic lupus erythematosus, hashimoto's thyroidis, multiple sclerosis, myasthenia gravis, diabetes type I or II and the disorders associated therewith, vasculitis, pernicious anemia, Sjoegren syndrome, uveitis, psoriasis, Graves ophthalmopathy, alopecia areata and others; allergic diseases, e.g., allergic asthma, atopic dermatitis, allergic rhinitis/conjunctivitis, allergic contact dermatitis; inflammatory diseases optionally with underlying aberrant reactions, e.g., inflammatory bowel disease, Crohn's disease or ulcerative colitis, intrinsic asthma, inflammatory lung injury, inflammatory liver injury, inflammatory glomerular injury, atherosclerosis, osteoarthritis, irritant contact dermatitis and further eczematous dermatitises, seborrhoeic dermatitis, cutaneous manifestations of immunologically-mediated disorders, inflammatory eye disease, keratoconjunctivitis, inflammatory myopathy; myocarditis or hepatitis; ischemia/reperfusion injury, e.g., myocardial infarction, stroke, gut ischemia, renal failure or hemorrhage shock, traumatic shock; T cell lymphomas or T cell leukemias; infectious diseases, e.g., toxic shock (e.g., superantigen induced), septic shock, adult respiratory distress syndrome or viral infections, e.g., AIDS, viral hepatitis, chronic bacterial infection; muscle diseases, e.g., polymyositis; or senile dementia. Examples of cell, tissue or solid organ transplants include, e.g., pancreatic islets, stem cells, bone marrow, corneal tissue, neuronal tissue, heart, lung, combined heart-lung, kidney, liver, bowel, pancreas, trachea or oesophagus. In one embodiment, the solid form is selected from the group consisting of Form A, Form B, Form C, Form D, Form E, Form F, Form G, Form H, or Form I. In one embodiment, the solid form is selected from the group consisting of Form J, Form K, Form L, Form M, or Form N. - In another embodiment, provided herein are methods for the treatment of a disease or disorder associated with sphingosine 1-phosphate, wherein the method comprises administering to said subject a solid
form comprising Compound 1, or a tautomer thereof, provided herein or a pharmaceutical composition thereof. In certain embodiments, the disease or disorder associated with sphingosine 1-phosphate is multiple sclerosis, relapse-remitting multiple sclerosis, systemic lupus,Type 1 diabetes, amyotrophic lateral sclerosis, refractory rheumatoid arthritis, inflammatory bowel disease, biliary cirrhosis, Crohn's disease, ulcerative colitis, bullous pemphigoid, sarcoidosis, psoriasis, autoimmune myositis, Wegener's granulomatosis, ichthyosis, or Graves' disease. In one embodiment, the solid form is selected from the group consisting of Form A, Form B, Form C, Form D, Form E, Form F, Form G, Form H, or Form I. In one embodiment, the solid form is selected from the group consisting of Form J, Form K, Form L, Form M, or Form N. - In another embodiment, provided herein are methods for the treatment of a disease or disorder associated with the
interferon alpha receptor 1, wherein the method comprises administering to said subject a solidform comprising Compound 1, or a tautomer thereof, or a pharmaceutical composition thereof. In certain embodiments, the disease or disorder associated with the interferon alpha receptor is psoriasis, ulcerative colitis, systemic lupus, multiple sclerosis, or rheumatoid arthritis. In one embodiment, the solid form is selected from the group consisting of Form A, Form B, Form C, Form D, Form E, Form F, Form G, Form H, or Form I. In one embodiment, the solid form is selected from the group consisting of Form J, Form K, Form L, Form M, or Form N. - The compounds, compositions, methods, and uses disclosed herein are not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the compounds, compositions, methods, and uses in addition to those described will become apparent to those skilled in the art from the foregoing description and accompanying figures. Such modifications are intended to fall within the scope of the appended claims.
- Various publications, patents and patent applications are cited herein, the disclosures of which are incorporated by reference in their entities.
- 5.5 Pharmaceutical Compositions
- Solid
forms comprising Compound 1, or a tautomer thereof, provided herein are useful for the preparation of pharmaceutical compositions, comprising an effective amount of a solidform comprising Compound 1, or a tautomer thereof, and a pharmaceutically acceptable vehicle, carrier, diluent, or excipient, or a mixture thereof. In certain embodiments, the pharmaceutically acceptable carrier is hydroxypropyl methylcellulose. In some embodiments, the pharmaceutical compositions described herein are suitable for oral, parenteral, mucosal, transdermal or topical administration. - 5.6 Oral Administration
- The pharmaceutical compositions provided herein may be administered orally, for example in solid, semisolid, or liquid dosage forms. As used herein, oral administration also includes buccal, lingual, and sublingual administration. Suitable oral dosage forms include, but are not limited to, tablets, fastmelts, chewable tablets, capsules, pills, strips, troches, lozenges, pastilles, cachets, pellets, medicated chewing gum, bulk powders, effervescent or non-effervescent powders or granules, oral mists, solutions, emulsions, suspensions, wafers, sprinkles, elixirs, and syrups. In addition to the active ingredient(s), the pharmaceutical compositions can contain one or more pharmaceutically acceptable carriers or excipients, including, but not limited to, binders, fillers, diluents, disintegrants, wetting agents, lubricants, glidants, coloring agents, dye-migration inhibitors, sweetening agents, flavoring agents, emulsifying agents, suspending and dispersing agents, preservatives, solvents, non-aqueous liquids, organic acids, and sources of carbon dioxide.
- In one embodiment, the pharmaceutically acceptable carrier or excipient is selected from the group consisting of lactose (e.g., as lactose monohydrate); microcrystalline cellulose; non-basic polymers (e.g., homopolymers of cross-linked N-vinyl-2-pyrrolidone (crospovidone), hypromellose (hydroxypropylmethyl cellulose), and ethyl cellulose); waxes; colloidal silicon dioxide; stearic acid; hydrogenated vegetable oil; mineral oil; polyethylene glycol (e.g., polyethylene glycol 4000-6000); glyceryl palmitostearate; and glyceryl behenate. In another embodiment, the pharmaceutically acceptable carrier or excipient is microcrystalline cellulose.
- Binders or granulators impart cohesiveness to a tablet to ensure the tablet remains intact after compression. Suitable binders or granulators include, but are not limited to, starches, such as corn starch, potato starch, and pre-gelatinized starch (e.g., STARCH 1500); gelatin; sugars, such as sucrose, glucose, dextrose, molasses, and lactose; natural and synthetic gums, such as acacia, alginic acid, alginates, extract of Irish moss, panwar gum, ghatti gum, mucilage of isabgol husks, carboxymethylcellulose, methylcellulose, polyvinylpyrrolidone (PVP), Veegum, larch arabogalactan, powdered tragacanth, and guar gum; celluloses, such as ethyl cellulose, cellulose acetate, carboxymethyl cellulose calcium, sodium carboxymethyl cellulose, methyl cellulose, hydroxyethylcellulose (HEC), hydroxypropylcellulose (HPC), hydroxypropyl methyl cellulose (HPMC); microcrystalline celluloses, such as AVICEL-PH-101, AVICEL-PH-103, AVICEL RC-581, AVICEL-PH-105 (FMC Corp., Marcus Hook, Pa.); and mixtures thereof. Suitable fillers include, but are not limited to, talc, calcium carbonate, microcrystalline cellulose, powdered cellulose, dextrates, kaolin, mannitol, silicic acid, sorbitol, starch, pre-gelatinized starch, and mixtures thereof. The amount of a binder or filler in the pharmaceutical compositions provided herein varies upon the type of formulation, and is readily discernible to those of ordinary skill in the art. The binder or filler may be present from about 50 to about 99% by weight in the pharmaceutical compositions provided herein.
- Suitable diluents include, but are not limited to, dicalcium phosphate, calcium sulfate, lactose, sorbitol, sucrose, inositol, cellulose, kaolin, mannitol, sodium chloride, dry starch, and powdered sugar. Certain diluents, such as mannitol, lactose, sorbitol, sucrose, and inositol, when present in sufficient quantity, can impart properties to some compressed tablets that permit disintegration in the mouth by chewing. Such compressed tablets can be used as chewable tablets. The amount of a diluent in the pharmaceutical compositions provided herein varies upon the type of formulation, and is readily discernible to those of ordinary skill in the art.
- Suitable disintegrants include, but are not limited to, agar; bentonite; celluloses, such as methylcellulose and carboxymethylcellulose; wood products; natural sponge; cation-exchange resins; alginic acid; gums, such as guar gum and Veegum HV; citrus pulp; cross-linked celluloses, such as croscarmellose; cross-linked polymers, such as crospovidone; cross-linked starches; calcium carbonate; microcrystalline cellulose, such as sodium starch glycolate; polacrilin potassium; starches, such as corn starch, potato starch, tapioca starch, and pre-gelatinized starch; clays; aligns; and mixtures thereof. The amount of a disintegrant in the pharmaceutical compositions provided herein varies upon the type of formulation, and is readily discernible to those of ordinary skill in the art. The pharmaceutical compositions provided herein may contain from about 0.5% to about 15% or from about 1% to about 5% by weight of a disintegrant.
- Suitable lubricants include, but are not limited to, calcium stearate; magnesium stearate; mineral oil; light mineral oil; glycerin; sorbitol; mannitol; glycols, such as glycerol behenate and polyethylene glycol (PEG); stearic acid; sodium lauryl sulfate; talc; hydrogenated vegetable oil, including peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil, and soybean oil; zinc stearate; ethyl oleate; ethyl laureate; agar; starch; lycopodium; silica or silica gels, such as AEROSIL® 200 (W.R. Grace Co., Baltimore, Md.) and CAB-O-SIL® (Cabot Co. of Boston, Mass.); and mixtures thereof. The pharmaceutical compositions provided herein may contain about 0.1% to about 5% by weight of a lubricant.
- Suitable glidants include, but are not limited to, colloidal silicon dioxide, CAB-O-SIL® (Cabot Co. of Boston, Mass.), and asbestos-free talc. Suitable coloring agents include, but are not limited to, any of the approved, certified, water soluble FD&C dyes, and water insoluble FD&C dyes suspended on alumina hydrate, and color lakes and mixtures thereof. A color lake is the combination by adsorption of a water-soluble dye to a hydrous oxide of a heavy metal, resulting in an insoluble form of the dye. Suitable flavoring agents include, but are not limited to, natural flavors extracted from plants, such as fruits, and synthetic blends of compounds which produce a pleasant taste sensation, such as peppermint and methyl salicylate. Suitable sweetening agents include, but are not limited to, sucrose, lactose, mannitol, syrups, glycerin, and artificial sweeteners, such as saccharin and aspartame. Suitable emulsifying agents include, but are not limited to, gelatin, acacia, tragacanth, bentonite, and surfactants, such as polyoxyethylene sorbitan monooleate (TWEEN® 20), polyoxyethylene sorbitan monooleate 80 (TWEEN® 80), and triethanolamine oleate. Suitable suspending and dispersing agents include, but are not limited to, sodium carboxymethylcellulose, pectin, tragacanth, Veegum, acacia, sodium carbomethylcellulose, hydroxypropyl methylcellulose, and polyvinylpyrrolidone. Suitable preservatives include, but are not limited to, glycerin, methyl and propylparaben, benzoic acid, sodium benzoate, and alcohol. Suitable wetting agents include, but are not limited to, propylene glycol monostearate, sorbitan monooleate, diethylene glycol monolaurate, and polyoxyethylene lauryl ether. Suitable solvents include, but are not limited to, glycerin, sorbitol, ethyl alcohol, and syrup. Suitable non-aqueous liquids utilized in emulsions include, but are not limited to, mineral oil and cottonseed oil. Suitable organic acids include, but are not limited to, citric and tartaric acid. Suitable sources of carbon dioxide include, but are not limited to, sodium bicarbonate and sodium carbonate.
- The pharmaceutical compositions provided herein for oral administration can be provided as compressed tablets, tablet triturates, chewable lozenges, rapidly dissolving tablets, multiple compressed tablets, or enteric-coating tablets, sugar-coated, or film-coated tablets. Enteric-coated tablets are compressed tablets coated with substances that resist the action of stomach acid but dissolve or disintegrate in the intestine, thus protecting the active ingredients from the acidic environment of the stomach. Enteric-coatings include, but are not limited to, fatty acids, fats, phenyl salicylate, waxes, shellac, ammoniated shellac, and cellulose acetate phthalates. Sugar-coated tablets are compressed tablets surrounded by a sugar coating, which may be beneficial in covering up objectionable tastes or odors and in protecting the tablets from oxidation. Film-coated tablets are compressed tablets that are covered with a thin layer or film of a water-soluble material. Film coatings include, but are not limited to, hydroxyethylcellulose, sodium carboxymethylcellulose,
polyethylene glycol 4000, and cellulose acetate phthalate. Film coating imparts the same general characteristics as sugar coating. Multiple compressed tablets are compressed tablets made by more than one compression cycle, including layered tablets, and press-coated or dry-coated tablets. - The solid forms and the pharmaceutical
compositions comprising Compound 1, or a tautomer thereof, provided herein can be formulated as an oral dosage form. In certain embodiments the oral dosage form comprises one or more of Form A, Form B, Form C, Form D, Form E, Form F, Form G, Form H, Form I, Form J, Form K, Form L, Form M, or Form N. In certain embodiments the oral dosage form comprises at least 0.001 mg, at least 0.005 mg, at least 0.01 mg, at least 0.05 mg, at least 0.1 mg, at least 0.5 mg, at least 1.0 mg or at least 2.0 mg of Form A, Form B, Form C, Form D, Form E, Form F, Form G, Form H, Form I, Form J, Form K, Form L, Form M, or Form N. - 5.7 Parenteral Administration
- The pharmaceutical compositions provided herein can be administered parenterally, for example, by injection, infusion, or implantation techniques, for local or systemic administration. Parenteral administration, as used herein, include intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular, intrasynovial, intravesical, and subcutaneous administration.
- The pharmaceutical compositions provided herein for parenteral administration can be formulated in any dosage forms that are suitable for parenteral administration, including solutions, suspensions, emulsions, micelles, liposomes, microspheres, nanosystems, and solid forms suitable for solutions or suspensions in liquid prior to injection. Such dosage forms can be prepared according to conventional methods known to those skilled in the art of pharmaceutical science (see, Remington: The Science and Practice of Pharmacy, supra).
- The pharmaceutical compositions intended for parenteral administration can include one or more pharmaceutically acceptable carriers and excipients, including, but not limited to, aqueous vehicles, water-miscible vehicles, non-aqueous vehicles, antimicrobial agents or preservatives against the growth of microorganisms, stabilizers, solubility enhancers, isotonic agents, buffering agents, antioxidants, local anesthetics, suspending and dispersing agents, wetting or emulsifying agents, complexing agents, sequestering or chelating agents, cryoprotectants, lyoprotectants, thickening agents, pH adjusting agents, and inert gases.
- Suitable aqueous vehicles include, but are not limited to, water, saline, physiological saline or phosphate buffered saline (PBS), sodium chloride injection, Ringers injection, isotonic dextrose injection, sterile water injection, dextrose and lactated Ringers injection. Suitable non-aqueous vehicles include, but are not limited to, fixed oils of vegetable origin, castor oil, corn oil, cottonseed oil, olive oil, peanut oil, peppermint oil, safflower oil, sesame oil, soybean oil, hydrogenated vegetable oils, hydrogenated soybean oil, and medium-chain triglycerides of coconut oil, and palm seed oil. Suitable water-miscible vehicles include, but are not limited to, ethanol, 1,3-butanediol, liquid polyethylene glycol (e.g.,
polyethylene glycol 300 and polyethylene glycol 400), propylene glycol, glycerin, N-methyl-2-pyrrolidone, N,N-dimethylacetamide, and dimethyl sulfoxide. - Suitable antimicrobial agents or preservatives include, but are not limited to, phenols, cresols, mercurials, benzyl alcohol, chlorobutanol, methyl and propyl p-hydroxybenzoates, thimerosal, benzalkonium chloride (e.g., benzethonium chloride), methyl- and propyl-parabens, and sorbic acid. Suitable isotonic agents include, but are not limited to, sodium chloride, glycerin, and dextrose. Suitable buffering agents include, but are not limited to, phosphate and citrate. Suitable antioxidants are those as described herein, including bisulfate and sodium metabisulfite. Suitable local anesthetics include, but are not limited to, procaine hydrochloride. Suitable suspending and dispersing agents are those as described herein, including sodium carboxymethylcelluose, hydroxypropyl methylcellulose, and polyvinylpyrrolidone. Suitable emulsifying agents are those described herein, including polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan monooleate 80, and triethanolamine oleate. Suitable sequestering or chelating agents include, but are not limited to EDTA. Suitable pH adjusting agents include, but are not limited to, sodium hydroxide, hydrochloric acid, citric acid, and lactic acid. Suitable complexing agents include, but are not limited to, cyclodextrins, including α-cyclodextrin, β-cyclodextrin, hydroxypropyl-β-cyclodextrin, sulfobutylether-β-cyclodextrin, and sulfobutylether 7-β-cyclodextrin (CAPTISOL®, CyDex, Lenexa, Kans.).
- When the pharmaceutical compositions provided herein are formulated for multiple dosage administration, the multiple dosage parenteral formulations must contain an antimicrobial agent at bacteriostatic or fungistatic concentrations. All parenteral formulations must be sterile, as known and practiced in the art.
- In one embodiment, the pharmaceutical compositions for parenteral administration are provided as ready-to-use sterile solutions. In another embodiment, the pharmaceutical compositions are provided as sterile dry soluble products, including lyophilized powders and hypodermic tablets, to be reconstituted with a vehicle prior to use. In yet another embodiment, the pharmaceutical compositions are provided as ready-to-use sterile suspensions. In yet another embodiment, the pharmaceutical compositions are provided as sterile dry insoluble products to be reconstituted with a vehicle prior to use. In still another embodiment, the pharmaceutical compositions are provided as ready-to-use sterile emulsions.
- The pharmaceutical compositions provided herein for parenteral administration can be formulated as immediate or modified release dosage forms, including delayed-, sustained, pulsed-, controlled, targeted-, and programmed-release forms.
- The pharmaceutical compositions provided herein for parenteral administration can be formulated as a suspension, solid, semi-solid, or thixotropic liquid, for administration as an implanted depot. In one embodiment, the pharmaceutical compositions provided herein are dispersed in a solid inner matrix, which is surrounded by an outer polymeric membrane that is insoluble in body fluids but allows the active ingredient in the pharmaceutical compositions diffuse through.
- Suitable inner matrixes include, but are not limited to, polymethylmethacrylate, polybutyl-methacrylate, plasticized or unplasticized polyvinylchloride, plasticized nylon, plasticized polyethylene terephthalate, natural rubber, polyisoprene, polyisobutylene, polybutadiene, polyethylene, ethylene-vinyl acetate copolymers, silicone rubbers, polydimethylsiloxanes, silicone carbonate copolymers, hydrophilic polymers, such as hydrogels of esters of acrylic and methacrylic acid, collagen, cross-linked polyvinyl alcohol, and cross-linked partially hydrolyzed polyvinyl acetate.
- Suitable outer polymeric membranes include but are not limited to, polyethylene, polypropylene, ethylene/propylene copolymers, ethylene/ethyl acrylate copolymers, ethylene/vinyl acetate copolymers, silicone rubbers, polydimethyl siloxanes, neoprene rubber, chlorinated polyethylene, polyvinylchloride, vinyl chloride copolymers with vinyl acetate, vinylidene chloride, ethylene and propylene, ionomer polyethylene terephthalate, butyl rubber epichlorohydrin rubbers, ethylene/vinyl alcohol copolymer, ethylene/vinyl acetate/vinyl alcohol terpolymer, and ethylene/vinyloxyethanol copolymer.
- The following Examples are presented by way of illustration, not limitation.
- 6.1 Analytical Methods
- Powder X-ray diffraction (PXRD) patterns were obtained using a PANalytical X'Pert Pro diffractometer using Ni-filtered Cu Ka (45 kV/40 mA) radiation and a step size of 0.02° 2θ and X'celerator Real Time Multi-Strip (RTMS) detector. Configuration on the incidental beam side is a fixed divergence slit)(0.25°), 0.04 radian Soller slits, anti-scatter slit)(0.25°), and 10 mm beam mask. Configuration on the diffracted beam side is a fixed divergence slit)(0.25°) and 0.04 radian Soller slit. Samples were mounted flat on zero-background Si wafers and covered with Kapton film to comply with safety policies.
- FT-Raman spectra were collected with a Nicolet NXR9650 or NXR 960 spectrometer (Thermo Electron) equipped with 1064 nm Nd:YVO4 excitation laser, InGaAs and liquid-N2 cooled Ge detectors, and a MicroStage. Spectra were acquired at 4 cm−1 resolution, 64 scans, using Happ-Genzel apodization function and 2-level zero-filling.
- Differential Scanning calorimetry (DSC) was conducted with a TA Instruments Q100 differential scanning calorimeter equipped with an autosampler and a refrigerated cooling system under 40 mL/min N2 purge. DSC thermograms were obtained at 15° C./min in crimped Al pans.
- Polarized-light microscopy (PLM) photomicrographs were collected using an Olympus BX60 polarized-light microscope equipped with an Olympus DP70 camera.
- Thermogravimetric Analysis (TGA) thermograms were obtained with a TA Instruments Q500 thermogravimetric analyzer under 40 mL/min N2 purge at 15° C./min in Al pans.
- Thermogravimetric Analysis with IR Off-Gas Detection (TGA-IR) was conducted with a TA Instruments Q5000 thermogravimetric analyzer interfaced to a Nicolet 6700 FT-IR spectrometer (Thermo Electron) equipped with an external TGA-IR module with a gas flow cell and DTGS detector. TGA was conducted with 60 mL/min N2 flow and heating rate of 15° C./min in Al pans. IR spectra were collected at 4 cm−1 resolution and 32 scans at each time point.
- Proton Nuclear Magnetic Resonance (1H NMR) spectra were collected using an
Agilent DD2 500 MHz spectrometer with tetramethylsilane reference. Samples were dissolved in deuterated dimethyl sulfoxide. - Powder X-ray diffraction (PXRD) patterns were obtained on a Rigaku SmartLab Guidance diffractometer with Cu-Ka radiation and D/teX Ultra detector. The powder samples were deposited on a zero-background polished silicon sample holder and were spun during measurement. Measurements were performed as follows: 40 kV/44 mA tube power, 0.02° 2θ step size, 5° 2θ/min scan rate, and 3-40° 2θ scan range. Data were processed using Rigaku PDXL2 software.
- Raman spectra were collected using a Raman Work Station (Kaiser Optical Systems, Inc, Ann Arbor, Mich.) with Holograms software. Data was acquired using 785 nm excitation laser with 300 mW in a reflection mode, 4 cm−1 resolution through a 10× objective with 10 accumulations. Data were processed using Grams/AI software (Thermo Fisher Scientific Inc). Data may also be acquired using 785 nm excitation laser with 300 mW in a reflection mode, 4 cm−1 resolution through a 10× objective.
- Differential Scanning calorimetry (DSC) was conducted with a TA Instruments Q2000 differential scanning calorimeter equipped with an autosampler and a refrigerated cooling system under 40 mL/min nitrogen (N2) purge. DSC thermograms were obtained at 10° C./min in crimped aluminum (Al) pans with pin holes on lids.
- Thermogravimetric Analysis (TGA) thermograms were obtained with a TA Instruments Q5000 thermogravimetric analyzer under 40 mL/min N2 purge at 10° C./min in Al pans.
- For Examples 6.2(a) through 6.2(h) below, the analytical methods regarding PXRD, FT-Raman spectra, DSC and TGA as described in paragraphs [00291], [00292], [00293] and [00295], respectively, were employed. For Examples 6.2(i) through 6.2(m) below, the analytical methods regarding PXRD, Raman spectra, DSC and TGA as described in paragraphs [00298], [00299], [00300] and [00301], respectively, were employed.
- 6.2 Preparation and Analysis of Crystal Forms
- (a) Form A
- Compound 1 (59.5 mg) was suspended in isopropyl ether (0.75 mL) and the temperature of the slurry was cycled between 5° C. and 40° C. for 72 h. The slurry was filtered to yield Form A of
Compound 1. - Form A has an FT-Raman Spectrum as depicted in
FIG. 2 . Form A has a DSC thermograph substantially as depicted inFIG. 3 , comprising an endothermic event with a peak maximum temperature of about 54° C., and a second endotherm with an onset temperature of about 102° C. Form A has a TGA thermograph as depicted inFIG. 3 , comprising a total mass loss of approximately 6.2% of the total mass of the sample when heated to 150° C. - A list of X-Ray diffraction peaks for Form A is provided below in Table 1.
-
TABLE 1 X-Ray Diffraction Peaks for Form A. Two-theta angle (°) d Space (Å) Height (counts) 2.3 37.813 4109.4 3.9 22.913 594.2 6.9 12.738 317.3 7.7 11.488 673.0 9.2 9.562 71.0 9.9 8.896 112.6 11.5 7.667 661.7 12.1 7.338 37.4 14.3 6.192 322.0 15.5 5.705 150.9 18.2 4.868 162.4 19.3 4.599 255.6 20.9 4.246 462.4 21.7 4.102 136.2 23.2 3.831 121.5 24.5 3.636 189.3 32.0 2.796 45.2 - (b) Form B
- Compound 1 (60.8 mg) was suspended in cyclohexane (0.75 mL) and the temperature of the slurry was cycled between 5° C. and 40° C. for 72 h. The slurry was filtered to yield Form B of
Compound 1. - Form B has an FT-Raman Spectrum as depicted in
FIG. 6 . Form B has a DSC thermograph substantially as depicted inFIG. 7 , comprising a first endothermic event with an onset temperature of about 40.2° C. and a peak maximum temperature of about 47.7° C. Form B has a TGA thermograph as depicted inFIG. 7 , comprising a total mass loss of approximately 8.5% of the total mass of the sample when heated from approximately 25° C. and 150° C. - A list of X-Ray diffraction peaks for Form B is provided below in Table 2.
-
TABLE 2 X-Ray Diffraction Peaks for Form B. Two-theta angle (°) d Space (Å) Height (counts) 2.3 37.850 3551.4 2.8 31.403 743.4 3.8 22.993 413.8 5.6 15.757 238.2 7.0 12.649 327.0 7.7 11.506 502.4 8.4 10.506 1254.6 9.3 9.495 75.9 11.5 7.669 464.9 14.0 6.305 259.2 14.3 6.188 190.1 15.5 5.712 103.1 18.2 4.867 95.6 19.3 4.605 165.6 20.9 4.246 281.8 21.7 4.095 93.8 22.5 3.946 90.9 23.2 3.842 142.3 24.6 3.625 107.0 32.0 2.793 24.1 - (c) Form C
- Compound 1 (61 mg) was suspended in heptane (0.75 mL) and the temperature of the slurry was cycled between 5° C. and 40° C. for 72 h. The slurry was filtered to yield Form C.
- Form C has an FT-Raman Spectrum as depicted in
FIG. 10 . Form C has a DSC thermograph substantially as depicted inFIG. 11 , comprising an endothermic event with an onset temperature of about 101.7° C. Form B has a TGA thermograph as depicted inFIG. 11 , comprising a total mass loss of approximately 14.3% of the total mass of the sample when heated to about 150° C. - A list of X-Ray diffraction peaks for Form C is provided below in Table 3.
-
TABLE 3 X-Ray Diffraction Peaks for Form C. Two-theta angle (°) d Space (Å) Height (counts) 2.2 40.419 4109.4 3.9 22.928 594.2 6.5 13.589 317.3 7.7 11.498 673.0 8.7 10.113 71.0 9.9 8.923 112.6 11.5 7.669 661.7 14.3 6.186 37.4 15.6 5.680 322.0 18.3 4.859 9004.0 19.3 4.606 368.4 20.9 4.242 404.2 21.8 4.084 466.5 23.2 3.831 60.2 24.5 3.631 43.7 32.0 2.798 532.5 - (d) Form D
- Compound 1 (120 mg) was suspended in dimethyl carbonate (0.5 mL) and the temperature of the slurry was cycled between 5° C. and 40° C. overnight. The slurry was filtered and dried under a blanket of nitrogen gas for 1 h. Drying under vacuum with nitrogen gas bleed at 65° C. overnight yielded Form D (50 mg) of
Compound 1 as a free-flowing powder. - Form D has an FT-Raman Spectrum as depicted in
FIG. 14 . Form D has a DSC thermograph substantially as depicted inFIG. 15 , comprising an endothermic event with an onset temperature of about 96° C. and a peak maximum temperature of about 111° C. Form D has a TGA thermograph as depicted inFIG. 15 , comprising a total mass loss of approximately 0.4% of the total mass of the sample when heated from approximately 25° C. to 125° C. - A list of X-Ray diffraction peaks for Form D is provided below in Table 4.
-
TABLE 4 X-Ray Diffraction Peaks for Form D. Two-theta angle (°) d Space (Å) Height (counts) 2.8 31.747 129.7 3.7 23.981 641.7 7.3 12.049 469.1 11.0 8.047 242.6 14.4 6.139 75.1 16.4 5.391 204.4 18.3 4.859 259.9 20.8 4.274 91.9 22.9 3.878 270.0 - (e) Form E
- Compound 1 (1.3 g) was suspended in isopropyl ether (6 mL). The slurry became a solution at 40° C., was seeded with Form E (1 mg), and temperature-cycled between 5° C. and 40° C. overnight. The slurry was filtered, washed with isopropyl ether (3×1 mL) and dried under vacuum at 65° C. with nitrogen gas bleed for 1 h to provide Form E (470 mg) of
Compound 1 as a free-flowing solid. - Form E has an FT-Raman Spectrum as depicted in
FIG. 18 . Form E has a DSC thermograph substantially as depicted inFIG. 19 , comprising a possible melting endotherm with an onset temperature of about 106° C. Form E has a TGA thermograph as depicted inFIG. 19 , comprising a total mass loss of approximately 0.3% of the total mass of the sample when heated from approximately 25° C. to about 125° C. - A list of X-Ray diffraction peaks for Form E is provided below in Table 5.
-
TABLE 5 X-Ray Diffraction Peaks for Form E. Two-theta angle (°) d Space (Å) Height (counts) 3.9 22.793 934.1 7.7 11.461 1086.7 9.9 8.903 109.1 11.6 7.653 1152.7 12.1 7.310 134.6 14.3 6.183 651.5 15.5 5.715 207.6 17.3 5.114 27.6 18.2 4.871 384.5 19.3 4.607 349.2 20.9 4.244 1307.1 21.7 4.102 434.1 23.3 3.825 199.5 24.5 3.631 574.0 25.3 3.517 72.1 32.0 2.799 116.1 - (f) Form F
- Compound 1 (120 mg) was suspended in dimethyl carbonate (0.5 mL) and stirred at 20° C. for 1 h. The slurry was seeded with Form D (1 mg) and stirred at 20° C. overnight. The slurry was collected by centrifugation, followed by decanting, and dried in a centrifuge evaporator overnight to yield Form F (45 mg) of
Compound 1 as a crystalline solid. - Form F has an FT-Raman Spectrum as depicted in
FIG. 22 . Form F has a DSC thermograph substantially as depicted inFIG. 23 , comprising an endothermic event with an onset temperature of about 48° C. and a peak maximum temperature of about 63° C. Form F has a TGA thermograph as depicted inFIG. 23 , comprising a total mass loss of approximately 8.9% of the total mass of the sample when heated from approximately 25° C. to about 125° C. - A list of X-Ray diffraction peaks for Form F is provided below in Table 6.
-
TABLE 6 X-Ray Diffraction Peaks for Form F. Two-theta angle (°) d Space (Å) Height (counts) 2.5 35.603 301.3 3.3 26.604 496.8 6.6 13.355 129.9 9.9 8.934 783.2 10.5 8.410 108.8 12.4 7.126 164.3 13.2 6.708 199.4 14.8 5.977 404.5 19.9 4.472 365.2 20.4 4.344 748.9 21.9 4.057 184.3 22.9 3.890 159.2 23.5 3.790 607.4 26.6 3.351 150.9 - (g) Form H
- Form E was suspended in a 10% mixture of water in acetonitrile and seeded with a small amount of Form D (1 mg) or Form I (1 mg) and the suspension was allowed to stir at ambient temperature overnight. The resulting mixture was then stirred while cycling the temperature between 5° C. and 30° C. over a period of 48 h. The resulting mixture was filtered to yield Form H of
Compound 1. - Form E was suspended in a 10% mixture of water in 1-propanol and seeded with a small amount of Form D (1 mg) or Form I (1 mg) and the suspension was allowed to stir at ambient temperature overnight. The resulting mixture was then stirred while cycling the temperature between 5° C. and 30° C. over a period of 48 h. The resulting mixture was filtered to yield Form H of
Compound 1. - Form H has an FT-Raman Spectrum as depicted in
FIG. 26 . Form H has a DSC thermograph substantially as depicted inFIG. 27 , comprising an endothermic event with a peak maximum temperature of about 56° C. and a second endothermic event with a peak maximum temperature of about 94° C. Form H has a TGA thermograph as depicted inFIG. 27 , comprising a total mass loss of approximately 7.7% of the total mass of the sample when heated from approximately 25° C. and 80° C. - A list of X-Ray diffraction peaks for Form H is provided below in Table 7.
-
TABLE 7 X-Ray Diffraction Peaks for Form H. Two-theta angle (°) d Space (Å) Height (counts) 3.6 24.580 881.7 7.2 12.279 629.4 10.8 8.194 2646.7 11.7 7.589 520.9 12.4 7.164 135.3 13.6 6.494 274.5 14.4 6.148 173.8 16.1 5.512 141.2 17.8 4.987 626.5 18.0 4.922 707.3 18.3 4.861 618.1 19.2 4.615 117.0 19.6 4.526 87.0 20.1 4.415 235.3 20.7 4.293 76.9 21.2 4.200 383.0 21.7 4.100 1506.8 23.1 3.843 72.8 23.7 3.751 223.7 24.2 3.672 318.1 25.3 3.518 327.1 27.5 3.242 103.3 29.1 3.073 114.5 36.5 2.459 86.6 - (h) Form I
-
Compound 1 is dissolved in dimethylformamide at ambient temperature and stirred overnight, and followed by addition of water. The resulting mixture is stirred for about 4 days while cycling the temperature between about 20° C. and about 50° C. The resulting mixture is evaporated under a blanket of nitrogen gas over 14 days to yield Form I ofCompound 1. - Alternatively, Form H of
Compound 1 is dried under vacuum with nitrogen gas bleed at 65° C. overnight or two days to yield Form I ofCompound 1. - Form I has an FT-Raman Spectrum as depicted in
FIG. 30 . Form I has a DSC thermograph substantially as depicted inFIG. 31 , comprising an endothermic event with an onset temperature of about 82° C. and a peak maximum temperature of about 93° C. In addition, DSC analysis showed a possible dehydration endotherm between 25° C. and 80° C. Form I has a TGA thermograph as depicted inFIG. 31 , comprising a total mass loss of approximately 1.6% of the total mass of the sample when heated from approximately 25° C. to about 110° C. - A list of X-Ray diffraction peaks for Form I is provided below in Table 8.
-
TABLE 8 X-Ray Diffraction Peaks for Form I. Two-theta angle (°) d Space (Å) Height (counts) 4.0 22.036 626.0 8.0 11.045 87.4 12.0 7.363 3274.5 13.5 6.563 195.8 17.6 5.040 300.6 19.2 4.621 139.1 20.1 4.419 2712.7 21.5 4.141 244.6 32.4 2.764 53.1 - (i) Form J
- Compound 1 (80.3 mg) was mixed with ethyl methyl ketone (11 mL), sonicated for 5 min, and filtered via 0.2 μm PTFE-membraned syringe filter. The filtrate was evaporated to dryness in fume hood under nitrogen purge. Ethyl methyl ketone (0.6 mL) was added to the sample. The sample was capped and stirred at 500 rotations per minute at ambient temperature for about a day. The solids were isolated via 0.2 μm Nylon-membraned centrifuge tube filter and further dried in vacuum oven at 35° C. for about a day to yield Form J of
Compound 1. - Form J has a Raman Spectrum as depicted in
FIG. 34 . Form J has a DSC thermograph substantially as depicted inFIG. 35 , comprising an endothermic peak with onset temperature of 143.4° C. Form J has a TGA thermograph as depicted inFIG. 35 , comprising a total mass loss of approximately 0.1% of the total mass of the sample when heated to 100° C. - A list of X-Ray diffraction peaks for Form J is provided below in Table 9.
-
TABLE 9 X-Ray Diffraction Peaks for Form J. Two-theta angle (°) d Space (Å) Height (counts) 7.9 11.177 699 11.5 7.706 1109 11.9 7.407 3267 13.4 6.606 937 13.8 6.432 676 14.0 6.325 436 15.7 5.642 1033 17.4 5.081 1973 18.9 4.689 495 19.6 4.537 664 20.0 4.429 3353 21.0 4.227 375 21.4 4.157 1325 23.5 3.785 1010 - (j) Form K
- Compound 1 (130 mg) was dried in a vacuum oven at 35° C. for 3 hours, then mixed with ethyl methyl ketone (3.5 mL). The sample was filtered via 0.2 μm PTFE-membraned syringe filter. The filtrate was evaporated in fume hood under nitrogen purge until precipitates were visually observed. The sample was capped and stirred at 500 rotations per minute at ambient temperature for about a day. The solids were isolated via 0.2 μm Nylon-membraned centrifuge tube filter and further dried in vacuum oven at 35° C. for about a day to yield Form J of
Compound 1. - Form K has a DSC thermograph substantially as depicted in
FIG. 37 , comprising endothermic peaks with peak maximum temperatures of approximately 98.9° C. and 113.7° C., respectively. Form K has a TGA thermograph as depicted inFIG. 37 , comprising a total mass loss of approximately 0.1% of the total mass of the sample when heated to 90° C. - A list of X-Ray diffraction peaks for Form K is provided below in Table 10.
-
TABLE 10 X-Ray Diffraction Peaks for Form K. Two-theta angle (°) d Space (Å) Height (counts) 7.3 12.160 1412 8.0 11.053 427 10.0 8.832 847 10.9 8.096 1585 11.5 7.667 1069 12.0 7.392 2072 13.4 6.600 937 14.1 6.265 1205 15.7 5.638 1317 17.5 5.073 2312 19.0 4.665 688 20.1 4.413 1774 21.3 4.160 1309 23.5 3.790 1521 - (k) Form L
- Form K of
Compound 1 was dried in vacuum oven at 35° C. for two days. A portion of the sample was heated to 121° C. at 10° C./min on DSC in a crimped pan with a pin hole on its lid. The solid residue was recovered as Form L ofCompound 1. - Form L has a Raman Spectrum as depicted in
FIG. 39 . A list of X-Ray diffraction peaks for Form L is provided below in Table 11. -
TABLE 11 X-Ray Diffraction Peaks for Form L. Two-theta angle (°) d Space (Å) Height (counts) 11.5 7.658 903 12.0 7.370 1001 13.4 6.605 637 15.7 5.634 856 17.5 5.070 1378 19.0 4.676 489 19.6 4.529 516 20.1 4.415 1127 21.0 4.233 481 21.3 4.167 1018 23.5 3.790 977 - (1) Form M
- Form K of
Compound 1 was dried in vacuum oven at 35° C. for two days. A portion of the sample was heated to 102° C. at 10° C./min on DSC in a crimped pan with a pin hole on its lid. The solid residue was recovered as Form M ofCompound 1. - Form M has a Raman Spectrum as depicted in
FIG. 41 . A list of X-Ray diffraction peaks for Form M is provided below in Table 12. -
TABLE 12 X-Ray Diffraction Peaks for Form M. Two-theta angle (°) d Space (Å) Height (counts) 7.2 12.230 2115 8.0 11.100 676 9.5 9.325 660 10.9 8.108 1173 11.5 7.674 1098 12.0 7.387 1702 13.4 6.594 860 15.7 5.639 1533 16.4 5.415 1555 17.5 5.075 1748 18.2 4.878 1455 19.0 4.674 905 19.5 4.540 860 20.1 4.413 1729 20.7 4.294 555 21.3 4.162 1650 22.8 3.895 2910 23.4 3.794 1134 - (m) Form N
- Form E of Compound 1 (8.6 mg) was mixed with Milli-Q water (0.12 mL) in a clear glass vial. The sample was capped and stirred at 400 rotations per minute at ambient temperature for 5 days. The solids were isolated via 0.2 μm Nylon-membraned centrifuge tube filter, and dried in vacuum oven at 35° C. for one day to obtain Form N of
Compound 1. - Form N has a Raman Spectrum as depicted in
FIG. 43 . Form N has a DSC thermograph substantially as depicted inFIG. 44 , comprising an endothermic peak with onset temperature of approximately 85.7° C. Form N has a TGA thermograph as depicted inFIG. 44 , comprising a total mass loss of approximately 1.2% of the total mass of the sample when heated to 105.5° C. - A list of X-Ray diffraction peaks for Form N is provided below in Table 13.
-
TABLE 13 X-Ray Diffraction Peaks for Form N. Two-theta angle (°) d Space (Å) Height (counts) 11.6 7.651 1067 12.0 7.346 6347 13.5 6.541 1684 13.8 6.427 1502 14.0 6.313 1238 14.6 6.070 724 15.8 5.591 1268 16.2 5.461 1232 17.7 5.021 4116 19.2 4.610 1089 19.6 4.532 789 20.1 4.415 5822 21.6 4.117 2900 21.7 4.096 2489 23.2 3.825 430 23.7 3.748 2498 24.1 3.694 1196 - 6.3 Evaluation of Solid Forms
- (a) Solubility Measurements
- A weighed sample of each of Form A, Form B, Form C, Form D, Form E, Form F, Form H, and Form I is treated with aliquots of the test solvent at ambient temperature or elevated temperature. Complete dissolution of the test material is determined by visual inspection. Solubility is estimated based on the total solvent used to provide complete dissolution of the sample. The actual solubility may be greater than the value calculated because of the use of solvent aliquots that were too large or due to a slow rate of dissolution.
- In addition, a weighed sample of each of Form J, Form K, Form L, Form M, or Form N is treated with aliquots of the test solvent at ambient temperature or elevated temperature. Complete dissolution of the test material is determined by visual inspection. Solubility is estimated based on the total solvent used to provide complete dissolution of the sample. The actual solubility may be greater than the value calculated because of the use of solvent aliquots that were too large or due to a slow rate of dissolution.
- (b) Stability Measurements
- Stability of each of Form A, Form B, Form C, Form D, Form E, Form F, Form H, and Form I is determined by exposing the sample to a 40° C./75% relative humidity (RH) environment for four weeks or 11% RH at ambient temperature for four days.
- In addition, stability of each of Form J, Form K, Form L, Form M, or Form N is determined by exposing the sample to a 40° C./75% relative humidity (RH) environment for four weeks or 11% RH at ambient temperature for four days.
- 6.4 Biological Evaluation
- (a) S1P1 Assays
- The compounds are useful in the treatment of a variety of S1P1 receptor-mediated clinical conditions, including autoimmune/inflammatory diseases; rheumatoid arthritis; lupus; insulin dependent diabetes (Type I); non-insulin dependent diabetes (Type II); multiple sclerosis; psoriasis; ulcerative colitis; inflammatory bowel disease; Crohn's disease; acute and chronic lymphocytic leukemias and lymphomas. Therefore, the compounds of the invention may be assayed for their ability to modulate the S1P1 receptor activity. See Colandrea, Biorg. Med. Chem. Lett. 2006, 16(11):2905-2908.
- In Vitro Binding Assay
- The solid forms described herein (e.g., Form A, Form B, Form C, Form D, Form E, Form F, Form H, and Form I) are evaluated using a [35S]-GTPgammaS binding assay to monitor dose-dependent selectivity against S1P1 receptors. The assay is completed with sample solid forms subjected to an eight-point, four-fold dose response curve with starting concentration of 10 μM. Selectivity is determined upon initial addition of solid forms followed by an incubation period. Following compound incubation, bounded [35S]-GTPgammaS is determined by filtration and scintillation counting. Percentage activation and inhibition values are determined relative to the reference agonist at S1P1.
- In addition, the solid forms described herein (e.g., Form J, Form K, Form L, Form M, and Form N) are evaluated using a [35S]-GTPgammaS binding assay to monitor dose-dependent selectivity against S1P1 receptors. The assay is completed with sample solid forms subjected to an eight-point, four-fold dose response curve with starting concentration of 10 μM. Selectivity is determined upon initial addition of solid forms followed by an incubation period. Following compound incubation, bounded [35S]-GTPgammaS is determined by filtration and scintillation counting. Percentage activation and inhibition values are determined relative to the reference agonist at S1P1.
- (ii) In Vivo Blood Lymphocyte Depletion Assay
- In addition to their S1P1 binding properties, modulators of the S1P1 receptor also have accelerating lymphocyte homing properties. These properties may be measured using a blood lymphocyte depletion assay. The solid forms described herein (e.g., Form A, Form B, Form C, Form D, Form E, Form F, Form H, and Form I) are administered orally by gavage to rats. Tail blood for hematological monitoring is obtained on
day 1 to give the baseline individual values, and at 2, 6, 24, 48 and 72 hours after application. The change in peripheral blood lymphocytes is measured across different doses of the solid forms. - In addition, the solid forms described herein (e.g., Form J, Form K, Form L, Form M, and Form N) are administered orally by gavage to rats. Tail blood for hematological monitoring is obtained on
day 1 to give the baseline individual values, and at 2, 6, 24, 48 and 72 hours after application. The change in peripheral blood lymphocytes is measured across different doses of the solid forms. - (b) In Vitro Metabolic Disposition in Liver Microsomal Fractions
- The stability of each of Form A, Form B, Form C, Form D, Form E, Form F, Form H, and Form I is determined according to standard procedures known in the art. For example, stability of each of Form A, Form B, Form C, Form D, Form E, Form F, Form H, and Form I is established by an in vitro assay. An in vitro hepatic microsome stability assay measures the stability of one or more subject compounds when reacting with mouse, rat or human microsomes.
- In addition, the stability of each of Form J, Form K, Form L, Form M, and Form N is determined according to standard procedures known in the art. For example, stability of each of Form J, Form K, Form L, Form M, and Form N is established by an in vitro assay. An in vitro hepatic microsome stability assay measures the stability of one or more subject compounds when reacting with mouse, rat or human microsomes.
- Incubations with liver microsomes are conducted in a final volume of 0.1 mL per incubation time point. 10 μM of the subject compound from a stock solution in DMSO (final DMSO concentration of 0.1%) is incubated at 37° C. from 0-60 min with pooled microsomal protein (1.0 mg/mL), suspended in incubation buffer (0.1 M potassium phosphate, pH 7.4, 5 mM MgCl2, and 0.1 mM EDTA). The microsomal reaction is initiated by the addition of NADPH (3 mM final concentration). Incubations with (a) no protein or (b) no NADPH serve as controls. Reactions are terminated by the addition of 0.2 mL of stop solution (acetonitrile). The samples are vortex-mixed for 30 sec and then centrifuged at 10,000×g for 10 min. The supernatant is dried using a Labconco CentriVap concentrator and the dry residue reconstituted in water, transferred to an HPLC glass vial and analyzed by HPLC-UV. The disappearance of the subject compound is used to evaluate the in vitro metabolism thereof.
- The embodiments disclosed herein are not to be limited in scope by the specific embodiments disclosed in the examples which are intended as illustrations of a few aspects of the disclosed embodiments and any embodiments that are functionally equivalent are encompassed by the present disclosure. Indeed, various modifications of the embodiments disclosed herein are in addition to those shown and described herein will become apparent to those skilled in the art and are intended to fall within the scope of the appended claims.
- A number of references have been cited, the disclosures of which are incorporated herein by reference in their entirety.
Claims (21)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/185,555 US20230219887A1 (en) | 2017-03-09 | 2023-03-17 | Solid forms comprising an oxime ether compound, compositions and methods of use thereof |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762469150P | 2017-03-09 | 2017-03-09 | |
US201762591880P | 2017-11-29 | 2017-11-29 | |
US201815916015A | 2018-03-08 | 2018-03-08 | |
US16/752,041 US11629124B2 (en) | 2017-03-09 | 2020-01-24 | Solid forms comprising an oxime ether compound, compositions and methods of use thereof |
US18/185,555 US20230219887A1 (en) | 2017-03-09 | 2023-03-17 | Solid forms comprising an oxime ether compound, compositions and methods of use thereof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/752,041 Continuation US11629124B2 (en) | 2017-03-09 | 2020-01-24 | Solid forms comprising an oxime ether compound, compositions and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230219887A1 true US20230219887A1 (en) | 2023-07-13 |
Family
ID=74039083
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/752,041 Active US11629124B2 (en) | 2017-03-09 | 2020-01-24 | Solid forms comprising an oxime ether compound, compositions and methods of use thereof |
US18/185,555 Pending US20230219887A1 (en) | 2017-03-09 | 2023-03-17 | Solid forms comprising an oxime ether compound, compositions and methods of use thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/752,041 Active US11629124B2 (en) | 2017-03-09 | 2020-01-24 | Solid forms comprising an oxime ether compound, compositions and methods of use thereof |
Country Status (1)
Country | Link |
---|---|
US (2) | US11629124B2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11958805B2 (en) | 2017-03-09 | 2024-04-16 | Novartis Ag | Solid forms comprising an oxime ether compound, compositions and methods of use thereof |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4158015A (en) | 1978-08-16 | 1979-06-12 | Mobil Oil Corporation | Process for the stereoselective synthesis of the E isomer of aryl alkyl oximes |
MY150088A (en) | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
JP4944613B2 (en) | 2003-05-19 | 2012-06-06 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Immunosuppressive compounds and compositions |
GB0500020D0 (en) | 2005-01-04 | 2005-02-09 | Novartis Ag | Organic compounds |
KR20070085465A (en) | 2004-11-29 | 2007-08-27 | 노파르티스 아게 | Dosage regimen of an s1p receptor agonist |
GT200600350A (en) | 2005-08-09 | 2007-03-28 | LIQUID FORMULATIONS | |
GB0612721D0 (en) | 2006-06-27 | 2006-08-09 | Novartis Ag | Organic compounds |
JP2010526116A (en) | 2007-05-04 | 2010-07-29 | ノバルティス アーゲー | Use of S1P receptor modulators |
EP3733162A1 (en) | 2007-10-12 | 2020-11-04 | Novartis AG | Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators |
US7854603B2 (en) * | 2007-12-21 | 2010-12-21 | The Goodyear Tire & Rubber Company | Tire building core assembly and disassembly station |
US9149459B2 (en) | 2008-07-23 | 2015-10-06 | Novartis Ag | Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation |
CA2733508A1 (en) | 2008-08-18 | 2010-02-25 | David Leppert | Compounds for the treatment of peripheral neuropathies |
WO2010071794A1 (en) * | 2008-12-18 | 2010-06-24 | Novartis Ag | New polymorphic form of 1- (4- { l- [ (e) -4-cyclohexyl--3-trifluoromethyl-benzyloxyimino] -ethyl) -2-ethyl-benzy l) -azetidine-3-carboxylic |
CA2747558A1 (en) | 2008-12-18 | 2010-07-15 | Novartis Ag | New salts |
IL294514A (en) | 2008-12-18 | 2022-09-01 | Novartis Ag | Hemifumarate salt of 1- [4- [1- ( 4 -cyclohexyl-3 -trifluoromethyl-benzyloxyimino ) -ethyl] -2 -ethyl-benzyl] -a zetidine-3-carboxylic acid |
WO2010072703A1 (en) | 2008-12-22 | 2010-07-01 | Novartis Ag | Dosage regimen of an s1p receptor agonist |
WO2011116091A1 (en) | 2010-03-17 | 2011-09-22 | Novartis Ag | Dispenser |
EP2463289A1 (en) * | 2010-11-26 | 2012-06-13 | Almirall, S.A. | Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors |
DK2661261T3 (en) | 2011-01-07 | 2019-10-21 | Novartis Ag | Immunosuppressive Formulations |
WO2012095853A1 (en) | 2011-01-10 | 2012-07-19 | Novartis Pharma Ag | Modified release formulations comprising sip receptor modulators |
EP2768494A1 (en) | 2011-10-21 | 2014-08-27 | Novartis AG | Dosage regimen for an s1p receptor modulator or agonist |
US9604914B2 (en) | 2012-02-03 | 2017-03-28 | Novartis Ag | Process for preparing N-(4-cyclohexyl-3-trifluoromethyl-benzyloxy)-acetimidic acid ethyl ester |
EP3199947A3 (en) | 2013-04-04 | 2017-09-13 | Novartis AG | Identifying patient response to s1p receptor modulator administration |
WO2015091531A1 (en) * | 2013-12-19 | 2015-06-25 | Almirall, S.A. | Imidazolopyrimidin-2-yl derivatives as jak inhibitors |
SG11201607894RA (en) | 2014-04-10 | 2016-10-28 | Novartis Ag | S1p modulator immediate release dosage regimen |
WO2015155711A1 (en) | 2014-04-10 | 2015-10-15 | Novartis Ag | Immunosuppressant formulation |
-
2020
- 2020-01-24 US US16/752,041 patent/US11629124B2/en active Active
-
2023
- 2023-03-17 US US18/185,555 patent/US20230219887A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20200399213A1 (en) | 2020-12-24 |
US11629124B2 (en) | 2023-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230015251A1 (en) | Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof | |
US9895336B2 (en) | Crystalline forms of (N, N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, methods of synthesis and use | |
US10100032B2 (en) | Crystalline forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione | |
JP5791500B2 (en) | 5-lipoxygenase activating protein inhibitor | |
US20230219887A1 (en) | Solid forms comprising an oxime ether compound, compositions and methods of use thereof | |
US20080216562A1 (en) | Pure darifenacin hydrobromide substantially free of oxidized darifenacin and salts thereof and processes for the preparation thereof | |
JP2010522227A (en) | Quinoline derivatives for the treatment of inflammatory diseases | |
EP2212312A2 (en) | 5-lipoxygenase activating protein (flap) inhibitor | |
JP2014510133A (en) | Crystal form of 1- (3-cyano-1-isopropyl-indol-5-yl) pyrazole-4-carboxylic acid and process for producing the same | |
US9856270B2 (en) | Dolutegravir salts | |
EP1700858B1 (en) | Salts of a quinuclidine derivative as muscarinic M3 receptor antagonists | |
WO2016054959A1 (en) | Crystal form of bisulfate of jak inhibitor and preparation method therefor | |
CN115770244A (en) | Compounds for the treatment of neurogenic orthostatic hypotension | |
US11958805B2 (en) | Solid forms comprising an oxime ether compound, compositions and methods of use thereof | |
RU2042680C1 (en) | 1-[pyrido(3,4-b)-1,4-oxazinyl-4-yl]-1h-indoles, method of their synthesis, composition on their basis and derivative of n-(4-pyridinyl)-1h-indole-1-amine | |
US9085607B2 (en) | ACH-0142684 sodium salt polymorph, composition including the same, and method of manufacture thereof | |
US11013723B1 (en) | Solid forms of a thiazolidinone compound, compositions and methods of use thereof | |
EP1375497B1 (en) | Magnesium salt of s-omeprazole | |
US11014897B1 (en) | Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof | |
US11186556B1 (en) | Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof | |
JP2021512910A (en) | Co-crystal morphology of novobiocin analog and proline | |
EP3560944A1 (en) | Solid form of 4'-thio-2'-fluoronucleoside phosphamide compound and preparation method therefor and use thereof | |
EP2943454B1 (en) | Tapentadol maleate and crystalline forms thereof | |
RU2203888C2 (en) | Method of synthesis of (1s,2s)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4- phenylpiperidin-1-yl)-1-propanol methanesulfonate trihydrate and d-(-)-tartrate salt | |
US20230105181A1 (en) | Salts and polymorphic forms of 6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1h-pyrazol-4-yl)-3h-imidazo[4,5-b]pyridine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: NOVARTIS INTERNATIONAL PHARMACEUTICAL AG, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CELGENE CORPORATION;REEL/FRAME:063982/0675 Effective date: 20200117 Owner name: NOVARTIS AG, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CELGENE CORPORATION;REEL/FRAME:063982/0675 Effective date: 20200117 Owner name: NOVARTIS AG, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:NOVARTIS INTERNATIONAL PHARMACEUTICAL AG;NOVARTIS AG;REEL/FRAME:063926/0924 Effective date: 20200225 Owner name: CELGENE CORPORATION, NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HUANG, LIANFENG;ZOU, DAOZHONG;REEL/FRAME:063926/0834 Effective date: 20190125 |